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Ras proteins are small GTPases that act as molecular switches within cells that link 
extracellular stimuli to intracellular effectors. Ras proteins play a conserved role in the control 
of both cell growth and proliferation. As a result, mutations that induce the constitutive 
activation of Ras proteins are often associated with changes in cell behaviour that can lead to 
disease, such as human cancer. The localisation of Ras is crucial for its function and this is 
controlled by post-translational modifications. However, the roles for such modifications in 
regulating Ras localisation and its activity are poorly understood. We have identified that the 
phosphorylation of Serine225 of Ras2, a protein that is essential for the control of both growth 
and proliferation in S. cerevisiae, plays an important role in the regulation of its localisation 
and activity. Modification of this residue leads to changes in the distribution of GTP-bound 
Ras2 within the cell. This drives cells towards a novel state of growth cessation that is 
dependent upon the activity of the cAMP/PKA signalling pathway. We show that this 
quiescent state is characterised by an uncoupling of cytoplasmic and nuclear process that 
govern cell growth and division. We suggest that cells can escape growth arrest and re-engage 
in the cell cycle if the Ras/cAMP/PKA pathway activity is reduced, additional nutritional 
supplementation is provided or if nutrient uptake processes are elevated. Thus, the 
Serine225 reside plays an important role in the control of Ras2 localisation and activity that 
allows the cell to co-ordinate nutritional availability with growth and cell division. My thesis 
highlights that post-translational modifications in regions outside of the highly conserved Ras 
GTPase domain may be targeted to change cell fate, for example by switching a pro-growth 
signalling programme to one that drives a growth cessation.  This has implications for the 




















1.1 S. cerevisiae as a model organism 
 
The exploitation of eukaryotic organisms as biological models has been fundamental for 
biological discovery. Model organisms such as yeast, nematodes and flies can be utilized to 
rapidly elucidate the function of genes and their role in cellular pathways, processes, and 
compartments. Enhancing the understanding of how genes function is crucial if we are to 
understand basic cell biology and why mutation can lead to dysfunction that underlies 
disease.  
Saccharomyces cerevisiae (S. cerevisiae) is a single-celled eukaryote and therefore shares the 
cellular structure and organisation of higher eukaryote cells. Coupled with the relative 
simplicity of genetic manipulation, short-doubling time and broad range of molecular tools 
and resources available, S. cerevisiae is regarded as an important model organism [1][2]. In 
1996, S. cerevisiae became the first eukaryote to have its complete genome sequenced and 
published [2]. A wide range of genetic and molecular tools have been developed to facilitate 
research using S. cerevisiae. For instance, a collection of yeast strains comprising deletions of 
non-essential open reading frames (ORF) was generated and made accessible [3][4]. 
Furthermore, other collections exist with genome-wide coverage such as a collection 
comprising of GFP-fused chimera proteins that aid in the visualisation of endogenous yeast 
proteins [5][6]. Supporting these resources is a freely accessible online database; ‘The 
Saccharomyces genome database (SGD)” which provides key biological information on S. 
cerevisiae along with research and analytical tools to enable investigations on the relationship 




The available resources have enabled the roles of almost 85 % of the 5800 protein-coding 
genes of S. cerevisiae to be determined. Such annotation, coupled with the advantages of the 
system as a whole offers an important resource, for example it has been shown that ~ 17 % 
of yeast genes exist as members of orthologous gene families associated with human diseases 
[7]. The expression of human proteins in yeast cells can also be instrumental for the discovery 
of chemical or protein inhibitors of their activity using high throughput screening methods 
[8]. Such assays are based on the principle that demonstrable functions of human proteins 
may be manipulated by chemical compounds or further genetic manipulation [9][10]. As such 
research conducted on S. cerevisiae has been instrumental in uncovering the role of many 
proteins in higher eukaryotes, including humans [9]. A good example lies in the study of small 
GTPase proteins of the Ras superfamily 
1.2 The Ras superfamily 
 
The Ras superfamily comprises of small Guanosine Triphosphate Hydrolases (GTPases), which 
range from 20 to 40 kDa in size. The Ras superfamily includes over 150 members in humans 
with evolutionary conserved orthologues present in several organisms including Drosophila 
melanogaster, Caenorhabditis elegans and S. cerevisiae.  The superfamily is divided into five 
main branches based on sequence and functional similarities; Ras, Rho, Arf/Sar, Rab and Ran 
[11]. While similar to the heterotrimeric G protein α subunits in biochemistry and function, 
Ras family proteins act as monomeric G proteins, functioning as molecular control switches 
[12]. Post-translational modifications and structural differences dictate their subcellular 
localisation and the proteins that serve as their regulators enable GTPases to function as 
efficient modulators of complex cellular processes.  
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Rab family proteins make up the largest branch of the Ras superfamily with 61 members 
currently identified [13]. Rab proteins are associated with membrane organisation due to 
their regulatory role in intracellular vesicular transport between organelles in both the 
endocytic and secretory pathway [14]. The second branch of the superfamily comprises of the 
ADP-ribosylation factor (Arf) family proteins and like Rab proteins, have been implicated in 
the regulation of vesicular transport [13][14]. The regulation of Arf GDP/GTP cycling is 
controlled by distinct GEF’s and GAP’s [15].   
Rho proteins form the third branch of the superfamily with twenty known Rho proteins 
identified with RhoA, Rac1 and cdc42 being the most studied. Rho proteins function as vital 
regulators of extracellular-stimulus-mediated signalling networks which regulate gene 
expression, cell cycle progression and actin organization [16]. Moreover, Rho GTPases are also 
involved in cell polarity, cell shape and cell-matrix interactions [17].  
The fourth branch encompassing the most abundant small GTPase in the cell, is the Ras-like 
nuclear (Ran) protein. Ran is best characterised for its role in nucleocytoplasmic transport of 
RNA and proteins [18]. Unlike other small GTPases, Ran activity is dependent on a spatial 
gradient of the GTP-bound form of Ran. A single human Ran protein is regulated by a Ran-
specific nuclear GEF and cytoplasmic GAP. The resulting effect is a high concentration of Ran-






1.3 The Ras protein subfamily 
 
The final branch of the Ras superfamily and the focus for this study are the Ras proteins. The 
activation of Ras proteins, as with all G proteins, is dependent on the exchange of bound GDP 
for GTP and is deactivated through the hydrolysis of GTP to GDP [20] (Figure 1). Ras proteins 
function as intracellular signalling molecules transforming extracellular stimuli into 
intracellular responses at a given target via the utilization of complex intracellular signalling 
pathways.  
All Ras proteins share a conserved G-domain, the functional domain that binds to GTP/GDP, 
therefor it is not surprising that all Ras proteins present a common mechanism of action. Ras 
proteins function as binary molecules switching between an inactive GPD-bound state and an 
active GTP-bound state. The activation of Ras proteins leads to subsequent activation of 
signalling cascades which differ depending on the organism and specific Ras protein activated 
[21][22]. Most proteins who interact with Ras to activate downstream signalling pathways, 
share a conserved domain known as the RAS-binding-domain, or RAS association (RA) 
domain. The presence of this domain was exploited and used for the identification of novel 
Ras effectors which were found via cDNA library screens by probing for the presence of RA 
domains [21]. The conserved mechanism of action shared between Ras proteins is reliant on 
a conserved sequence consisting of a set (1-5) of G box GDP/GTP- binding motif elements 
which begins at the N-terminal domain and form a G-domain of approximately 20 kDA in size 
[23]. The N-terminal domain contains short sequences of amino acids involved in the 
recognition of phosphates and guanine nucleotides. Important motifs within the G-box 
domain include switch I and switch II, which regulate the conformational changes between 
GTP- and GDP-bound Ras proteins [24][25]. The conformations of active and inactive sites 
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present significant changes which correspond to the switch I and II regions with these small 
variations leading to different affinities for active or inactive Ras proteins towards Ras 
regulators and effectors [20]. 
As with all G-proteins, Ras activation is dependent on the exchange of bound GDP for GTP 
and is deactivated through the hydrolysis of GTP to GDP; this cycling between active and non-
active states is regulated by GEF’s and GAPs (Figure 1) [26]. The Guanine Exchange Factors 
(GEFs) regulate Ras activation via the exchange of GDP bound to the Ras nucleotide binding 
pocket for GTP and GTPase Activating Proteins (GAPS) regulate the subsequent deactivation 
[26]. The cycling between activation and deactivation of Ras proteins is integral for the 
coupling of external stimuli to effector proteins within signal transduction cascades.  
An example of such an effector protein found in higher eukaryotic systems is RAF, a serine-
threonine kinase which interacts with Ras through the previously mentioned RBD, the Raf1 
protein binds to active GTP-bound Ras making it a very useful tool for the investigation of Ras 
activation within living cells [27]. Ras1 and Ras2 guanine nucleotide binding and GTPase 
activities have been characterised and the C-terminal third of the nucleotide sequence of 
yeast Ras displays significant overlap with human RAS. Furthermore, human RAS suppresses 
the loss of yeast RAS genes, thus supporting functional similarities between yeast and human 








Figure 1. Ras protein cycling between active and inactive states through the action of GEF 
and GAP proteins.  
Active Ras interacts with the downstream targets in signalling cascades to induce a cellular 
response. Ras activation is dependent on the exchange of bound GDP for GTP and is 
deactivated through the hydrolysis of GTP to GDP; this cycling between active and non-active 
states is regulated by GEF’s and GAPs [26]. 
 
In S. cerevisiae two proteins are expressed which are homologous to human Ras, Ras1 and 
Ras2. The RAS1 and RAS2 genes are located on chromosome XV and XIV [29], respectively, 
and encode two highly similar proteins of 309 and 322 amino acids in size [29] [30].  
Ras proteins function as GTP-binding proteins which regulate the nitrogen starvation 
response, sporulation, and filamentous growth in yeast. In S. cerevisiae, RAS2 has a paralog, 
RAS1, which arose from the whole genome duplication [31]. Ras1p and Ras2p share the same 




Figure 2. A 3D representation of the crystal structure of the human Ras protein in its GDP-
bound conformation.  
Courtesy of http://www.rcsb.org/structure/2ERY.  
 
Previously, the yeast Ras proteins were thought to have exclusive roles within the cell as Ras1 
was unable to complement growth defects caused by the deletion of RAS2, such as reduced 
growth on non-fermentable carbon sources and decreased levels of intracellular cAMP 
[34][35]. However, these questions have been explained by the differential regulation of the 
mRNA production and protein translation of RAS1. The level of RAS1 mRNA and protein 
synthesis are reduced during the mid-logarithmic growth phase and during growth on non-
fermentable carbon sources [32], while RAS2 mRNA levels are high during all growth phases 
on both fermentable and non-fermentable carbon sources [36][32]. To confirm that RAS1 and 
RAS2 differ only by their level of expression, RAS1 was put under the constitutive ADH1 
promotor. Here, RAS1 was able to fully supress the phenotype of a ras2 strain and the 
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hyperactive mutant of RAS1 replicated the phenotypes observed in an constitutively 
expressed RAS2 strain [37].  
In humans the Ras protein family is comprised of 25 members, which are predominantly 
localised to the plasma membrane. These proteins are highly conserved within the GTPase 
domain, but mutations can lead to the constitutive activation of Ras. Investigations have 
estimated that ~50 % of all tumours are result of mutations involved in the constitutive 
activation of Ras signalling [26]. A number of human oncogenes implicated in a variety of 
cancers have been identified including N-RAS, H-RAS and K-RAS [38][39][40][29].  
Proto-oncogenes play an essential role in signal transduction and the execution of mitogenic 
signals, therefore when over-activated they become tumour-inducing agents. Ras genes are 
examples of proto-oncogenes, which encode for proteins involved in the regulation of cell 
proliferation and differentiation. Ras plays an important role in the cell cycle and is linked to 
several human cancers and as such has been extensively researched in recent years. Previous 
investigations have identified that mutant alleles of the human Ras protein are linked to a 
number of human cancers, further highlighting Ras as an important target for cancer research 
[41]. Sequence analyses have revealed the importance of the amino acids at positions 12, 13 
and 61 in Ras proteins. Mutations that cause the alternation of residues can lead to the over-
activation of Ras via GAP impairment [41].  
The proto-oncogenes K-RAS, H-RAS and N-RAS are often termed as the ‘classical’ mammalian 
Ras proto-oncogenes and as such are the most extensively studied among all the Ras 
superfamily members due to their direct involvement in tumorigenesis. H-RAS mutants are 
present in 12 % of cases of bladder carcinoma whereas N-RAS mutations are predominantly 
found in malignant melanomas and hematopoietic tumours [42]. Mutations in K-RAS are the 
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most common mutation associated with cancer disease with 60 % of pancreatic cancers, 34 
% of colorectal and 16 % of lung cancers expressing oncogenic K-RAS isoforms [43].  
1.4 Posttranslational modifications of Ras 
 
Posttranslational modifications such as methylation, ubiquitination and most commonly 
phosphorylation can diversify protein function and enhance regulation [44]. The regulation of 
yeast Ras proteins is not explicitly regulated by their GTP/GDP binding state, but also by post 
translational modifications, which can dictate Ras sub-cellular localisation. The sub-cellular 
localisation of Ras proteins determines the class of effectors and regulators that are available 
and thus determines the downstream signalling activity [22][21].  
 Ras proteins undergo a series of posttranslational modifications which are important to 
control both activation and its localisation to the cytoplasmic side of the plasma membrane 
[21]. The C-terminal domain of the Ras protein contains a CAAX (C= cysteine, A = aliphatic 
amino acid, x + terminal amino acid) motif, which is essential for membrane targeting and 
activity [44][45][46][47]. The first posttranslational modification of Ras processing is 
farnesylation. The cysteine in the CAAX motif is targeted by farnesyltransferase, which 
catalyses the addition of a farnesyl isoprenoid [48]. It has been shown that the addition of 
geranylgeranyl isoprenoid to the CAAX motif can substitute farnesylation but only when 
farnesyltransferase is blocked by specific inhibitors [49][49][47].  Following this modification, 
Ras membrane interaction is initiated and Ras is targeted to the endoplasmic reticulum (ER) 
[50]. After farnesylation the proteolytic removal of the AAX amino acids from the CAAX motif 
via the enzyme Rec1 occurs, leaving a prenyl cysteine at the C-terminus [51]. 
Isoprenylcysteine Carboxymethyltransferase (ICMT) performs carboxyl methylation on the 
prenyl cysteine, which has been hypothesised to play an essential role in Ras signalling [52]. 
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The previously mentioned posttranslational modifications are the minimum signals required 
for movement and tenure to the plasma membrane.  
1.5 Ras protein trafficking  
 
Ras proteins are most frequently found associated with membranes and research has focused 
upon its function at the plasma membrane. Importantly, the site of Ras localisation can dictate 
its function via its interaction with regulatory partners and downstream effectors [21][53].  
In S. cerevisiae, the precise mechanism of Ras trafficking from cytosol to endomembranes has 
yet to be elucidated but in the mammalian system it is known that N-Ras and H-Ras transit to 
the plasma membranes occurs via vesicular transport following palmitoylation [54][55]. 
Experimental evidence exists to suggest that N-Ras and H-Ras localised on the plasma 
membrane can also be depalmitoylated which promotes its translocation back to the golgi 
apparatus [56]. Due to the lack of palmitoylation sites in K-Ras (Figure 3), the mechanisms 
controlling its movement to the plasma membrane is unknown but it is known to be 
dependent on a poly-lysine region close to the hypervariable region that does not rely on 
golgi/endomembrane trafficking [53]. A fluorescent probe consisting of the Ras Binding 
Domain (RBD) of Raf-1 fused to GFP was developed to confirm that signalling occurs from Ras 
proteins on the surface of the golgi apparatus. The probe binds specifically to active Ras 
proteins, revealing that Ras activation can be found to occur at both the ER and golgi 
apparatus [57]. Furthermore, in addition to signalling from the golgi, studies have shown Ras 
activation at the ER compartment when N-Ras and H-Ras proteins deficient in palmitoylation 
accumulate on the ER and in the cytosol [53][50]. Collectively these studies highlight the 




Figure 3. The human Ras protein hypervariable region (HVR).  
The HVR influences the variability in function between the Ras isoforms, it undergoes PTM’s 
to allow membrane interaction and localisation.  
 
In yeast, Ras proteins also undergo PTM to regulate their localisation and activity [50][58]. 
The initial PTM observed for both Ras1 and Ras2 is the removal of a methionine at the N-
terminus, followed by C-terminal modifications such as carboxyl methylation, farnesylation 
and palmitic acid addition [59][60][61]. Ras1p and Ras2p farnesylation at the cysteine of the 
CAAX box motif is catalysed by a farnesyltransferase, comprised of α and β subunits encoded 
by RAM2 and DPR1/RAM2. Experimental evidence has shown that Ras protein localisation in 
mutants of either RAM1 or DPR1 present a cytoplasmic localisation [62]. In S. cerevisiae the 
palmitoylation of Ras proteins is catalysed by Palmitoyltransferase (PAT), encoded by the 
ERF2 and ERF4 genes [60]. The protein products of these genes are localised in the ER and 
perform palmitoylation using palmitoyl-CoA [62].  
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Through the use of fluorescent labelling of Ras proteins and their partners, it has been shown 
that Cdc25, Ira2 and Cyr1 are localized on endomembrane’s although the activation of 
adenylyl cyclase by Ras2 occurs solely on the plasma membrane in S. cerevisiae [63][64] . Ras 
has been shown to be anchored to the ER by the Ras inhibitor, Eri1 [65]. More current studies 
highlight that the localisation of active Ras is dependent on the activity of Protein Kinase A 
(PKA). A feedback regulation on Ras2 localisation has been suggested, based on PKA-
dependent phosphorylation; Ras2 was shown to localize mainly on the plasma membrane in 
glycerol-growing cells, while glucose-addition causes a rapid re-localisation of large part of 
the protein to the cytoplasm [66]. The overexpression of the TPK1 subunit drives both Cdc25 
and Ras2 away from the plasma membrane [67]. Furthermore, active Ras has been shown to 
localise in the nuclear compartment [68][69]. 
Other studies reveal a potential role for the mitochondria for correct Ras localisation [70]. For 
example, an aberrant accumulation of activated Ras at the mitochondria in response to 
nutritional depletion was reported in cells lacking whi2, a protein phosphatase activator 




Figure 4. Posttranslational modifications play an important role in dictating sub-cellular 
Ras trafficking and localisation. 
 Although the mechanisms of Ras trafficking to many intracellular sites has yet to be 
determined. 
Despite our extensive knowledge on how Ras protein modifications lead to plasma membrane 
localisation, we know relatively little on how they are targeted to other compartments of the 
cell (Figure 4). This lack of knowledge necessitates future investigations to elucidate which 
modifications and mechanisms regulating Ras localisation within eukaryotic cells and the 
significance of localisation for cell function.  
1.6 Ras protein phosphorylation 
 
Phosphorylation is an important posttranslational modification and is used to control the 
function, localisation, or activity of many proteins [71]. Phosphorylation is the chemical 
addition of a phosphoryl group to an organic molecule and is catalysed by a kinase. The 
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subsequent removal of a phosphoryl group is called dephosphorylation and is catalysed by a 
phosphatase. Protein phosphorylation can occur on serine, threonine and tyrosine residues 
and is widely considered as the most abundant post-translational modification in eukaryotes 
[72][73].  
In yeast, both Ras1 and Ras2 are phosphorylated and phosphorylation occurs exclusively on 
serine residues [74]. Tryptic phosphopeptide analysis highlighted only two major 
phosphorylated tryptic peptides of the Ras2 protein[74][75]. Further investigations showed 
that phosphorylated Ras2 proteins are predominantly localised in the plasma membrane, 
where the action of these proteins occurs [74]. Thus, suggesting that phosphorylation may 
not merely be a random event but rather play a physiologically significant role [74][75].  
Specific serine residues have been identified within yeast Ras1 and Ras2 proteins that can be 
phosphorylated [74][75].  Although there are 31 serine residues in the mature Ras2 protein, 
it has been shown that only serine residues at positions 6, 198, 202, 207, 214, 224, 225, 235, 
238, 262, 275, 285 and 291 are identified as putative Ras2 phosphorylation sites [75]. 
Interestingly, activated alleles of both RAS1 and RAS2 proteins have been shown to be less 
stable and less phosphorylated than proteins from cells expressing wild-type alleles of Ras2 
[75].  
Serine214 of Ras2 is the preferred site of phosphorylation; however, the protein kinase(s) 
responsible for Ras2 phosphorylation can phosphorylate a variety of serine residues in the 
vicinity of serine214 when this site is altered [75]. When Ras2S214 is replaced by the non-
phosphorylatable residue alanine, cells exhibit reduced glycogen accumulation, elevated 
cAMP levels and increased activation of cAMP signalling by glucose [74]. Furthermore, 
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increased PKA-dependent activation of Ras2-GTP was observed suggesting that 
phosphorylation is controlled via feedback regulation of the Ras-cAMP/PKA pathway.  
Among ras gene products, phosphorylation is not limited to yeast proteins. In humans, the 
activity of H-Ras mutant proteins can be modulated by phosphorylation. The constitutively 
activated H-RasG12V mutant can develop a second mutation resulting in the substitution of 
alanine for a threonine at position 59. Phosphorylation occurs on the HRASval12-Thr59 mutant 
proteins at threonine-59 and functions as a suppressor of the G12V mutation [76]. 
Furthermore, experimental evidence also shows that PKC agonists induced phosphorylation 
of serine181 resulting in the fast translocation of K-Ras from the plasma to endo-membranes 
[77].  
Although evidence exists to suggest that Ras proteins can undergo phosphorylation events 
which regulate its activity. Surprisingly, the phosphorylation of Ras2p in S. cerevisiae has not 
been studied regarding its regulation of intracellular localisation despite significant evidence 
existing linking Ras phosphorylation to its localisation in humans. 
1.7 RAS/cAMP/PKA signalling in S. cerevisiae 
 
In S. cerevisiae, Ras proteins, once activated, interact with adenylate cyclase at the plasma 
membrane, triggering the synthesis of cAMP from ATP (Figure 5) [78]. Adenylyl cyclase, 
encoded by CYR1, is a large protein consisting of 2,026 amino acids. The protein structure 
comprises of four domains: N-terminal, middle repetitive, catalytic and a C-terminal domain. 
The middle repeat consists of a 23-residue amphipathic leucine-rich motif called the LRR 
domain (674-1300 aa). The LRR domain is the principal site of Ras interaction and the N-
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terminal domain of the LRR (676-756) has been identified to be a Ras Associating Domain 
(RAD).  
Upon cAMP production by adenylyl cyclase, cAMP binds to the Bcy1 protein, the regulatory 
subunit of PKA, activating PKA. The regulation of Ras/cAMP/PKA signalling is essential for 
orchestrating many cellular processes including growth, proliferation, cell cycle progression, 
stress responses and the control of ageing in yeast cells (Figure 5) [79]. Mutations resulting in 
the inappropriate activation of PKA induce cell cycle arrest in G1, glycogen accumulation and 
prolonged survival when exposed to starvation [78].   
An increase in intracellular cAMP levels results in the activation of PKA via the dissociation of 
the PKA regulatory subunit Bcy1 [80] and the PKA catalytic subunit(s) encoded by TPK1, TPK2 
and TPK3 [81][78]. The genes TPK1, TPK2 and TPK3, control cAMP-dependant protein kinase 
activity in S. cerevisiae. The PKA subunits Tpk1, 2 and 3 share overlapping functions but also 
have been shown to be involved in the regulation of several separable functions.  Tpk1 has 
been identified to play a role in the branched chain amino acid biosynthesis pathway, 
mitochondrial DNA stability and mitochondrial iron homeostasis [82]. Whereas Tpk2 has been 
shown to impact iron uptake, trehalase synthesis and water homeostasis [82][83]. However, 
constitutive PKA activity can prove deleterious, with the overexpression of TPK3 shown to 
inhibit growth [84].  
The production of intracellular cAMP is tightly regulated through feedback loops and the 
action of phosphodiesterases, which catalyse the degradation of cAMP [85][86]. 
Saccharomyces cerevisiae contains two cAMP phosphodiesterases, PDE1 and PDE2, which 
encode a low-affinity (Pde1) and a high-affinity cAMP phosphodiesterase (Pde2) that are 
unrelated in primary sequence [85][86]. Pde2 is an Mg2-requiring, zinc-binding enzyme with 
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a Km for cAMP of 170 nM [87][88]. It controls the basal cAMP levels in the cell and thereby 
protects it from changes in the extracellular environment [89]. 
 
Figure 5. The activation of Ras1 and Ras2 is dependent on nutrient availability.  
In the presence of glucose Ras proteins are activated via the GEF proteins cdc25 or Sdc25 which 
catalyse the liberation of GDP and the binding of GTP. Adenylate cycle is activated inducing the 
production of cAMP. cAMP functions as a secondary messenger and binds to the inhibitory unit of 
PKA, releasing the catalytic unit, phosphorylating downstream targets resulting in the activation of 
multiple downstream cellular processes or the inhibition of transcription factors that control the stress 
response. This pathway is inhibited by the hydrolysis of cAMP via the action of Pde1 and Pde2 and by 
the GTPase activity of the GAP’s Ira1 and Ira2. 
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1.8 Regulation of RAS/cAMP/PKA pathway activity 
 
In S. cerevisiae, Ras protein activation is finely tuned by two classes of regulatory proteins: 
Cdc25 and Sdc25 guanine nucleotide exchange factors (GEFs) [90][91][92], and Ira1 and Ira2 
GTPase activating proteins (GAPs) (Figure 6) [93][94] [95]. The molecular mechanism of the 
modulation of Ras proteins activity is conserved in higher eukaryotes, as highlighted by the 
functional interchangeability of Ras proteins and their regulators in yeast and mammals [96].  
The CDC25 gene of S. cerevisiae encodes for the Ras protein activator (GEF) and is required to 
produce cAMP. The Cdc25 gene product is a ~180 kDa polypeptide with a C-terminal highly 
conserved RAS-GEF catalytic domain (1,121–1,573 aa) [97]. Mutants that result in the 
constitutive activation of Ras2, such as Rasval19, have been shown to supress the effects of 
mutations in CDC25, as constitutively activated Rasval19 does not require the exchange factors 
for its activation [98]. Furthermore, the gene SDC25 has also been shown to prevent Ras GEF 
activity [90].  
Despite Cdc25 being the first Ras GEF characterised [99], the precise mechanism of how its 
activity is regulated and how the Cdc25/Ras/cAMP pathway transduces the signal originated 
by nutrients is still unclear. Inconsistent reports have put forward either the necessity 
[100][101] or the dispensability [102] of Cdc25 for Ras and adenylate cyclase activation upon 
glucose stimulation, however Cdc25 was eventually shown as necessary for Ras2 GTP-loading 
after glucose refeeding [103].  
The Cdc25 protein is tightly bound to membranes [104], although protein solubility increases 
upon hyper-phosphorylation within the 114-348 amino acid region and results in Cdc25 
becoming less available for the association with Ras [105]. Glucose-induced hyper-
phosphorylation of Cdc25 upon glucose addition has been shown to directly inhibit Ras GEF 
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activity rather than affinity for Ras [106][105]. Cdc25 activity modulation by phosphorylation 
is prevented by nutrient starvation and is hypothesized to be a part of a negative feedback 
loop resulting from PKA activity (Figure 6) [105][106].  
The IRA proteins, encoded by the genes IRA1 and IRA2 have been shown to inhibit Ras activity 
in yeast [95].The IRA1 and IRA2 genes encode large proteins, 3092 and 3079 amino acids 
respectively, that share similar amino acid sequence and have related, even if not identical, 
functions. A region of approximately 360 amino acids in the middle of these gene products, 
called the GAP domain, is responsible for activating intrinsic GTPase activity of Ras [95]. It has 
been shown that IRA1/IRA2 gene mutations suppress CDC25 mutations, double deletion 
mutant’s of Δcdc25 and Δira1/Δira2 are viable. Ira2 (Ras-GAP) is regulated by ubiquitination, 
a posttranslational modification resulting in protein degradation by the proteasome. 
 More recent studies have shown that the Ubp3 protein interacts with the Ras GTPase-
accelerating protein, Ira2, and regulates its level of ubiquitination. Ubp3 is an Ubiquitin-
specific protease and regulates PKA activity by controlling the ubiquitination status of Ira2p 
[107]. It has been suggested that the addition of glucose to the growth media stimulates 
ubiquitination and Ira2p inactivation resulting in Ras-GTP accumulation and therefore 
elevated PKA activity. The regulation of Ira2 by ubiquitination is a highly conserved 



















Figure 6. Positive and negative feedback in the Ras/cAMP/PKA pathway.  
This schematic shows the relationships among the main components of the Ras/cAMP/PKA 
pathway. The cycling of the Ras2 protein between its inactive state (Ras2-GDP) and active 
state (Ras2-GTP) is regulated by Cdc25 (A) and Ira2 (B). Ras2-GTP activates adenylate cyclase 
Cyr1 (C), which induces the synthesis of the second messenger, cAMP (D). Increased cAMP 
levels result in PKA activation (E) through binding to the PKA regulatory subunits and liberating 
its catalytic subunits. The degradation of cAMP is catalysed by Pde1 (I) and Pde2 (J), which 
functions as a major negative feedback mechanism in this pathway, as both contribute to the 
decrease in the intracellular level of the second messenger. The active form of PKA performs 
three main regulations in this pathway via the phosphorylation of different components: a 
positive regulation of Pde1 (H) and of Ira2 (G), and a negative regulation of Cdc25 (F). The 
increased activity of the phosphorylated forms of both Pde1 and Ira2 result in switching off 
the signal—by either a faster degradation of cAMP by Pde1 (I) or to a diminished fraction of 
active Ras2 by Ira2 proteins (B), both positive regulations result in a negative feedback control 
of the whole pathway. The negative regulation of Cdc25 by PKA results in a partial inactivation 
of the GEF activity (A), and therefore a reduced activation of the Ras2 protein, which results 




1.9 The GPCR System- Regulator of the cAMP/PKA pathway 
 
Working in parallel with Ras to activate PKA is the GPCR (G-protein coupled receptor) glucose-
sensing system, composed of the Gpr1 receptor and its cognate G protein, Gpa2 (Figure 7) 
[109][110]. GPR1 encodes a seven-transmembrane G protein-coupled receptor that interacts 
with Gpa2 [111][112], a small GTP-binding protein which is homologous to the mammalian 
Gα subunit of the heterotrimeric G proteins [113]. The binding of glucose to Gpr1 activates 
Gpa2, which stimulates adenylate cyclase to increase cAMP levels and thus activation of PKA 
[112]. The Gpr1-Gpa2 system is responsive to both glucose and sucrose but not structurally 
similar sugars including fructose or glucose analogues [114]. The deletion of GPA2 has been 
shown to confer the typical phenotype associated with reduced PKA activity [112], with GPA2 
or GPR1 inactivation slowing several PKA-controlled processes including the repression of STR 
responsive genes and the induction of genes encoding ribosomal proteins [115]. Addition of 
glucose to cells elicits a rapid acidification of the yeast cytoplasm inducing PKA signalling 
(Figure 7) [116]. However the Gpr1-Gpa2 system is not required for intracellular acidification-
induced PKA activation and does not play major role in controlling the basal cAMP level [112] 
[115]. 
Surprisingly, activation of Ras is dependent on sugar uptake but it does not require the 
presence of a functional GPCR system [117]. The precise mechanisms by which glucose 
activates Ras activity is still unknown with no sugar-sensing system identified that could 
function as an upstream activator of Cdc25 to transmit the glucose signal to the Ras protein 
[118]. Evidence suggests that Cdc25 may not itself be the signal receiver for the glucose 
induced cAMP response but instead the glucose induced increase in Ras2 activation may be 
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mediated through the inhibition of Ira1/2 proteins, thus confirming the early reports 
indicating Ras as an important mediator in glucose-induced cAMP signalling [102].  
 
Figure 7. Mechanisms of how glucose and intracellular acidification modulate adenylate 
cyclase activity. 
 Glucose binds to the Gpr1 receptor, activating cAMP synthesis through the Gpa2 protein, 
while intracellular acidification functions through the Ras proteins. Gpr1 and Gpa2 constitute 
a glucose sensing GPCR system. The transient cAMP accumulation triggered by glucose 
activates PKA, which causes transient changes in several systems containing components 
controlled by PKA‐mediated phosphorylation. The phosphorylation of downstream targets 
resulting in the activation of multiple downstream cellular processes or the inhibition of 
transcription factors that control the stress response. The red arrows represent 




1.10 Processes regulated by PKA activity 
 
1.10.1 PKA modulation of ribosome biogenesis 
 
The activation of PKA regulates growth by promoting the expression of the cell’s translation 
machinery. PKA activates Rap1, which in conjunction with the high mobility protein Hmo1, 
recruits the nutrient-regulated Fhl1-Ifh1 complex to RP gene promotors to induce the 
expression of the corresponding genes [119][120][121][122][123][124]. Furthermore, PKA 
inhibits Yak1-mediated activation of the transcriptional repressor Crf1, which, following 
phosphorylation by Yak1, substitutes the coactivator Ifh1 of the fork head transcription factor 
Fhl1 to downregulate RP gene expression [123][124]. In addition to the regulation of 
ribosome biogenesis, PKA functions to control the regulation of the elongation step of RNA 
Pol II-mediated transcription [125].  
1.10.2 PKA modulation of the stress response 
 
As well as stimulating growth, PKA also functions to supresses several stress responses, such 
as the inhibition of the dual-specificity tyrosine phosphorylation-regulated protein kinase, 
Yak1. PKA sequesters Yak1 in the cytoplasm through the phosphorylation of Serine295 
[126][127]. Whereas the downregulation of PKA, as seen during the transition into the diauxic 
shift, enables Yak1 to enter the nucleus and upregulate its transcriptional targets. These 
include Pop2 of the Ccr-Pop2-Not1-5 complex, which when phosphorylated by Yak1 results in 
G1 arrest and the activation of the zinc-finger transcription factor Msn2, which in combination 
with its paralog Msn4, induces the expression of ~ 200 stress response element-containing 
genes in response to a multitude of environment stimuli, including glucose depletion during 
the diauxic shift (Figure 8) [126][128][129]. Moreover, the protein kinase Rim15 has been 
shown to mediate growth inhibition in the absence of PKA activation. Rim15, a PAS protein 
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kinase family member, positively controls the initiation of the quiescence program and its 
kinase activity is directly inhibited through PKA-mediated phosphorylation [130].  
 
Figure 8. The protein kinase PKA, switches on or off the activities and signals transmitted 
through the Sch9 and TOR pathways.  
Sch9 positively controls the post-diauxic shift (PDS) driven gene expression via Gis1 and Rim15. 
TOR and PKA control the stress response element (STRE) driven gene expression via Msn2/4 
and Rim15. GTF stands for general transcription complex. Arrows and bars refer to positive 
and negative interactions. Dashed lines refer to potential cross-regulation. 
 
Lastly, PKA inhibits autophagy through the phosphorylation of the protein kinase Atg1 and its 
regulator Atg13. This inhibits the recruitment of the Atg1–Atg13 complex to the pre-





1.10.3 Regulation of metabolism 
 
Many of the physiological changes that occur as cells approach and/or transition into the 
diauxic shift phase of growth are under the post-transcriptional control of PKA. PKA 
antagonizes the metabolic transition from glycolysis to gluconeogenesis as well as the 
induction of trehalose and glycogen synthesis. This is achieved via the activation of the 
glycolytic 6-phosphofructo-2-kinase, Pfk2 and pyruvate kinases Pyk1/2 [131][132], the 
inhibition of the gluconeogenic fructose 1,6-bisphosphatase, Fpb1 [133], the activation of the 
glycogen phosphorylase Gph1 [134] and inhibition of the glycogen synthase Gsy2 [135].  
1.11 Ras and the Cell Cycle in S. cerevisiae 
 
Ras activation is dependent on the presence of growth factors and pro-survival signals, 
specifically growth factors in the case of human Ras and glucose in the case of yeast Ras 
[136][137]. Ras stimulates cell cycle progression which is associated with an increase in cell 
size and protein synthesis in yeast [138][139][140].  
The RAS/cAMP/PKA pathway in yeast regulates several essential intracellular processes 
including the cell cycle, ribosome production, cells size and mass, and growth rate. These 
processes are strictly interdependent [109]. The specific growth rate of the cell is determined 
by the rate of mass accumulation, which in turn depends on nutrient availability, with cell 
cycle progression and cell size both dependent on growth rate and mass accumulation 
[141][142][143][144]. The modulation of the cell cycle is also under the influence of the 
RAS/cAMP/PKA pathway. Ras activation can lead to a change in the expression of cyclins (Clns) 
[145], which form complexes with cyclin-dependent kinases (Cdks) to promote entry into S 
phase of the cell cycle. Ras activation leads to the suppression of CLN1 and CLN2 expression 
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but not CLN3 [145][146]. Moreover, PKA has been shown to directly phosphorylate Whi3, a 
negative regulator of G1 cyclins leading to progression into S Phase of the cell cycle [147].   
Ras signalling has also been identified as a regulator of DNA damage checkpoint recovery. The 
DNA damage checkpoint functions to maintain genome stability by arresting the cell cycle and 
promoting DNA repair. Upon the deletion of ira1/2, PKA regulatory elements are hyper 
activated and after checkpoint downregulation cells undergo a permanent mitotic arrest 
[148].   
1.12 Ras and its involvement in Cell fate in Yeast  
 
1.12.1 The involvement of the Ras/cAMP/PKA signalling network in regulating 
quiescence   
 
Cells spend a large proportion of their life in a temporary non-proliferating cellular state, 
known as quiescence. Establishing quiescence and maintaining the capacity to re-enter the 
proliferation cycle are critical for cell survival and must be closely regulated to avoid 
pathological proliferation. Quiescence is linked with a number of phenotypes, including a 
reduced rate of protein synthesis, thermo-resistance, and accumulation of storage molecules 
[149]. Quiescent cells are often considered as G1-arrested cells with only 5-10 % of cells 
entering quiescence from other cell cycles other than G1 [150]. Although, in both yeast and 
mammalian systems, a prolonged G1 arrest does not recapitulate the hallmarks of quiescence 
establishment [151]. Therefore suggesting that quiescent cells are not wholly G1-arrested 
cells, although the molecular mechanisms linking quiescence entry and cell cycle regulation 
are still yet to be elucidated [152].  
In S. cerevisiae, quiescence entry is initiated by nutrient limitation, and is regulated, at least 
in part, by a complex interplay between nutrient-sensitive protein kinases , PKA and Tor [153].  
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Both PKA and TORC1 are positive key regulators of cell growth that participate in the cell's 
decision whether to transition into quiescence. For example, cells with dysregulated, 
enhanced PKA activity, such as the RAS2val19 mutant, characteristically fail to acquire many 
physiological features of the quiescence program as they enter stationary phase growth [154]. 
Whereas cells with absent or reduced PKA activity, induce growth arrest and hold cells in a 
G0-like state [154][147].  
1.12.2 Ras and its role in yeast apoptosis and regulated cell death 
 
The RAS/cAMP/PKA signalling has been shown to be an important regulator of cell death in 
yeast [155][156][157]. An increase in Ras signalling has been correlated with an increase in 
typical apoptotic markers such as phosphatidylerine externalization, increased reactive 
oxygen species (ROS) accumulation and DNA fragmentation [158][159]. There are three 
distinct known stimuli that induce RAS/cAMP/PKA hyper-activation and subsequent cell death 
and these include; changes in actin cytoskeletal dynamics, exposure to ammonium and 
osmotin [158][160][161]. Osmotin is a protein synthesized by plants in response to the 
presence of pathogenic fungi. When in contact with S. cerevisiae, osmotic binds to Pho36 ─ a 
seven transmembrane domain receptor-like polypeptide that regulates lipid and phosphate 
metabolism, resulting in the inappropriate inactivation of Ras signalling leading to the 
induction of regulated cell death [162]. 
An alternate stimulus for Ras-mediated apoptosis in yeast is mediated by the actin 
cytoskeleton. Changes in the actin cytoskeleton caused by either the use of drugs or the 
presence of mutations can lead to the formation of F-actin aggregates, which function as a 
trigger for the constitutive activation of Ras2 and apoptosis [158]. Ammonia was also shown 
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to cause programmed cell death in ageing yeast cultures via the activation of the 
RAS/cAMP/PKA pathway [158][160].  
In S. cerevisiae, the role of mitochondria is fundamental in the regulation of cell death. When 
dysfunctional the mitochondria have been shown to be the main source of ROS accumulation 
in yeast cells [160]. The accumulation of ROS within cells is a central event in the regulation 
of programmed cell death in yeast as the addition of antioxidants to yeast cells was shown to 
supress the apoptotic phenotype [156][163][164]. The RAS/cAMP/PKA pathway has also been 
shown to regulate cell death in acidic environments [164]. Supplementation of acetic acid 
induces intracellular acidification, which leads to RAS/cAMP/PKA activation and subsequent 
cell death [164]. Further supporting the integral role of Ras within the regulation of apoptosis, 
is that the deletion of the RAS genes has been shown to suppress the apoptopic phenotype 
of yeast cells. However, following the suppression the apoptosis, necrosis is induced within 
these cells. Furthermore, the hyper activation of the Ras pathway by the constitutive active 
allele RAS2val19 or by deletion of PDE2 increases apoptotic cell death [164][165].   
1.13 Ras signalling in the regulation of autophagy 
 
Autophagy is the natural, regulated mechanism of the cell that disassembles unnecessary or 
dysfunctional cell components allowing the orderly degradation and recycling of cellular 
products. In S. cerevisiae, both macroautophagy and microautophagy take place (Figure 9).  
Macroautophagy occurs when random cytoplasm and dysfunctional organelles are 
sequestered by an expanding phagophore, resulting in the formation of the autophagosome. 
The autophagosome fuses with the vacuole membrane, discharging the autophagic body into 
the vacuole lumen and sequestered cargo is broken down by vacuolar hydrolases. 
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Microautophagy occurs when cargos are directly taken in by the invagination and exposed to 
vacuolar hydrolases for degradation 
In S. cerevisiae, Ras proteins mediate autophagy through the activity of PKA. Upon activation, 
PKA phosphorylates Rim15 and Msn2/4 which inhibits the translocation of these proteins to 
the nucleus to initiate the transcription of autophagy genes [162][163]. Furthermore, PKA 
activity also inhibits autophagy via the direct inhibition of ATG13, which is integral for 










Figure 9. A schematic illustrating the two predominant types of autophagy in yeast ─ 
macroautophagy and microautophagy.   
Macroautophagy occurs when random cytoplasm and dysfunctional organelles are 
sequestered by an expanding phagophore, resulting in the formation of the autophagosome. 
The autophagosome fuses with the vacuole membrane, discharging the autophagic body into 
the vacuole lumen and sequestered cargo is broken down by vacuolar hydrolases. 
Microautophagy occurs when cargos are directly taken in by the invagination and exposed to 




The RAS/cAMP/PKA pathway has been shown to be highly interconnected with the TOR 
pathways which are also involved in the regulation of autophagy in yeast. Both Tor and Ras 
often control overlapping effectors, including effectors involved in autophagy, resulting in a 
similar cellular response, such as the inhibition of the stress response, cell cycle progression 
and ageing. S. cerevisiae encodes for two Tor kinases, TOR1 and TOR2 respectively, with TOR1 
providing the most significant contribution to autophagy [166]. Upon the presence of 
nitrogen, Tor1 is activated, resulting in the repression of autophagy via the direct inhibition 
of the Atg1 complex and sequestration of the transcription factors Rim15 and Msn2/4 in the 
cytosol [167][168]. During starvation conditions or treatment with rapamycin, TOR is inhibited 
and autophagy is induced [168]. Moreover, the Tor1 complex directly phosphorylates and 
activates Sch9p, which inhibits the autophagy process. The inactivation of both PKA and Sch9p 
is sufficient to initiate autophagy, suggesting that both kinases are synergistically involved in 
the negative regulation of the autophagy process [168][169]. 
1.14 Ras in nutrient acquisition  
 
The availability of key nutrients, such as amino acids, nitrogen compounds, and sugars, dictate 
the developmental programs and growth rates of yeast cells. Several overlapping signalling 
networks including the Ras/cAMP/PKA, AMP-activated kinase, and the TOR1 complex, apprise 
cells on nutrient availability and influence the cells transcriptional, translational, 
posttranslational, and metabolic profiles as well as dictating cell fate. 
Much of the glucose-induced signalling in yeast functions through the Ras/cAMP/PKA 
pathway. 90 % of the transcriptional changes that occur on the addition of glucose to glucose 
depressed cells can be recapitulated by activating this pathway. Conversely, inhibiting this 
pathway concurrent with glucose addition eliminates most of the glucose induced responses. 
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Thus, Ras and the PKA pathway is necessary for the majority of the transcription changes of 
the cell in response to glucose addition [170]. Considering the Ras proteins role in glucose 
signalling it would not be wrong to postulate that Ras may function within the processes 
underpinning other nutritional sensing pathways in yeast, including peptide transport. 
1.14.1 Di/Tri-peptide uptake mechanisms in S. cerevisiae 
 
Peptides are composed of sequences of amino acids and once catabolized provide the 
essential building blocks required for protein synthesis. In addition, certain peptides and 
amino acids can be utilized as a nitrogen source and can act as signalling molecules that alter 
cell behaviour. For example, the branched-chain amino acid leucine, has been shown to 
control TORC1 activity [171][172]. TORC1 senses and responds to nutrients to promote cell 
growth and the inhibition of catabolic processes, such as autophagy. Branched-chain amino 
acids such as leucine function by affecting the ‘nucleotide binding status of the Exit 
from G 0 Complex’ (EGOC) GTPase subunits Gtr1 and Gtr2 in Saccharomyces cerevisiae 
[173][174]. Amongst other TORC1-stimulating amino acids, arginine abundance in 
mammalian cells is proposed to be sensed by the lysosomal transporter SLC38A9 and 
conveyed to mTORC1 via the Rag GTPases [175][176], while glutamine levels appear to be 
transduced to control both yeast and mammalian TORC1 independently of the EGO/Rag 
GTPases [172]. 
In mammals, amino acids exert a major role on the regulation of protein synthesis through 
the control of the kinases mTOR and Gcn2, which have been shown to have opposing effects 
on protein synthesis [172][177]. The regulation of Gcn2 activity by amino acid availability 
relies on the capacity of Gcn2 to sense the increased levels of uncharged tRNAs upon amino 
acid scarcity [177]. Gcn2 is activated during scarcity of an essential amino acids and 
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phosphorylates the α-subunit of eukaryotic initiation factor 2 alpha (eIF2α) [178]. This leads 
to the general inhibition of protein synthesis. 
Due to the multifaceted role of amino acids and peptides in biological systems, it is therefore 
not surprising that microbes have evolved a multitude of mechanisms to facilitate peptide 
and amino acid uptake. The study of such mechanisms has been extensively examined in 
yeast, with amino acid uptake mechanisms presenting high conservation in mammals.  
Saccharomyces cerevisiae has two distinct peptide transport mechanisms, a di-/tripeptide 
(the PTR system) and a tetra-/pentapeptides (the OPT) transport system. The PTR family of 
peptide transporters transport a number of substrates, including amino acids, nitrates and 
di/tri-peptides [179]. PTR2 encodes an integral membrane protein (Ptr2p) involved in the 
physical translocation of peptides across the plasma membrane. 
PTR2 encodes an integral membrane protein of 601 amino acids containing 12 membrane-
spanning domains which transport substrates by the means of proton-motive force [180]. The 
transporter is specific for di-/tripeptides, with a preference for peptides containing 
hydrophobic amino acids. In S. cerevisiae the regulation of PTR2 expression is strongly 
affected by the composition of the extracellular environment. In the absence of the preferred 
nitrogen sources PTR2 expression is induced [181][182].The import of di/tripeptides 
composed of basic or bulky hydrophobic N-terminal residues increases PTR2 expression via 
reducing cellular levels of Cup9p, the homeodomain-containing transcriptional repressor of 
PTR2. Specific di/tri-peptides function as both as ligands and regulators of the E3 ubiquitin 
ligase Ubr1p. Ubr1p mediates Cup9p degradation system that is governed by the identity of 
N-terminal amino acids [183][184]. Most di/tripeptides are too small to be degraded by the 
proteasome and are assimilated as nutrients by intracellular peptidases. However, 
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di/tripeptides with basic (Type 1: His, Lys, or Arg) and bulky (Type 2: Ile, Trp, Leu, Tyr, or Phe) 
N-terminal residues can compete with larger protein substrates and bind at the Type 1 and 
Type 2 Ubr1p substrate-binding sites. Once bound, Ubr1p-mediated degradation of Cup9p is 
allosterically activated via the release of the Ubr1p auto inhibitory domain, revealing a 
substrate-binding domain that binds an internal degron in Cup9p [185]. Relief of Cup9p 
repression of PTR2 results in enhanced PTR2 expression. A positive regulatory feedback loop 
is created where di/tripeptide uptake perpetuates Ubr1p-mediated Cup9p degradation, 
upregulating PTR2 expression and thus increased di/tripeptide uptake. 
Although Ptr2p is the major transporter of di/tripeptides in S. cerevisiae, di/tripeptides can 
also be imported with a low efficacy by Dal5, whose primary function is the import of nitrogen 
sources, such as allantoate and ureidosuccinate [186]. As aforementioned, the peptide 
transporters Opt1 and Opt2, which have partially overlapping functions, import peptides of 
4–5 residues. In addition, Opt1 is a high affinity importer of glutathione, a “noncanonical” 
tripeptide [187]. In the same way as the Ptr2 transporter of di/tripeptides, the expression of 
OTP2 is down-regulated by Cup9p, whereas the expression of OPT1 is independent of Cup9p 
[187]. In addition to PTR2 and OPT2, the N-end rule pathway also controls the expression of 
DAL5, but in a manner contrary to that of the other two transporters: whereas Cup9p is a 
transcriptional repressor of PTR2 and OPT2, Cup9p up-regulates the expression 




1.15 Ras signalling in human cells  
 
Human Ras proteins transduce pro-survival signals from the extracellular space to the 
intracellular compartment via tyrosine kinase receptors (TKRs). Upon ligand binding, the 
dimerization of the receptors triggers a conformational change that activates the catalytic 
tyrosine kinase domain, which enables the autophosphorylation of the intracellular carboxyl-
terminal domain and therefore induces its activation [188][189]. The phosphorylated domain 
of the TKR recruits GEFs, activating Ras, allowing it to signal downstream [190]. Active Ras 
proteins can activate at least 20 different effectors, including the RAF (rapidly-accelerate 
fibrosarcoma) kinases, phosphatidylinositol-3-kinase (PI3K) and RAL guanine nucleotide-
dissociation stimulator (RALGDS) (Figure 10). Other effectors associated with Ras protein 
activation include RIN1, T-lymphoma invasion and metastasis-inducing 1 (Tiam 1), Af6, Nore1, 
PLCS and PKC [191][192]. 
Activated RAF kinases phosphorylate and activate the MAPK/ERK kinase. Signal transduction 
along the Raf/MEK/ERK pathway starts with the activation of Ras by TKR’s, G-protein-coupled 
receptors and/or intergrins (Figure 10) [193]. These membrane proteins form large signalling 
complexes upon activation and recruit and activate Ras proteins by promoting the exchange 
of Ras-bound GDP with GTP. The process is regulated by the interaction of Ras with GDP/GTP-
exchange factors, such as SOS (son of sevenless). After the small G-proteins recruit the MKKKs 
c-Raf (and, if present, A- and B-Raf) to the plasma membrane, where RAF is activating causing 
phosphorylation, changes in its conformation and protein interactions occur [193] . The MEK-
1/2 serine residues are phosphorylated by RAF leading to MEK-1/2 activation. ERK-1/2 is then 
phosphorylated by MEK-1/2 at threonine and tyrosine residues in the TEY motif of the 
activation loop. This dual phosphorylation event is linked with ERK-1/2 activity and can be 
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used to measure indirect quantification of the serine/threonine kinase (ERK) activation [194]. 
Upon activation, ERK can phosphorylate over 80 different substrates in the cytoplasm and 
nucleus. 
In the phosphatidylinositol-3-kinase PI3K pathway, activated PI3K catalyses the production of 
Pip3 (phosphatidylinositol-3,4-triphosphate) by the phosphorylation of Pip2 
(phosphatidylinositol-4,5-diphosphate). Pip3 activates the phosphatidylinositol dependent 
kinase 1 (PDK1), resulting in the activation and recruitment of AKT to the membrane [195]. 
The primary downstream effecter of activated AKT is mTOR (the mammalian target of 
rapamycin), which is a serine/threonine kinase. mTOR can form two distinct complexes, 
depending on the proteins it interacts with. The mTOR complex (mTORC1) primarily functions 
to promote the transcription of genes associated with energy metabolism, cell cycle 
progression and cell proliferation.  
The mTOR complex 2 (mTORC2) mainly functions to phosphorylate AKT which results in cell 
survival and proliferation. Furthermore, AKT phosphorylation promotes telomerase activity, 
inhibition of apoptosis and blocking the release of cytochrome C from the mitochondria, 
downregulation of pro-apoptopic factos and pro-caspase 9, and regulates modulators of 
angiogenesis via activation of nitric oxide synthases [196][137][195].  
Ras stimulates the RAL (RAS-like), GTPases, promoting the activation of phospholipase DI 
(PLD) and CDC42/RAC-GAP RAL binding protein 1 (RALBP1). These, among other pro-survival  
59 
 
functions, promote the progression of the cell cycle, inhibiting transcription factors involved 



















Figure 10. Schematic representation of the multiple effectors activated by human Ras 
proteins and the different impact these interactions have on cell fate.  
 
1.16 The use of S. cerevisiae for the study of human Ras proteins 
 
Human Ras proteins play a fundamental role in tumorigenesis and exhibit sequence homology 
with yeast Ras homologous [198] [199]. As such efforts have been made to use S. cerevisiae 
to investigate the molecular mechanisms of Ras proteins with the aim of understanding their 
roles and regulation in higher eukaryotes. The use of S. cerevisiae as a model to study the role 
of Ras proteins has been important for understanding the post-translational processes 
required for the translocation of Ras proteins to the plasma membrane [200]. Notably, the 
use of the S. cerevisiae mutant, Δdpr1, revealed that the acylation was not the first 
60 
 
translational modification in the processing of Ras proteins [201]. Furthermore, the first Ras 
effector and first guanine-nucleotide exchange factor (GEF), adenylate cyclase and Cdc25, 
were identified in yeast [30] [78]. Such discoveries, particularly that of Cdc25, facilitated the 
identification of analogous proteins in humans [78]. In addition to the discovery of GEF 
proteins, yeast has been valuable for enhancing our understanding of the GTPase activating 
proteins (GAPs) through the discovery of IRA1 and IRA2. The functions of the GAP-coding NF1 
gene, which when mutated is responsible for neurofibromatosis type 1, were uncovered 
thanks to the similarity with the IRA genes of S. cerevisiae [78]. Moreover, the expression of 
the NF1 gene in yeast suppressed the phenotypes associated with the deletion of IRA genes, 
such as heat shock sensitivity, demonstrating that the mammalian and yeast GAPs are 
interchangeable and therefor highlighting the similarity between yeast and mammalian Ras 
protein activation [38]. Such examples highlight the importance of the use of S. cerevisiae as 
a model organism in modern biology. 
1.17 Aims of this study 
 
The localisation and signalling of Ras on the plasma membrane has been extensively studied. 
It has been shown that Ras undergoes a series of posttranslational modifications that dictate 
its subcellular localisation. Evidence exists to suggest that Ras proteins can undergo 
phosphorylation events which regulate its activity. Surprisingly, the phosphorylation of Ras2p 
in S. cerevisiae has not been studied regarding its regulation of intracellular localisation, 
despite significant evidence existing linking Ras phosphorylation to its localisation in humans. 
This study aims to further investigate whether Ras2p phosphorylation provides a mechanism 




In the laboratory of Dr Campbell Gourlay, previous bioinformatics investigations identified 
potential kinase and phosphatase enzymes that may influence Ras2 protein phosphorylation. 
This data was generated using the PhosphoPep (v2.0) database, which provides information 
sourced from tandem mass spectrometry experiments regarding phosphopeptides and 
phosphoproteins. The PhosphoPep database proposed twelve phosphatase and kinase 
enzymes that effect Ras2p phosphorylation and identified several serine residues that may 
be phosphorylated (Table 1 and Figure 11). 
Table 1. Phosphatase and kinase enzymes predicted by the PhosphoPep database to effect 
Ras2p phosphorylation.  
Gene 
deletion 
Protein function Ras2 phospho-peptide 






Protein kinase, functions in cell 












Mitochondrial protein kinase, 
functions in the negative 







phosphatase, involved in 





Protein kinase, involved in 
chromosome segregation, 





Cycline dependant protein 
kinase, involved in 
phosphorylation of RNA 







Phosphatase, required for golgi 





Protein kinase; phosphorylates 
flippase activator Fpk1p, 








Catalytic subunit of C terminal 






Cycline dependant protein 
kinase, involved in 
phosphorylation of RNA 






involved in cellular response to 
nutrient levels and 






Plasma membrane phosphatase 













Figure 11. A schematic of the Ras2 protein sequence indicating the location of the 
phosphorylated serine residues.  
Residues circled are those identified to be phosphorylated by the PhosphoPep database. 
Previous studies from the laboratory of Dr Campbell Gourlay reported that the deletion of 
either Δsit4 or Δssn3 led to significant changes in GFP-Ras2 protein localisation during both 
logarithmic and stationary phases of growth. Interestingly, the phosphorylation sites that 
were predicted to be affected upon the deletion of either SSN3 or SIT4 were found to be 
identical and focussed upon the serine residue at position 225 of Ras2p. Two-dimensional 
electrophoresis was used to identify whether the deletion of either SIT4 or SSN3 resulted in 
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changes to Ras2 protein phosphorylation. Two-dimensional electrophoresis of Δsit4, Δssn3 
and wild type cells identified a putative Ras2 phosphorylation event occurring in both Δsit4 
and Δssn3 cells that was not present in wild type cells. This was represented by the 
appearance of a negatively charged spot in Δsit4 and Δssn3 cells which disappeared following 
the treatment with alkaline phosphatase. The negatively charged spot occurring in a similar 
position in both Δsit4 and Δssn3 cells was hypothesized to be the phosphorylation of serine225 
of the Ras2p. 
In the present study, we therefor sought to investigate whether modification of Serine225 led 
to any changes in Ras2 protein localisation or activity within the cell and whether this was 






 Materials and Methods   
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2.1 Growth conditions and media for the culture of Saccharomyces Cerevisiae 
and Escherichia coli  
 
A Prestige Medical bench-top autoclave was used to sterilise all media. Media was autoclaved 
at 121 °C, 15 lb/sq.in for 11 mins. All liquid cultures of Saccharomyces cerevisiae were 
incubated at 30 °C with constant rotation at 200 rpm. All liquid cultures of Escherichia coli 
were incubated at 37 °C with constant rotation at 180 rpm. For solid medium 2 % w/v 
granulated agar (Oxoid technical agar No. 3) was added prior to autoclaving. 
2.1.1 Water used in study 
 
Pure deionised water (dH20) was produced by Thermo Scientific Barnstead NanoPure 
Diamond water system. dH20 was then further sterilized via autoclaving. 
2.1.2 Yeast extract, peptone, dextrose (YPD) growth media 
 
Ingredients included 2 % w/v glucose (Fisher), 1 % w/v yeast extract (Oxoid) and 2 % w/v 
bactopeptone (Difco).  
2.1.3 Synthetic complete (SC) drop-out medium 
 
This media was prepared as follows; 2 % w/v glucose (Fisher), 0.77 % Yeast Nitrogen Base 
without amino acids (Kaiser, Formedium), yeast synthetic complete drop-out media 
supplement (Formedium).  The source of nitrogen for yeast cells grown in this media is 
ammonium sulphate. 
Upon the transformation of cells with plasmid DNA, successful transformants were selected 
for using auxotrophic selection media through the addition of the appropriate Yeast Synthetic 




Table 2. Percentage of auxotrophic selection drop-out supplement added to media  
Amino acid drop-out Required % 
Uracil 0.19 
Leucine 0.164 
Uracil and Leucine 0.174 
 
 
2.1.4 Nitrogen Starvation Media (NS) 
 
The media was prepared as follows; 2 % glucose (Fisher), 0.675 % Yeast Nitrogen base without 
amino acids and ammonium sulphate (Difco), 0.193 % yeast synthetic dropout Kaiser mixture 
without Uracil (Formedium). 
2.1.5 Yeast extract and Tryptone (YT) Growth Media 
 
YT growth media was prepared as follows; 0.1 % w/v yeast extract (Oxoid), 1 % w/v analytical 
grade sodium chloride (Fisher) and 1 % w/v bacto-tryptone (Difco). 
For the selection of successfully transformed E. coli containing the plasmid of interest, 
antibiotic resistance markers were used. Ampicillin (Sigma-Aldrich) was added to the growth 
medium after autoclaving to select for successfully transformed E. coli containing plasmids 
with the AmpR gene integrated. Ampicillin was added to a final concentration of 100 μg/ml, 
from a 100 mg/ml stock solution in sterile deionised water. To select for E. coli colonies 
containing the gene for kanamycin resistance, kanamycin (Sigma-Aldrich) was supplemented 
to the growth media after autoclaving. Kanamycin was added to a final concentration of 50 




2.2 Saccharomyces cerevisiae strains used in this study 
 
 Table 3. The Saccharomyces cerevisiae strains used in this study  
Strain Genotype Source/strain ID 
BY4741 MATa hisΔ1 leu2Δ0 met15Δ0 ura3Δ0  CGY424 
BY4741 Δcup9 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
Δcup9::KANMX  




MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
Δubr1::KANMX  
KO collection*  
 
BY4741 Δptr2 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
Δptr2::KANMX  
KO collection*  
 
BY4741 Δras2 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
Δras2::KANMX  
KO collection*  
 
BY4741 Δpde2 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
Δpde2::KANMX  
KO collection*  
 
KAY836 – wt  MATa ura 3-52 leu 2 his4-539  CGY370 
KAY23- Δras2   Δras2::leu2 MATa ura 3-52 leu2 his4-
539  
CGY371 
BY4741 + Δcox4 MATa his3Δ1 leu2Δ met15Δ ura3Δ 
Δcox4::HIS 
CGY638 




*Yeast MATa Collection was purchased from Open Biosystems and was produced by the 
EUROpean Saccharomyces Cerevisiae Archive for Functional analysis (EUROSCARF).  
2.3 Escherichia coli strains used in this studyDH5α:  
 
Competent E. coli cells were used in this study, the genotype of these cells:  F- endA1 glnV44 




DB3.1: Competent E. coli cells were used in this study, the genotype of these cells: F- gyrA462 
endA1 glnV44 Δ(sr1-recA) mcrB mrr hsdS20(rB-, mB-) ara14 galK2 lacY1 proA2 rpsL20(Smr) 
xyl5 Δleu mtl1.  
 TOP10: Competent E. coli cells were used in this study, the genotype of these cells: F- mcrA 
Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacΧ74 recA1 araD139 Δ(araleu)7697 galU galK rpsL 
(StrR) endA1 nupG.  
 Strataclone Solopack: Competent E. coli cells were used in this study, supplied by Agilent 
technologies (Product reference: 200184), the genotype is not published. 
2.4 DNA Methods 
 
2.4.1 Plasmids used in the study 
 
Table 4. Plasmids used in the study 
Strain Description Selective marker Source 
pDONR221 Gateway Entry Vector N/A Addgene 
pAG426GPD-EGFPccdB Gateway Destination 
Vector 
URA3  Addgene 
pAG416GPD-EGFPccdB Gateway Destination 
Vector 
URA3 Addgene 
pCG347- Active GFP-Ras2 PYX212 RBD x3GFP 
URA3- TPI 
URA3 Leadsham 
pCG46 pYX142-mtGFP LEU2 (Westermann & Neupert 
2000) 
pCG381 Gateway entry vector 
PDONR221 RAS2 KANR 
URA3 Addgene 
pCG502 PDE2 LEU2 CWG plasmid collection 
pCG557 Gateway Destination 
Vector 1H2 416-GPD-
ccdB- AMPR 
URA3 CWG plasmid collection 
pCG558 Gateway Destination 
Vector 
1H3 426-GPD-ccdB - 
AMPR  
URA3 CWG plasmid collection 
pCG565 Gateway Expression 
Clone Ras2S225E 416-
GPD-EGFP- AMPR 
URA3 CWG plasmid collection 
pCG566 Gateway Expression 
Clone  





pCG571 Gateway Expression 
Clone Ras2S225E 426-
GPD-EGFPAMPR 
URA3 CWG plasmid collection 
pCG572 Gateway Expression 
Clone Ras2S225A 426-
GPD-EGFP AMPR  
URA3 CWG plasmid collection 
pCG582 RAS2 in PCG557 AMPR URA3 This study 
pCG583 RAS2 in PCG558 AMPR URA3 This study 
pCG586 Ras2S225E in PCG558 
AMPR  
URA3 This study 
pCG587 Ras2S225A in PCG558 
AMPR 
URA3 This Study 
pCG588 Ras2S225E in PCG557 
AMPR  
URA3 This Study 
pCG589 Ras2S225A in PCG558 
AMPR  
URA3 This Study 
PCG593 N-RasS173A in PCG558 
AMPR 
URA3 This study 
PCG594 N-RasS173E  in PCG558 
AMPR 
URA3 This study 
PCG595 N-Ras in PCG558 AMPR URA3 This Study 
PCG597 Gateway Expression 
Vector N-Ras 416-GPD-
EGFP- AMPR   
URA3 This Study 
PCG598 Gateway Expression 
Vector N-RasS173A 416-
GPD-EGFP- AMPR 
URA3 This Study 
PCG599 Gateway Expression 
Vector N-RasS173E 416-
GPD-EGFP- AMPR 
URA3 This Study 
PCG600 Gateway Expression 
Vector N-Ras 426-GPD-
EGFP AMP 
URA3 This Study 
PCG601 Gateway Expression 
Vector N-RasS173A 426-
GPD-EGFP AMPR 
URA3 This Study 
PCG602 Gateway Expression 
Vector N-RasS173E 426-
GPD-EGFP AMPR 
URA3 This Study 
PCG636 Low copy plasmid 
expressing GFP-ATG8 
URA3 Professor Frank Madeo, 
































Figure 12. Maps of the plasmids used in the Gateway cloning reaction. 
 A) pAG416GPDccdB destination vector. B) pAG426GPD destination vector. C) pAG426GPD-
ccdB-EGFP destination vector. D) pAG416GPD-ccdB-EGFP destination vector.  
 
2.5 Transformation of plasmid DNA into S. cerevisiae and Escherichia coli 
 
2.5.1 Transformation of S. cerevisiae using the lithium acetate method 
 
A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated 
into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm.  A 1 
ml volume of fresh overnight culture was transferred to a 1.5 ml microcentrifuge tube and 
harvested in a bench-top centrifuge at 3000 rpm for 4 min at room temperature. The 
supernatant was discarded, and the pellet resuspended in 1 ml of 1x TE buffer at pH 8.0. The 
cells were pelleted as previously described and resuspended in 1 ml of 1M lithium acetate 
(LiAc) in TE at pH 8. Cells were pelleted again and resuspended in 0.1 ml of 0.1 M lithium 
acetate (LiAc) in TE at pH 8. 15 μl of single stranded carrier DNA (boiled herring sperm DNA, 
10 mg/ml) was added to the suspension and mixed. 2μl of plasmid DNA at 100 ng/μl was 
added to the mixture and the mixture vortexed briefly. 700 μl of 40 % polyethylene glycol 
(PEG 4000 [Sigma]) in 0.1 M LiAc in TE was added and the mixture vortexed briefly. The 
microcentrifuge tube was then incubated at room temperature for 90 mins with rotation. A 
42 °C heat shock for 20 mins followed. Cells were pelleted by centrifugation as previously 
described and resuspended in 200 μl of sterile deionised water. The cell suspension was 
spread onto agar plates with the appropriate selective media and incubated at 30 °C for at 




2.5.2 Transformation of S. cerevisiae using the lithium acetate method without 
heat shock 
 
For some strains that displayed sensitivity to heat shock an alternative protocol was used. In 
these cases, a sterile inoculation loop was used to pick a fresh colony of yeast. The colony was 
inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 
rpm.  A 2 ml volume of fresh overnight culture was transferred to a 1.5 ml microcentrifuge 
tube and harvested in a bench-top centrifuge at 3000 rpm for 4 mins at room temperature. 
The supernatant was removed, and the pellet was resuspended, using a bench top vortex, in 
the reagent cocktail listed in Table 2.5. The microcentrifuge tube was incubated at room 
temperature overnight. The supernatant was removed, and the pellet was resuspended in 
200 μl of sterile water and plated on the appropriate media. Plates were incubated at 30 °C 
for at least 2 days to allow colonies to grow. 
Table 5. Yeast transformation reagents for the heat sensitive transformation protocol 
Transformation reagents 
37 % polyethylene glycol (PEG)-4000 from a 50 % w/v stock 
0.1 M LiAc from a 1 M stock 
0.1mg ssDNA from a 10 mg/ml stock  
0.11 M 2-Mercaptoethnaol (Sigma M6250) 
0.4 – 1 μg plasmid DNA 






2.5.3 Transformation of Escherichia coli with plasmid DNA 
 
A 50 μl aliquot of competent cell (for preparation protocol refer to Materials and Methods, 
Section 2.6) suspension was thawed on ice. A volume of plasmid DNA at a concentration of at 
least 20 ng/ml was added to the solution of competent cells and mixed gently. The suspension 
was incubated on ice for 1 hour and then incubated at 42 °C for 90 secs. 200 μl of YT media 
was added and the suspension was incubated at 37 °C for 30 mins. The suspension was then 
spread onto YT agar containing the appropriate antibiotic to select for transformants and 
incubated at 37 °C overnight. Plates were checked for colony growth the following morning. 
2.6 Escherichia coli competent cell preparation 
 
 E. coli cells (DH5α) were grown overnight in 10 ml of YT at 37 °C with constant shaking at 180 
rpm. The overnight culture was subcultured and diluted in 28 ml YT media to 0.2 OD600. The 
culture was incubated at 37 °C with constant shaking at 180 rpm until the culture reached an 
OD600 of ~0.7. The time at which the culture would reach the required OD600 was calculated 
using the following formula.  
[(Log (OD600 wanted) – Log (OD600 read))/Log2] x doubling time = time to required OD600 
 A 3.75 ml aliquot of pre-heated glycerol (35 °C) was slowly added to the culture. The cell 
suspension was then incubated on ice for 10 mins. Cells were then harvested by 
centrifugation at 4000 rpm for 10 mins at 4 °C. Harvested cells were then resuspended in 28 
ml of ice cold MgCl2/ glycerol solution (0.1 M MgCl2, 15 % glycerol [v/v]). After resuspension, 
cells were harvested by centrifugation at 3800 rpm for 8 mins at 4 °C and resuspended in 6.25 
ml of iced T-salts solution (0.0075 M CaCl2, 0.006 M MgCl2, 15 % glycerol [v/v]). A 20-minute 
incubation period followed. Cells were harvested via centrifugation at 3600 rpm for 6 mins 
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and resuspended in 1.35 ml of T-salts solution. The cell suspension was then aliquot into pre-
chilled microcentrifuge tubes and stored immediately at -80 °C. Competent cells were ready 
for use after 24 hours. 
2.7 Molecular Biology methods 
 
2.7.1 Plasmid DNA purification from Escherichia coli (mini prep)  
 
A sterile inoculation loop was used to pick a fresh colony of E. coli which contained the plasmid 
of interest. The colony was inoculated into 5 ml of YT media supplemented with the 
appropriate antibiotic and grown overnight at 37 °C with constant rotation at 180 rpm. Cells 
were harvested in a benchtop centrifuge at 8000 rpm for 3 mins at room temperature and 
the supernatant removed. The plasmid DNA of interest was extracted from the cell pellet 
using a Qiagen QIAprep Spin Miniprep Kit according to the manufactures’ instructions.   
2.7.2 Plasmid purification from S. cerevisiae 
 
To isolate plasmid DNA from a yeast strain, the Invitrogen ChargeSwitch plasmid yeast mini 
kit was used. A sterile inoculation loop was used to pick a fresh colony of yeast containing the 
plasmid of interest. The colony was inoculated into 5 ml of appropriate medium and grown 
overnight at 30 °C with shaking at 200 rpm. A 1 ml aliquot of the overnight culture was taken 
and placed in a sterile 1.5 ml Eppendorf. Cells were then spheroplasted and lysed. The lysate 
is extracted and placed in a fresh 1.5 ml Eppendorf in a low pH buffer and ChargeSwitch beads 
are added. The ChargeSwitch beads bind DNA of specific sizes in a low pH environment. The 
sample is then placed into a magnetic platform (MagnaRack). The beads and DNA are retained 
in the Eppendorf tubes containing them, and the remaining lysate is washed through and 
discarded. Following the wash phases, the DNA is eluted by the addition of a low salt buffer. 
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The addition of the low salt buffer raises the pH in solution and neutralizes the surface charge 
on the beads, causing the DNA to disassociate from the beads. The concentration of plasmid 
DNA isolated from yeast using this methodology is relatively low for any future processing or 
downstream applications. Therefore, the extracted plasmid DNA was then amplified by 
transforming into bacterial cells (Materials and Methods, Section 2.5.3).  
2.7.3 Yeast genomic DNA extraction 
 
Following the yeast transformation protocol described in Materials and Methods, Section 
2.5.1, individual colonies were re-streaked onto separate plates containing the appropriate 
media and labelled as individual clones. A sterile inoculation loop was used to pick a fresh 
colony of the clone of interest. The colony was inoculated into 5 ml of appropriate medium 
and grown overnight at 30 °C with shaking at 180 rpm. 1 ml of the overnight culture was 
aliquot into a fresh 1.5 ml Eppendorf tube and cells were harvested using a benchtop 
centrifuge spinning at 13 000 rpm for 1 minute. The supernatant was discarded, and cells 
were washed with 1 ml of sterile de-ionised water using the same centrifuge settings as 
previously described. The supernatant was discarded, and cells were re-suspended in 500 μl 
of lysis buffer (100mM Tris pH 8, 50 mM EDTA, 1% SDS). 50 mg of acid washed glass beads 
were added to each sample, bringing the sample volume up to 1.25 ml. Samples were then 
vortexed for 1 minute to lyse the cells. To separate the lysed cell debris from the glass beads; 
a heated needle was inserted into the bottom of the Eppendorf, the existing Eppendorf was 
placed into a fresh second Eppendorf and centrifuged at 2 000 rpm for 5 mins. To each sample, 
275 μl of 7M ammonium acetate (pH 7) was added. A 5-minute incubation period at 65 °C, 
then a further 5-minute incubation on ice followed. To each sample, 500 μl of chloroform was 
added, followed by a brief vortex stage, and then centrifuged at 13 000 rpm for 2 mins. The 
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supernatant was extracted and moved to a fresh Eppendorf tube and 1 ml isopropanol was 
added and briefly mixed by inversion and incubated at room temperature for 5 mins. The 
sample was then centrifuged at 13 000 rpm for 5 mins and the isopropanol facilitates the 
precipitation of genomic DNA out of solution. The supernatant was discarded, and the pellet 
was washed in 70 % ethanol. The ethanol was removed, and the pellet was air dried and 
suspended in 50 μl of sterile deionised water.    
2.7.4 Whole cell RNA extraction from S. cerevisiae  
 
The extraction of RNA from yeast cells was performed using the E.Z.N.A. Yeast RNA Kit Spin 
protocol. A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was 
inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 
rpm. The cells were then subcultured and diluted to a calculated OD600 of 0.1 and grown for 
24 hours. 5x107 yeast cells were harvested from the overnight culture in a 15 ml Falcon tube 
via centrifugation at 4 °C for 5 mins at 1000 g. The supernatant was discarded, and cells were 
resuspended in 480 microliters of SE Buffer/lyticase solution. The pellet was resuspended 
using a vortex for 1 minute. The cells were then incubated at 30 °C for 1 hour to ensure 
complete lyses of cells. The spheroplasts were then pelleted via centrifugation at 400 g for 5 
mins at room temperature. The supernatant was carefully removed and 350 μl of YRL buffer 
and 50 mg of glass beads was added to the pellet. Using a vortex at 13 000 rpm for 5 mins, 
the suspension was mixed to lyse and homogenize the sample. The homogenised suspension 
was then centrifuged at 13,000 g for 3 mins at room temperature. The supernatant was 
carefully removed and transferred into a new Eppendorf tube. An equal volume of 70 % 
ethanol to the lysate was added and mixed thoroughly using a vortex for 15 secs. The entire 
sample, which was around 700 μl, was added to a Hibind RNA mini column assembled in a 2 
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ml Eppendorf. The sample was then centrifuge at 10 000 g for 30 secs at room temperature 
and the flow through was discarded. 350 μl of RNA wash buffer 1 was added to the column 
and the sample was centrifuged as above.  
A DNA denaturing phase followed to ensure denaturing of any residual DNA in the sample. 75 
μl of the DNase1digestion reaction mixture was added onto the surface of the HiBind RNA 
membrane in each column and incubated at room temperature for 15 mins. 350 μl of the RNA 
Wash Buffer 1 was added onto the surface of the HiBind RNA membrane and allowed to soak 
for at least 5 mins. The sample was centrifuged at 10 000 g for 15 secs and the flow through 
was discarded. 500 μl of RNA Wash Buffer II was added to the column and centrifuged and 
flow through discarded, as in the preceding step.  Using the same collection tube, the spin 
cartridge was centrifuged at 10 000 g for 1 minute to dry the HiBind matrix. The column was 
transferred to a sterile RNase free 1.5 ml Eppendorf and the RNA was eluted with 50 μl of 
DEPC water. Samples were then stored at -80 °C until required for downstream applications.  
2.7.5 Illumina library preparation and sequencing  
 
Before library preparation, the quality and quantification of RNA samples were evaluated with 
TapeStation (Agilent) and Qubit (Thermal Fisher) at the Centre of Genome-Enabled Biology 
(Aberdeen) by Dr Jin Pu. The samples with the minimum RIN of 8.0 was proceeded.  The input 
of RNA was based on the specifically measured RNA concentration by Qubit.  The mRNA-Seq 
libraries were prepared using TruSq Sample Preparation Kit (Illumina) according to the 
manufacturer’s instructions. Briefly, Poly-A RNA were purified from 500 ng of total RNA with 
1ul (1:100) ERCC spike (Thermal Fisher) as an internal control using RNA purification oligo(dT) 
beads, fragmented and retrotranscribed using random primers. Complementary-DNAs were 
end-repaired, and 3-adenylated, indexed adapters were then ligated. 15 cycles of PCR 
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amplification were performed, and the PCR products were cleaned up with AMPure beads 
(Beckman Coulter).  Libraries were validated for quality on Agilent DNA1000 Kit and quantified 
with the qPCR NGS Library Quantification kit (Roche). The final libraries were equimolar 
pooling and sequenced using the High Output 1X75 kit on the Illumina NextSeq 500 platform 
producing 75 bp single end reads. For each library, a depth 20-30 M reads were generated. 
The quality of sequencing was analysed by FastQC and MultiQC.  
2.7.6 Analysis of RNA-Seq data 
 
The analysis of RNA–Seq samples was performed using the Galaxy web platform 
(www.usegalaxy.org) [202].  The quality of the RNA sequencing reads was checked using 
FastQC v0.11.5 [203] with default settings. Low quality ends (Phred score < 20) and any 
adaptor sequences were trimmed using TrimGalore! v0.4.3 [204]. Reads which became 
shorter than 40 bp after trimming were not progressed for further analysis. After trimming, 
the quality was checked again using FastQC v0.11.5 [203] to ensure correct trimming. There 
were no Poly-A reads (more than 90 % of the bases equal A), low quality reads (more than 50 
% of the bases with a Phred score < 25) or ambiguous reads (containing N). After processing, 
the mean Phred score per read was 37. Processed reads were aligned with the reference S. 
cerevisiae genome S288C version R64-2-1_20150113 (SacCer3) using HISAT2 v2.1.0 [205] with 
single-end reads and reverse strand settings, remainder of settings were set to default. After 
alignment, the number of mapped reads which overlapped CDS features in the genome (using 
S. cerevisiae genome S288C version R64-2-1_20150113 (SacCer3) were determined using 
featureCounts plug-in v1.6.3 with default settings [206]. Reads aligning to multiple positions 
or overlapping more than one gene were discarded, counting only reads mapping 
unambiguously to a single gene. Differential gene expression analysis between conditions was 
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performed using DESeq2 v1.18.1 [207] with default settings. To identify the cellular pathways 
which differentially expressed genes are within we conducted Gene Set Enrichment Analysis 
(GSEA; Broad Institute) [208]. To conduct a GSEA analysis, a list of significantly (q ≤ 0.05) 
differentially expressed genes, ranked from the most upregulated to the most downregulated 
were uploaded into the GSEA database and compared to a gene set data base (S288C version 
R64-2-1_20150113_features gtf annotation file). 
2.7.7 Quantification of nucleic acid samples 
 
The concentration of DNA in samples was obtained using either a Thermo Scientific 
Nanodrop-1000, Biophotometer (Eppendorf) or a Spectrostar Nano UV/Vis spectrum 
absorbance microplate reader (BMG Labtech). To determine the DNA/RNA concentration 
from the OD260 reading from the Biophotometer, the following equation was used: DNA/RNA 
concentration (μg/mL) = OD260/OD280 ratio dilution factor. No dilution of sample was required 
for use of the Nanodrop-1000 and readings were obtained from an analysis of a 1μl aliquot 
sample.  
2.7.8 Restriction enzyme digest of DNA 
 
Enzymatic scission of DNA at specific sequence points was achieved using restriction 
endonucleases from New England Biolabs, Promega and Roche. The buffers used were 









Table 6. The basic reaction mixture for a restriction digest used in this study 
Reagent Volume 
Restriction digest buffer (10x) 2 μl 
Bovine Serum Albumin (BSA) 0.2 μl 
Restriction Endonuclease 1 μl 
Plasmid DNA 1.5 μl 
Sterile water Up to a final volume of 22 μl 
 
The reagents listed above were added to the pre-determined volume of sterile water required 
for a 22 μl reaction mix. All digests underwent a 2-hour incubation at 37 °C. For analyses of 
the digested products, 10 μl of the sample was loaded onto an agarose gel.  
2.7.9 Agarose gel electrophoresis 
 
For the analysis of DNA fragments and plasmids, agarose gel electrophoresis was undertaken. 
Typically, agarose gels were composed of 0.8 % (w/v) agarose (Melford, MB12000) in TAE 
buffer. 
Recipe for 1x TAE Buffer: Tris base 4.84 g, Glacial acetic acid 1.14 ml, 0.5 M EDTA, pH 8.0 2 
mL, Milli-Q water to 1 L final volume.  
For higher percentage agarose gels, up to 1.5 % gels were used to better resolve smaller 
fragments. The agarose was dissolved in 1x TAE by heating in a microwave oven until the 
solution became clear. The solution was cooled to ~60 °C before ethidium bromide (10 mg/ml) 
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was added at a concentration of 0.0167 μg/ml. The mixture was poured carefully into a gel 
forming cassette, and a comb was inserted. The gel was left to cool and set for up to an hour.  
Once the gel had solidified, it was placed in an electrophoresis tank and 1x TAE buffer was 
added in sufficient quantity to cover the gel surface by 2-3 mm. The comb was then removed. 
A Promega 1 kb DNA ladder (G57511) was added to the first well and 6x loading buffer 
containing bromophenol blue was mixed 1 in 6 with the DNA samples. Typically, 10 μl of 
sample was loaded into the subsequent wells. For analysis of restriction digestion products, 
10 μl of sample was loaded. A voltage of 80 V was applied to the tank for 30-60 mins until the 
DNA bands had migrated the desired distance. The DNA fragments were visualised by short 
wavelength (312 nm) UV transillumination.  
2.7.10 Polymerase Chain Reaction (PCR) 
 
For the amplification of DNA sequences, the polymerase chain reaction (PCR) was utilized. 
The PCR reaction was performed using the Roche ‘High Fidelity PCR System and Techno TC-
3000 thermal cycler. 
1-5 μl of plasmid DNA was used as the source of the template for PCR reaction. The following 









Table 7. Standard PCR reaction composition used in this study 
 
PCR reactions were conducted using the cycling conditions described in Materials and 
Methods, Table 2.7.10.2. After the completion of the reaction, a 5 μl aliquot of the PCR 
product was run on an agarose gel. The products of the PCR reactions were purified with the 
Qiagen ‘PCR Purification’ kit according to manufactures instructions. 
Table 8. Standard 3-step PCR cycling protocol used in this study 
Cycle Step Cycle 
Temperature (°C) 
Time (mins) Number of Cycles 
Initial Denaturation 94 °C 5 mins 1 
Denaturation and 
Annealing/Extension 
1) 96 °C 
2) 52 °C 





Final Extension 72 °C 5 mins 5 
 
Reagent Volume Added Final concentration 
(10x) High Fidelity Buffer + 
15 mL MgCL2 
5 μl 1x (1.5 ml MgCl2) 
Reverse Primer, 100 pmol/ 
μl 
1-5 μl 300 nM 
Forward Primer, 100 pmol/ 
μl 
1-5 μl 300 nM 
Template DNA 1-5 μl 0.1-250 ng 
dNTP mix, 10 mM each dNTP 1 μl 200 μM each dNTP 
High Fidelity Enzyme Mix 1 μl 3.4 U/reaction 
Sterile Deionised water Up to 50 μl - 
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2.7.11 Generation of yeast gene knock outs using LoxP marker cassettes 
 
This procedure was taken from Gueldener et al (2002) [209]. For the generation of yeast 
strains that contained deletions of specific genes, DNA cassettes were created that 
recombined with specific regions of the genome to replace the genes encoded within that 
region.  
PCR primers were designed to incorporate 19 or 22 nucleotides that are adjacent to the LoxP 
sequences flanking the marker, as well as 45 5’nucleotides that anneal with sites on the 
beginning and end of the target gene to be deleted. The newly designed primers are used in 
a PCR reaction to generate a DNA sequence consisting of a selection marker flanked by the 
LoxP sites and a sequence corresponding to regions close to the start and end of the ORF of 
the target gene. Following the completion of the PCR reaction, the disruption DNA cassette 
was purified using the genomic DNA extraction (Materials and Methods, Section 2.7.3). The 
purified disruption cassette was transformed into yeast cells (Materials and Methods, Section 
2.5.1). The transformation of the disruption cassette leads to a recombination event allowing 
the selection marker to replace the target gene. This is achieved due to the recombination 
driven specificity of the 45 nucleotides flanking the selection marker that are specific for the 
ORF of the target gene. A successful transformation procedure therefore should produce null 
mutants of the target gene.    
 2.7.12 Invitrogen Gateway Cloning Reaction 
 
The Invitrogen Gateway© cloning method was used for the generation of plasmids used in 
this study. The Gateway system is a cloning method based upon the site-specific 
recombination of the lambda bacteriophage. Two types of recombination sites have been 
engineered to recombine uniquely between the two ends of a source sequence and a host 
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vector. The sites have been constricted to enable the recombination reaction to be 
completely reversible using two sets of catalytic proteins. These two reactions are called LR 
and BP, so named because of the recombination sites involved in each reaction: LR 
recombines attL and attR sites, BP recombines attB and attP sites. The recombined sites 
transform by swapping opposite halves into the opposite set, so attL and attR become attB 
and attP and vice versa. Vectors engineered to contain these sites have been given the names: 
Entry Clone, Expression Clone, Donor Vector, and Destination Vector. 
2.7.13 BP Cloning Reaction 
 
For the generation of the entry vectors used in this study the Invitrogen Gateway BP cloning 
reaction was performed. The plasmid containing the RAS2 nucleotide sequence was extracted 
and purified using a Qiagen Spin Miniprep Kit and sequenced by Source Bioscience. 0.5 μl of 
the purified plasmid DNA was mixed with 0.5 μl of pDONR221 and 4 μl of TE buffer in a clean 
PCR tube. The BP clonase II enzyme was thawed on ice for ~ 2 mins and then vortexed for 2 
secs. 1 μl of BP clonase II was added to the reaction mixture and incubated at room 
temperature for 1 hour. To terminate the reaction, 0.5 μl of Proteinase K solution was added 
to the reaction mixture. The mixture was then vortexed briefly and incubated at 37 °C for 10 
mins. Samples were incubated at -20 °C for 24 hours 
2.7.14 LR Cloning Reaction 
 
 For the generation of the expression clones used in this study, an Invitrogen Gateway LR 
cloning reaction was used. The LR reaction enables the recombination of the gene of interest 




Table 9. LR Cloning reaction 
Reagent Volume/Mass 
Entry Clone Plasmid DNA 75 ng/μl 
Destination Vector 50 ng/μl 
LR Clonase II 0.5 μl 
LR Reaction Buffer (5x) 2 μl 
TE Buffer pH 8 2.75 μl 
 
The LR reaction mixture listed above was incubated at room temperature for 1 hour. 0.5 μl of 
proteinase K was added followed by a 10-minute incubation period at 37 °C. All destination 
vectors used in this study contain ampicillin and chloramphenicol resistance genes. RAS2 
expression clones with a GPD promotor were sequenced with the GPDPro-F primers and the 
entry clones with M13F. 
2.7.15 DNA sequencing  
 
The sequencing of purified plasmid DNA samples was carried out by Source Bioscience 
Lifesciences, based in Cambridge. The plasmid DNA was sequenced via the Sanger sequencing 
methodology. Purified by plasmid DNA samples a concentration of 100 ng/μl were sent for 
sequencing with the associated primers at a concentration of 5 μM. The data from the 
sequencing reaction was received electronically and analysis of data was carried using ApE- a 






 2.8 Biochemical Methods 
 
2.8.1 Whole cell protein extraction for SDS PAGE 
 
The generation of protein samples required for polyacrylamide gel electrophoresis was 
achieved using the methodology described in von der Haar et al, (2007) [210]. The 
concentration of cells in a culture was estimated from the optical density. 2 x 108 cells were 
harvested via centrifugation for 2 mins at 13 000 rpm. For log phase cultures at an OD600 of 
0.7 this was around 10 ml. If quantitative electrophoretic analysis was required, the number 
of cells in a culture was counted under a microscope using a haemocytometer. The volume 
containing a defined number of cells was harvested using the centrifugation procedure as 
described above.  
Harvested cells were resuspended in 200 μl of lysis buffer (0.05 M EDTA, 0.1 M NaOH, 2% w/v 
SDS, 2% v/v -mercaptoethanol) and incubated at 90 °C for 10 mins. After incubation, 5 μl of 
4 M acetic acid was added and the sample was vortexed for 30 secs before a second 10-
minute incubation at 90 °C. 50 μl of loading buffer (50 % glycerol, 0.25 M Tris-HCl pH 6.8, 0.05 
% bromophenol blue) was added to the sample. The sample was then centrifuged for 90 secs 
at 13 000 rpm in a bench microcentrifuge prior to loading.  
2.8.2 Polyacrylamide gel electrophoresis 
 
 Polyacrylamide gels were prepared using the recipe listed in Materials and Methods, Table 
2.8.2. Each gel was composed of a standard 5 % acrylamide stacking gel and a 7.5-12 % 
resolving gel. SDSPAGE gels were casted in 0.75 mm glass cassettes (Bio-Rad). The resolving 
layer was poured into the cassette and allowed to set for 20-30 mins and layered with 1 ml of 
isopropanol to provide an even top layer surface after solidification of the gel. The 
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isopropanol was discarded, and the stacking gel solution was then poured into the cassette 
and an appropriately sized comb was inserted. The stacking layer  set for 20 mins. 
Table 10. SDS-Page reagents 
Stacking gel Resolving gel SDS running buffer 
126 mM Tris pH 8.8 
0.1 % SDS 
12 % acrylamide (29:1) 
0.15 % ammonium 
persulphate 
0.07 % TEMED 
 
240 mM Tris pH 6.8 
0.1 % SDS 
4.3 % acrylamide (29.1) 
0.23 % ammonium 
persulphate 
0.07 % TEMED 
0.3 % (w/v) Tris-HCL 
1.44 % (w/v) glycine 
0.15 % (w/v) SDS 
 
Polyacrylamide gels were mixed in sterile 50 ml falcon tubes. Ammonium persulfate was 
freshly dissolved in water at 10% (w/v).  
After the final incubation period the comb and gasket were carefully removed, and the 
cassette was inserted into a gel tank and sealed against the central column. 1x TGS was then 
added to the gel tank and wells were submerged in TGS buffer. A protein standard (ColorPlus 
marker p7709S, New England Biolabs) was loaded into the first well of each gel. Protein 
samples in loading buffer were then loaded into subsequent wells. The electrodes were 
connected to a BioRad power pack and a voltage of 90 V was applied until the protein front 
entered the resolving layer, at this point the voltage was increased to 130 V. Once the protein 
front had migrated through the acrylamide gel to ensure sufficient separation, the voltage 
was stopped. Careful notice was taken to ensure the protein front did not run off the gel. The 
gel tank was disconnected from the power pack and the cassettes removed. The gels used in 
this process were either used for staining with Coomassie blue, or the western blot protocol 
described in Materials and Methods, Section 2.8.5. 
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2.8.3 Coomassie staining of SDS-PAGE gels 
 
SDS-PAGE gels were visualised following a 20-minute shaking incubation phase at room 
temperature with Coomassie brilliant blue stain (40 % (v/v) Methanol, 20 % (v/v) Glacial acetic 
acid, 0.1 % Coomassie brilliant blue R250), followed by a 20-minute shaking incubation phase 
with de-stain solution (10 % (v/v) methanol, 10 % (v/v) Acetic acid). Gels were then 
submerged overnight in sterile water, shaking at room temperature.  
2.8.4 Semi-dry transfer of proteins to PVDF membranes 
 
Proteins were separated via molecular mass by SDS-PAGE. The polyacrylamide gel containing 
the protein samples was removed from the cassette and the stacking layer was discarded. 
The resolving gel was removed from the cassette and placed in transfer buffer (0.0058 % w/v 
Tris base, 0.0029 % w/v glycine, 0.00004 % w/v SDS, 20 % v/v methanol). Four pieces of 
Whatman blotting paper (Thermo Fisher) was cut into 8x9 cm pieces and soaked in transfer 
buffer. PVDF western blotting membrane (Thermo Fisher) was wet thoroughly in methanol 
(Thermo Fisher) and then placed in transfer buffer to 10 mins. Two pieces of blotting paper 
was placed on the anode plate of a Trans-Blot Semi-Dry Transfer cell (BioRad), followed by 
the PVDF membrane, the polyacrylamide gel, and the final two pieces of blotting paper. To 
ensure that there were no significant air bubbles present between layers, a roller was used 
to roll out any excess air. The cathode plate was place on top and the apparatus was 
connected to a power pack. A voltage of 25 V was applied for 30 mins. Upon completion of 
the semi-dry transfer the PVDF membrane was removed for use in the immunoblotting 





2.8.5 Immunoblotting procedure 
 
Following the completion of the semi-dry transfer protocol, the PVDF membrane was placed 
in 6 ml of blocking solution (5 % w/v Dried Skimmed Milk (Oxoid) and PBS/T (Phosphate 
Buffered Saline and 0.2 % Tween 20 [Sigma]) and incubated with shaking for 1 hour at room 
temperature. The membrane was briefly washed twice with PBS/T and placed in a 50 ml 
falcon tube with 6-12 ml of blocking solution containing the appropriate concentration of 
primary antibody, for details on primary antibodies used see Materials and Methods, Section 
2.8.8. A 1-hour incubation with shaking at room temperature followed. The PVDF was 
carefully removed from the 50 ml falcon tube and rinsed briefly with PBS/T. The membrane 
was then incubated with PBS/T and washed via shaking for 15 mins, followed by another two 
15 min washes, replacing the PBST/T each time. After the completion of the wash phases, the 
PVDF membrane was placed in a fresh 50 ml falcon tube containing 6-12 ml of blocking 
solution containing an appropriate concentration of secondary antibody conjugated to Horse-
Radish Peroxidase, for details on secondary antibodies used see Materials and Methods, 
Section 2.8.8. A 30-minute incubation period with shaking at room temperature followed. The 
PVDF membrane was then washed with PBS/T as previously undertaken after the primary 
antibody straining. The membrane was then placed in PBS.  
2.8.6 ECL detection (Enhanced Chemiluminescence) 
 
The PVDF membrane was placed in a clean polyethylene terephthalate box and the ECL 
solutions, listed in the table below, were mixed in a 1:1 ration. The PBS used to incubate the 
PVDF membrane was discarded and the ECL solution was added and incubated for 1 min with 
constant shaking. The ECL solution was discarded and the membrane was removed and 
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placed in a Sharon wrap. The membrane was placed into the SYNGENE G: BOX gel doc system 
and blots were visualised.  
The GeneSys Software (Version 1.6.5.0) was used to analyse blots and a Synoptics 6MP 
camera was used to capture images. To calculate the Ras2p band intensity relative to the 
Pgk1p loading control, ImageJ version 1.51n was used. Here the integrated intensity of the 
Ras2p band was calculated and divided by the integrated intensity of the Pgk1p band and 
normalised to the control strain. 
Table 11. Recipes for ECL solutions  
Name Recipe 
Solution 1 1 ml luminol 250 mM (3-aminophthalhydrazide from FLUKA No. 09253 
0.44 ml p-coumaric acid 90 mM (Sigma No C9008) 
10 ml 1 M Tris.HCL (pH 8.5)  
Water to 100 ml 
 
Solution 2 64 μl 30% hydrogen peroxide 
10 ml 1 M Tris.HCL (pH 8.5) 
Water to 100 ml 
 
2.8.7 Stripping of PVDF membrane 
 
Following the completion of an ECL detection on a PVDF membrane, a loading control was 
required to ensure an even loading of protein to the gel. Here previously bound antibodies 
were required to be removed from the PVDF to allow for re-probing with a new antibody. The 
Restore Western Blot Stripping Buffer (ThermoScientific) solution and protocol was used. The 
PVDF membrane was carefully removed from the 50 ml falcon tube and rinsed briefly with 
PBS/T. The membrane was then incubated with PBS/T and washed via shaking for 15 mins, 
followed by another two 15 min washes replacing the PBST/T each time. After the completion 
of the wash phases, the PVDF was immersed in 10 ml of stripping buffer and incubated for 30 
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mins at room temperature with shaking. The stripping buffer was discarded and the PVDF 
membrane was washed with PBS/T as previously undertaken before addition of stripping 
buffer. Following the completion of the stripping protocol, the PVDF membrane was placed 
in 6 ml of blocking solution (5 % w/v Dried Skimmed Milk (Oxoid) and PBS/T (Phosphate 
Buffered Saline and 0.2 % Tween 20 [Sigma]) and incubated with shaking for 1 hour at room 
temperature before probing with a fresh primary antibody.  
2.8.8 Antibodies used in study  
 
Antibodies were used to perform western blot analysis. The antibodies used within this study 
are listed below. 
Primary antibody used for Ras2p detection: Goat anti-Ras2 polyclonal IgG was purchased 
from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Inc. Bergheimer Str. 89-2, 
69115 Heidelberg, Germany) and was used at a dilution of 1/1000.   
Secondary antibody for Ras2p detection: Anti-sheep IgG HRP (Sigma, catalogue number 
A3415) and was used at a dilution of 1/5000.  
Primary antibody used for detection Pgk1p: Rabbit anti-Pgk1p (Supplied by Professor Mick 
Tuite a 1:10 000 dilution and was used as the loading control. 
Secondary antibody used for detection Pgk1p: Anti-rabbit (Supplied by Professor Mick Tuite) 
a 1:500 dilution was used as the following loading control. 
Primary antibody used for GFP detection: Mouse anti-GFP (Sigma, catalogue number 
1181446000) used at a dilution of 1/1000. 
Secondary antibody used for Porin and GFP detection: Anti-Mouse IgG HRP (Sigma, 





2.9 Cell biology techniques   
 
 2.9.1 Absorbance assays for growth rate analysis of S. cerevisiae cells 
 
A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated 
into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The 
optical density of the overnight culture was calculated by absorbance at OD600 using an 
Eppendorf Biophotometer plus. Cultures were diluted to an OD600 of 0.1 in 1 ml of the 
appropriate fresh medium in a sterile 24-well plate (Greiner). Alternatively, cultures were 
diluted to an OD600 of 0.1 in 500 μl of the appropriate fresh medium in a sterile 48-well plate 
(Greiner). Growth was measured using a BMG LABTECH FLUOstar OPTIMA or a BMG LABTECH 
SPECTROstar Nano plate reader.  
Table 12.  The protocol setting used to measure growth rate  
Cycle Time 1800 seconds 
Flashes Per Well 3 
Excitation 600 nm 
Shaking Frequency 400 nm 
Shaking Mode Double Orbital 
Additional Shaking Time 30 Seconds before each cycle 
Temperature 30 °C 
Positioning Delay 0.5 seconds 
 
For the analysis and processing of the data generated by the plate reader, the BMG LABTECH 
MARS data analysis software was used. The data processed in this software was then 
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exported to Microsoft Excel for further analysis. Each growth curve assay displayed in this 
thesis is the sum of three biological repeats, each of which includes three technical repeats.  
Doubling times for each strain were determined by separately plotting sequential 2-hour data 
sets individually, each overlapping by 30 minutes, with time in hours or mins (x-axis) against 
the OD600 (y-axis) using Microsoft Excel 2010.  For each 2-hour plot, an exponential trend line 
equation was generated, y= c*e^(b*x), which is equivalent to ln(y) = ln(c) + b*x, for which b 
represents the slope and ln(c) represents the y-axis intercept. The 2 hour plot with the highest 
x value (which represents the slope) in the exponential line equation was selected, and that 
x-value was used to generate the doubling time (hours) using the formula LN (2)/x. 
2.9.2 Cell counting using a haemocytometer 
 
To perform cells counts, a haemocytometer was used. An overnight culture was diluted 1/25 
and log phase cultures were enumerated without dilution. A 50 μL aliquot of culture was 
loaded onto the haemocytometer and counted under a light microscope using the 100x 
magnification. When counting budding yeast cells, cells with a bud size greater than one third 
the size of the mother cell were counted as two cells, if not, buds were not included in the 
cell count. Only cells existing within, or on the bottom or left-hand line of the box were 
counted. A minimum of 300 cells were counted when possible.  
2.9.3 Viability assay  
 
A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated 
into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The 
cell density of the overnight culture was measured using an Eppendorf Biophometer plus. 
Cells were diluted to an OD600 of 0.1 in 5 ml of the appropriate fresh media. Cells were 
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incubated at 30 °C shaking at 200 rpm for 24 hours. The number of cells in a culture was 
counted under a microscope using a haemocytometer. Cells were diluted to 2 x 103 cells/ml 
and 150 μl (300 cells) was plated on to the appropriate media. 300 cells from each sample 
was plated onto an agar plate, which, for 100 % viability, should lead to the growth of 300 
colony forming units (CFU). Plates were incubated at 30 °C for 2-4 days before counting to 
ensure that slow growing strains had sufficient time to grow. The percentage viability was 
determined by the dividing the number of observed CFU’s by the number of expected CFU’s 
and multiplied by 100.  
2.9.4 Di/Tri-peptide supplementation viability assay 
 
A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated 
into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The 
cell density of the overnight culture was measured using an Eppendorf Biophometer plus. 
Cells were diluted to an OD600 of 0.1 in 5 ml of the appropriate fresh media. Cells were 
incubated at 30 °C shaking at 200 rpm for 24 hours. The number of cells in a culture was 
counted under a microscope using a haemocytometer. Cells were diluted to 2 x 103 cells/ml 
and 300 cells were plated onto either SD-URA or SD –URA with the addition of a specific di-
peptide at a 1 mM concentration. The di-peptides used in this study; Leucine-Leucine (Sigma), 
Alanine-Leucine (Sigma), Tyrosine-Alanine (Sigma) or Histadine-Leucine (Sigma). 
Alternatively, cells were plated on media containing a mix of all the di-peptides listed above, 
added together at a 1 mM concentration. Plates were incubated at 30 °C for 2-4 days before 
counting to ensure that slow growing strains had sufficient time to grow. The percentage 
viability was determined by the dividing the number of observed CFU’s by the number of 
expected CFU’s and multiplied by 100.  
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2.9.5 Hydrogen Peroxide Sensitivity Assay 
 
A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated 
into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The 
cell density of the overnight culture was measured using an Eppendorf Biophotometer plus. 
Overnight cultures were then diluted to OD600 0.1 in 1 ml of the appropriate media. Cells were 
diluted to 1 x 107 cells/ml and were diluted 1000-fold over three serial dilutions. Each 1000-
fold dilution of the sample was plated onto four different agar plates differing in 
concentration of hydrogen peroxide (H202). A 3 % percent working stock of hydrogen peroxide 
(v/v) was made from a 30 % hydrogen peroxide stock solution (v/v). From this stock, 1 mM, 2 
mM, 3 mM, and 4 mM concentrations of hydrogen peroxide was added to 40 ml of agar 
media. Plates were dried and then incubated at 30 °C and checked after 48 and 72 hours. 
Following incubation, visual analysis was performed to observe the differences in growth.  
Images were taken on a scanner (CANOscan 4000), 48 hours after plating. 
2.9.6 Copper Sensitivity Assay 
 
A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated 
into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The 
cell density of the overnight culture was measured using an Eppendorf Biophotometer plus. 
Overnight cultures were then diluted to OD600 0.1 in 1 ml of the appropriate media. Cells were 
diluted to 1 x 107 cells/ml and were diluted 1000-fold over three serial dilutions. Each 1000-
fold dilution of the sample was plated onto four different agar plates differing in 
concentration of CuS04. A 100 mM working stock of CuS04 was made. From this stock, 1 mM, 
1.5 mM, 2 mM and 3 mM concentrations of CuS04 was added to 40 ml of agar media. Plates 
were dried and then incubated at 30 °C and checked after 48 and 72 hours. Following 
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incubation, visual analysis was performed to observe the differences in growth.  Images were 
taken on a scanner (CANOscan 4000), 48 hours after plating. 
2.9.7 GFP-ATG8 autophagy assay 
 
A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated 
into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The 
cell density of the overnight culture was measured using an Eppendorf Biophometer plus. 
Cells were diluted to an OD600 of 0.1 in 5 ml of the appropriate fresh media. Cells were 
incubated at 30 °C shaking at 200 rpm for 24 hours. Following this, 1ml of culture was 
transferred to the nitrogen starvation media (Materials and Methods, Section 2.1.4) lacking 
ammonium sulphate to induce autophagy via nitrogen starvation and incubated at 30 °C with 
200 rpm shaking for 6 hours. Total protein was extracted from cells pre- and post-induction 
of autophagy and subjected to western blotting (Materials and Methods, Section 2.8.5).  
2.9.8 Chronological Ageing Assay  
 
A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated 
into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The 
cell density of the overnight culture was measured using an Eppendorf Biophotometer plus. 
The overnight cultures were sub-cultured to a calculated OD600 of 0.1 in 10 ml of appropriate 
medium in 100 ml conical flasks. Samples were incubated at 30 °C with shaking at 200 rpm. 
After 24 hours of incubation, an aliquot of the culture was taken to calculate the colony 
forming units (Materials and Methods, Section 2.9.9) and for flow cytometry analysis to 
measure levels of propidium iodide (Materials and Methods, Section 2.9.12) and 
dihydroethidium fluorescence (Materials and Methods, Section 2.9.11). Once the aliquot of 
culture was taken, samples were immediately returned to the incubator to minimise sample 
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exposure time outside of the incubation parameters. Aliquots of cells were taken from the 
same culture sequentially at 24-hour intervals for 6 days and colony forming unit counts and 
flow cytometry analysis were undertaken. The final measurement was taken after 12 days of 
sample incubation. 
2.9.9 Clonogenic Survival Assay of wild type cells overexpressing RAS2S225A, 
RAS2S225E or a plasmid control 
 
An aliquot of 10 μl of suspended cells was taken from the original culture and diluted in 990 
μl of sterile water. The diluted sample was further diluted by a 1/100 dilution in PBS. The 
sample was then inserted into a CASY cell counter (Scharfe Systems) and the number of cells 
in a culture was calculated. Serial dilutions were performed to ensure that 300 cells of each 
sample were plated onto each agar plate, which, for 100 % viability, should lead to the growth 
of 300 colony forming units (CFU). Plates were incubated at 30 °C for 48 hours before counting 
to ensure that slow growing strains had sufficient time to grow. The percentage viability was 
determined by the dividing the number of observed CFU’s by the number of expected CFU’s 
and multiplied by 100.  
2.9.10 Flow Cytometry  
 
To detect the presence of fluorescence within yeast cells a BD FACSCalibur flow cytometer 
was used, and the BD FACStation data management system was used for acquisition and data 
analysis of samples. The system uses an air-cooled argon-ion laser exciting fluorophore. The 
FACS counted and analysed 10,000 cells per sample and the flow rate was set to ~60 μl/min.   




2.9.11Flow cytometry to monitor DHE fluorescence to detect superoxide radicals 
 
The dihydroethidium (DHE) dye (Invitrogen D23107) was used for the detection of superoxide 
radicals. The blue fluorescent DHE dye is oxidised by superoxide radicals to the red fluorescent 
form, hydroxyethidium. The 585 nm band pass filter (FL-2) placed in the light path before 
detection was used for red light detection. Approximately 2 x 106 cells were re-suspended in 
PBS containing 10μM DHE and incubated for 10-15 mins before FACS analysis. 
2.9.12 Flow cytometry to detect Propidium Iodide uptake to assess necrosis   
 
To check for the presence of necrotic cells in a population, 4 μl of propidium iodide was 
added 30 secs before being placed into the FACS. Propidium iodide (PI) accumulates in 
cells when the plasma membrane is compromised and intercalates into nucleic acids. PI 
can therefor only penetrate necrotic cells and is excluded by viable cells that have an 
intact plasma membrane. When PI is bound to nucleic acids, the fluorescent excitation 
maximum is 35 nm and the emission maximum is 617 nm.  Propidium iodide (PI) binds 
to DNA by intercalating between the bases, with little or no sequence preference, and 
with a stoichiometry of one dye per 4–5 base pairs of DNAs. PI also binds to RNA, 
necessitating treatment with nucleases to distinguish between RNA and DNA staining. 
Once the dye is bound to nucleic acids, its fluorescence is enhanced 20- to 30-fold, the 
fluorescence excitation maximum is shifted ~30–40 nm to the red, and this is relatively 
low, PI exhibits a sufficiently large Stokes shift to allow simultaneous detection of nuclear 




2.10 Fluorescence Microscopy of yeast cells 
 
2.10.1 Fluorescence Microscopy 
 
For the visualisation of fluorescent cells, an Olympus 1X81 inverted microscope was used. The 
light source was provided by a Cool LED pE4000 illumination system. All images were captured 
using an Andor’s Zyla 4.2 PLUS sCMOS camera. The acquisition software used to obtain images 
was Micro-Manger, version 1.4.22.  A single drop of Olympus Immoil-F30CC immersion oil 
was applied to the surface of the cover slip and an Olympus 60 x objective lens (NA = 1.35) 
was used to locate cells within a sample. An Olympus 100 x objective lens (NA = 1.4) was used 
to visualize individual cells. Cells with GFP-tagged proteins were observable using the GFP 
channel with excitation/emission wavelengths of 488/512 nm. DIC images were acquired 
using a halogen light source with identical settings to GFP imaging. To ensure images were 
representative of the whole population each microscopy experiment was repeated in 
triplicate. For the analysis and processing of images the ImageJ FIJI software was used. The 
counting of cells for phenotype characterisation was conducted by eye from images 
generated from fluorescent microscopy.   
2.10.2 Sample Preparation  
 
A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated 
into 5 ml of appropriate low fluorescence selective medium and grown overnight at 30 °C 
with shaking at 200 rpm. The optical density of the overnight culture was measured using an 
Eppendorf Biophotometer plus. For stationary phase microscopy analysis, overnight cultures 
were diluted to an OD600 of 0.1 in 5 ml of fresh media and grown for 24 hours. For the analysis 
of cells in logarithmic phase of cell growth, cells were sub-cultured and grown to OD600 0.7. A 
3 μl aliquot of the culture was placed on a microscope slide and covered with a 20 mm by 20 
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mm cover slip. A single drop of Olympus Immoil-F30CC immersion oil was added to the cover 
slip and examination under the microscope was carried out.  
2.11 High Resolution Respirometry 
 
The Oroboros O2K Oxygraph High Resolution Respirometer was used to determine the 
consumption of 02 from mitochondria in cell suspensions. The Datlab 4 software was used for 
the analysis and acquisition of data generated by the respirometer. The respirometer 
contained two chambers, each of which was maintained at 30 °C and held 2 ml of cells 
suspended in media without glucose. To calibrate the instrument, the medium from which 
the cells were grown in was used. An overnight liquid culture was diluted to a calculated OD600 
of 0.1 and cells were analysed at 24 hours post inoculation. To ensure that an equal volume 
of cells was present in each chamber, cells were counted using a haemocytometer. A 1/80 
dilution was performed, and a full haemocytometer grid of cells was counted to calculate the 
number of yeast cells present in 1 ml of culture. The samples were diluted to a cell density of 
106 cells/ml into 3 ml of appropriate media. 2.5 ml of each diluted culture was inserted into 
one of the two chambers to ensure each chamber was full. The chamber stoppers were 
inserted into position and any residual liquid culture was aspirated away. The exact cell 
concentration was then entered into the Datlab4 software for an accurate oxygen flux/cell 
reading.    
For the analysis of cells mitochondria, a series of drugs were introduced into the chamber 
using specifically engineered syringes, which target individual components of the electron 
transport chain. The following drugs: Triethiltyn bromide (TET) (Sigma-Aldrich), 
carbonylcyanidep-trifluoromethoxyphenylhydrazone (FCCP) (Fluka), and Antimycin A (AntA) 
(Sigma-Aldrich) were in added to each sample chamber. The sequence of drug addition was 
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as follows; a 0.2 mM final concentration TET was added to each chamber (8 μl from a 50 mM 
stock solution in DMSO), followed by 0.012 mM FCCP (2 μl of a 12 mM stock in ethanol) and 
finally 0.002 mM AntA (2 μl of a 2 mM stock solution in ethanol). To facilitate the detection 







Chapter 3  
Yeast as a model organism to study the 



















Ras proteins are small GTPases that act as molecular switches within cells that link 
extracellular stimuli to intracellular effectors. Ras proteins play a conserved role in the control 
of both cell growth and proliferation [211]. As a result, mutations that induce the constitutive 
activation of Ras proteins are often associated with changes in cell behaviour that can lead to 
disease, such as human cancer [41]. The localisation of Ras proteins are reported to be 
predominantly to the inner cytoplasmic surface of the plasma membrane, but they can also 
be observed on endomembrane’s, such as the endoplasmic reticulum, and the mitochondrial 
outer membrane [65][57][212]. 
 In recent years, the localisation and signalling of Ras on the plasma membrane has been 
extensively studied. It has been shown that Ras undergoes a series of posttranslational 
modifications that dictate its subcellular localisation. Firstly, farnesylation of the cysteine on 
the C-terminal CAAX motif targets Ras to the cytosolic surface of the ER where the AAX is 
proteolytically cleaved and the c- terminus methylated [51][53]. In the majority of Ras 
proteins cysteine residues close to the CAAX motif are palmitoylated, facilitating the 
translocation of Ras from the ER to the plasma membrane [60]. Evidence exists to suggest 
that Ras proteins can undergo phosphorylation events which regulate its activity. Whistler 
and Rine  identified Ser412  as an important phosphorylation site on the yeast Ras2 protein 
where substitution of serine with alanine at this residue lead to increased cAMP levels and 
elevated ration of Ras2-GTP compared to total Ras2 [74][213]. Surprisingly, the 
phosphorylation of Ras2p in S. cerevisiae has not been studied regarding its regulation of 
intracellular localisation, despite significant evidence existing linking Ras phosphorylation to 
its localisation in humans. For example, the phosphorylation by PKC of the Serine181  residue 
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within K-Ras, promotes rapid dissociation of K-Ras from the inner leaflet of plasma membrane 
to other intracellular membranes, including the outer membrane of mitochondria [77] .  
While phosphorylation is an important posttranslational modification, little is known on its 
effect on Ras2 protein activation and localisation. This study aims to further investigate 
whether Ras2p phosphorylation provides a mechanism that regulates Ras2p trafficking inside 
the cell.  
In the laboratory of Dr Campbell Gourlay, previous investigations using data obtained from 
the PhosphoPep version 2.0 project www.phosphopep.org/index.php, produced 
experimental information regarding putative Ras2 phosphorylation sites that are affected by 
the deletion of SSN3 and SIT4 respectively. Interestingly, the phosphorylation sites that were 
predicted to be affected upon the deletion of either SSN3 or SIT4 were found to be identical 
and focussed upon the serine residue at position 225 of Ras2p. We therefor sought to 
investigate whether modification of Serine225 lead to any changes in Ras2 protein localisation 
or activity within the cell and whether this was accompanied by any phenotypes in cells 
expressing either RAS2S225A or RAS2S225E.  
Figure 13. Sequence alignment of the yeast Ras2 and Ras1. 
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Interestingly, an independent group identified the Ser226 residue in Ras1 to be an important 
residue for Ras1 phosphorylation, as mutating this residue to an alanine drastically diminishes 
the level of Ras1 phosphorylation [214]. Upon sequence alignment of yeast Ras1 and Ras2 
(Figure 13) we show little sequence similarity outside of the GTPase domain. However, the 
serine site position in both Ras1 and Ras2 is similar suggesting that serine residues located 
around this position may play a conserved regulatory role within Ras proteins. 
3.2 Construction of the RAS2 mutant alleles- site-directed mutagenesis 
substitution of the putative Ras2p phosphorylation site Serine225 by Alanine 
or Glutamate 
 
To investigate whether Serine225 phosphorylation is important for the localisation of Ras2p, 
growth and viability a site directed mutagenesis approach was adopted. The wild type RAS2 
gene was mutated at Serine225 where the serine was either substituted with alanine to 
produce a non-phosphoryatable residue or glutamate to produce phosphomimetic residue. 
Site-directed mutagenesis was previously undertaken by Eman Badr of the Gourlay Lab to 
replace Serine225 in the Ras2p with alanine or glutamate in the gateway donor vector 
PDON221. To confirm the correct introduction of the necessary mutations, samples were sent 
off for DNA Sequencing as described in Materials and Methods, Section 2.7.15. Expression 
vectors were generated from the donor vector by use of the gateway LR clonase reaction as 
described in Materials and Methods, Section 2.7.14.  N-terminal tagged GFP vectors for the 
expression of GFP-Ras2p, GFP-Ras2pS225A and GFP-Ras2pS225E were generated to investigate 
fluorescently tagged protein localisation. Vectors expressing untagged RAS2, RAS2S225A and 




3.3 Expression of RAS2, RAS2S225A and RAS2S225E alleles in S. cerevisiae 
 
The levels of wild type and mutant Ras2p were determined by western blot analysis as 
described in Materials and Methods, Section 2.8. To examine whether the expression of the 
Ras2p changed during different phases of cell growth, samples were prepared from log and 
stationary cultures. To ensure uniform protein loading, the levels of 3-PhosphoGlycerate 
Kinase, Pgk1p, in each strain were examined as a control. After probing for the Pgk1p, the 
membrane was stained with coomassie brilliant blue as a further control for protein loading. 
To calculate the Ras2p band intensity relative to the Pgk1p loading control, ImageJ version 
1.51n was used. Here the integrated intensity of the Ras2p band was calculated and divided 
by the integrated intensity of the Pgk1p band and normalised to the control strain. 
Firstly, the levels of wild type and mutant Ras2p were analysed in a wild type background. As 
expected, exponentially growing cells expressing either the wild type or RAS2 mutant alleles 
presented an increase in Ras2p expression when compared to the wild type control (Figure 
14/15). An increase in Ras2p expression was observed in cells overexpressing RAS2S225A or 
RAS2S225E when compared to the RAS2 overexpression strain (Figure 14/15). Furthermore, in 
cells overexpressing RAS2S225A or RAS2S225E an increase in protein degradation products was 
observed when compared to the wild type control and cells overexpressing RAS2 (Figure 14).   
As cells reached stationary phase of cell growth, 24 hours after inoculation, the levels of Ras2p 
in all overexpression strains were increased when compared to the wild type control (Figure 
16/17). An increase in Ras2p expression was observed in wild type cells overexpressing 
RAS2S225A or RAS2S225E when compared to the RAS2 overexpression strain (Figure 16/17). No 
significant difference in Ras2p degradation products was observed between wild type cells 
overexpressing RAS2, RAS2S225A or RAS2S225E (Figure 16).   
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RAS2, RAS2S225A, RAS2S225E or an empty plasmid were expressed in a Δras2 strain to examine 
the affects that the mutants of RAS2 have on the levels of Ras2p produced in the absence of 
endogenous Ras2p. No Ras2p signal was detected in a Δras2 strain expressing the empty 
plasmid backbone control, confirming the deletion of RAS2 in this background (Figure 18). No 
significant difference in the levels of Ras2p in strains were observed in cells overexpressing 
RAS2S225A or RAS2S225E when compared to the RAS2 overexpression strain (Figure 18/19).  
 
Figure 14. A western blot showing the detection of Ras2p in cells overexpressing RAS2, 
RAS2S225A, RAS2S225E or an empty plasmid control in a wild type background.  
Cells were grown in SD –URA media and sampled during exponential phase of cell growth. To 
ensure uniform protein loading, the levels of Pgk1p were detected after probing for Ras2p. 



















Figure 15. A bar chart representing the change in Ras2p band intensity relative to the Pgkp 
loading control of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or empty 
plasmid control.  
Cells were grown in –URA media and sampled during the exponential phase of growth. The 














Figure 16. A western blot showing the detection of Ras2p in cells over expressing RAS2, 
RAS2S225A, RAS2S225E or an empty plasmid control in a wild type background. 
Cells were grown in SD –URA media and sampled during stationary phase of growth. To ensure 
uniform protein loading, the levels of Pgk1p were detected after probing for Ras2p. This 


















Figure 17. A bar chart representing the change in Ras2p band intensity relative to the Pgkp 
loading control of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or an empty 
plasmid control.  
Cells were grown in –URA media and sampled during stationary phase of growth. The data 










Figure 18. A western blot showing the detection of Ras2p in Δras2 cells over expressing 
RAS2, RAS2S225A, RAS2S225E or an empty plasmid control.  
Cells were grown in SD –URA media and sampled during stationary phase of growth. To ensure 
uniform protein loading, the levels of Pgk1p were detected after probing for Ras2p. This 


















Figure 19. A bar chart representing the change in Ras2p band intensity relative to the Pgkp 
loading control of Δras2 cells overexpressing RAS2, RAS2S225A, RAS2S225E or an empty plasmid 
control. 
Cells were grown in –URA media and sampled during stationary phase of growth. The data 
displayed is an average of three biological repeats and the error represent the standard 
deviation 
 
3.4 Analysis of the effects of phosphorylation of Serine225 upon Ras2p 
localisation 
 
3.4.1 Microscopic analysis of wild type cells expressing GFP-Ras2p, GFP-
Ras2pS225A or GFP-Ras2pS225E  
 
We sought to determine the localisation of N-terminally GFP-tagged Ras2p, Ras2pS225A and 
Ras2pS225E to determine whether disruption of this site of phosphorylation would affect 
localisation. An N-terminal GFP-tag was preferred over a C-terminal GFP-tag, as a C-terminal 
GFP-tag will be cleaved during Ras2 protein processing and furthermore interfere with the C-
terminal CAAX motif and hinder Ras2p membrane targeting. The localisation of Ras2p was 
examined upon overexpression of the mutant constructs in both stationary and logarithmic 
phases of cell growth. Plasmids expressing either GFP-Ras2p, GFP-Ras2pS225A or GFP-
Ras2pS225E were transformed into wild type cells and an expression vector containing only the 
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GFP label was used as a control. During logarithmic phase of cell growth, a 
widespread/diffused GFP signal was observed in wild type cells overexpressing GFP from the 
control plasmid. In wild type cells overexpressing either GFP-Ras2p, GFP-Ras2pS225A or GFP-
Ras2pS225E a strong plasma membrane localisation of fluorescently labelled Ras2p was seen 
(Figure 20).  
During stationary phase of cell growth wild type cells overexpressing the control plasmid 
displayed widespread/diffused GFP signal throughout the cytoplasm of the cell (Figure 20). In 
wild type cells overexpressing either GFP-Ras2p, GFP-Ras2pS225A or GFP-Ras2pS225E a 
predominant localisation of GFP-Ras2p was observed at the plasma membrane (Figure 20). It 
was noted that these strains were also seen to localise GFP-Ras2p to intracellular foci which 
was not observed in the control strain. However, such an observation was noted infrequently. 
To quantify which was the predominant localisation of GFP-Ras2p, 100 cells for each strain 
were counted on three separate days and the number of cells displaying either plasma 
membrane, diffused/widespread and nuclear GFP-Ras2 localisation was calculated and 
represented as a percentage of the total number of cells counted. In both stationary and 
logarithmic phases of cell growth, wild type cells expressing the control plasmid displayed no 
nuclear or plasma membrane localisation of GFP (Figure 21/22). Whereas 70-80 % of wild type 
cells expressing either GFP-Ras2p, GFP-Ras2pS225A or GFP-Ras2pS225E displayed a predominant 
localisation at the plasma membrane with a small population of cells displaying a 
widespread/diffused GFP signal. No Nuclear localisation of GFP-Ras2p, GFP-Ras2pS225A or GFP-
Ras2pS225E was observed (Figure 21/22). This data set suggest that GFP-Ras2p localises 
primarily to the plasma membrane in both log and stationary phase of growth regardless of 









Figure 20. Images taken by fluorescent microscopy of wild type cells overexpressing either 
GFP-RAS2, GFP-RAS2S225A or GFP-RAS2S225E during logarithmic and stationary phase of cell 
growth.  
The Fluorescent signal represents the presence of Ras2p within cells and a vector containing 
only the GFP probe was introduced into wild type cells as a control. Cells were cultured in SD 
– URA growth media. This experiment was repeated three times and a representative data set 
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Figure 21. Graphical representation of the localisation of GFP-Ras2p in wild type cells 
expressing either GFP-RAS2, GFP-RAS2S225A or GFP-RAS2S225E during logarithmic phase of cell 
growth. 
  A vector containing only the GFP probe was used as a control. Cells were cultured in SD –URA 
growth media. To quantify the localisation of GFP-Ras2p, 100 cells for each strain were 
counted on three separate days with a total 300 cells being counted and the number of cells 
displaying the different phenotypes observed was calculated and represented as a percentage 
of the total number of cells counted. The data represents an average of three biological 
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Figure 22. Graphical representation of the localisation of GFP-Ras2p in wild type cells 
expressing either GFP-RAS2, GFP-RAS2S225A or GFP-RAS2S225E during stationary phase of cell 
growth.  
 A vector containing only the GFP probe was used as a control. Cells were cultured in SD –URA 
growth media. To quantify the localisation of GFP-Ras2p 100 cells for each strain were counted 
on three separate days with a total 300 cells being counted and the number of cells displaying 
the different phenotypes observed was calculated and represented as a percentage of the 
total number of cells counted. The data represents an average of three biological repeats and 
error bars represents the standard deviation.  
 
3.5 Analysis of the effects of phosphorylation of Serine225 upon the activation 
of Ras 
 
3.5.1 Microscopic analysis of wild type cells expressing Ras2p, Ras2pS225A, 
Ras2pS225E co-expressed with an GFP-RBD probe 
 
To investigate whether the modification of the Serine225 residue of Ras2p influences Ras 
activity a construct was introduced that expresses the Ras binding domain of human Raf1 
fused to GFP [70]. The RBD domain binds to Ras proteins only in their GTP-bound state. The 
localisation of active-Ras proteins was analysed during the stationary and logarithmic phase 
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of growth. In these experiments a plasmid overexpressing Ras2p, Ras2pS225A or Ras2pS225E was 
introduced into wild type cells and their activity assessed by GFP-RBD localisation (Figure 23). 
In wild type actively growing yeast cells, the GFP-RBD signal is predominantly localised at both 
the plasma membrane and the nucleus as has previously been described [70]. During 
stationary phase, Ras activity is reduced as cells stop dividing and accordingly the probe was 
seen as a diffuse signal throughout the cell with a faint signal in the nucleus [70].  
Interestingly, during logarithmic phase of growth wild type cells overexpressing either 
Ras2pS225A or Ras2pS225E showed very little plasma membrane or nuclear localisation of the 
GFP-RBD signal (Figure 23/24). Instead the GFP-RBD probe was observed to accumulate at 
the nuclear envelope (Figure 23/24). Such nuclear envelope localisation was never observed 
in either the control or Ras2p overexpression strains. This provides evidence that the 
modification of Serine225 leads to a change in the localisation of the active population of Ras 
when compared to the control and Ras2p overexpression strains during logarithmic growth. 
As the localisation of GTP-bound Ras2p dictates its interaction with its effector proteins and 
thus downstream signalling pathways, we hypothesize that the change in the localisation of 
the active Ras population observed in wild type cells overexpressing RAS2S225A or RAS2S225E 
may result in significant phenotypic changes when compared to the control and RAS2 
overexpression strains.  
During stationary phase of cell growth, wild type cells expressing the control, or Ras2p 
overexpression plasmid presented an RBD-GFP probe signal that was predominantly seen as 
a diffused cytoplasmic signal with a faint nuclear signal (Figure 23/25). In a small percentage 
of cells, we observed the RBD-probe signal manifesting in intracellular foci, which was not 
observed during logarithmic growth (Figure 23).   
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Significant differences in RBD-GFP probe localisation was observed in wild type cells 
overexpressing Ras2pS225A or Ras2pS225E during stationary phase growth (Figure 23/25).  In wild 
type cells overexpressing either Ras2pS225A or Ras2pS225E, we observed nuclear envelope 
localisation of the RBD-probe, which again was not seen in the control or Ras2p 
overexpression strain (Figure 23/25). An increase in the number of intracellular foci in these 
mutants was also observed when compared to the control strain (Figure 25). Here we suggest 
that the modification of Ras2S225 leads to changes in active Ras localisation in both logarithmic 







Figure 23. Fluorescence microscopy images of wild type strains overexpressing RAS2, 
RAS2S225A, RAS2S225E or an empty plasmid backbone control using a GFP-RBD probe during 
logarithmic and stationary phase of growth.  
Fluorescence signal represents the presence of active Ras within cells. Cells were cultured in 
SD –URA/-LEU growth media. This experiment was repeated three times and a representative 
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Figure 24. Graphical representation of the localisation of active-Ras in wild type cells 
expressing either RAS2, RAS2S225A, RAS2S225E or an empty plasmid control during logarithmic 
phase of cell growth. Cells were cultured in SD –URA/-LEU growth media.  
To quantify the localisation of active Ras 100 cells for each strain were counted on three 
separate days with a total 300 cells being counted and the number of cells displaying the 
different phenotypes observed was calculated and represented as a percentage of the total 
number of cells counted. The data represents an average of three biological repeats and error 
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Figure 25. Graphical representation of the localisation of active-RAS in wild type cells 
expressing either RAS2, RAS2S225A, RAS2S225E or an empty plasmid control during stationary 
phase of cell growth.  
Cells were cultured in SD –URA/-LEU growth media. To quantify the localisation of active Ras 
100 cells for each strain were counted on three separate days with a total 300 cells being 
counted and the number of cells displaying the different phenotypes observed was calculated 
and represented as a percentage of the total number of cells counted. The data represents an 







3.6 Growth analysis of yeast cells overexpressing RAS2, RAS2S225A or RAS2S225E  
 
To investigate the growth of yeast strains that overexpress the yeast RAS2S225A or RAS2S225E 
mutant alleles, growth and viability was compared to wild type cells overexpressing RAS2 or 
an empty plasmid backbone control. The growth of S. cerevisiae in liquid culture is 
characterized into four distinct phases: lag, logarithmic (exponential), post-diauxic and 
stationary phase (Figure 26). Each growth phase reflects the availability of nutrients and the 
adaption to changes in nutrient levels or exposure to stress.  
 
Figure 26. A diagram depicting the growth phases of S. cerevisiae cultivated in rich medium 
supplemented with glucose. 
The optical density (OD) of yeast cells is measured at 600nm. The logarithmic (log) phase of 
growth represents fermentation of glucose. In log phase the presence of glucose suppresses 
mitochondrial respiratory function via the mechanism of glucose repression, and cells obtain 
their energy requirements from fermentative glycolysis resulting in the production of ethanol. 
The diauxic shift occurs when glucose levels become depleted and cells must shift their 
metabolism from fermentative growth to respiratory growth, and the aerobic utilisation of 
ethanol. The post-diauxic phase occurs when cells have fully shifted to respiratory growth and 
utilise oxidative phosphorylation to support cellular functions. Stationary phase represents a 
period of minimal growth because of nutrient depletion and high cell density. Solid colours 




The lag phase represents the period during in which cells are adapting to new media addition 
or adaption to the environment and represents a period of minimal growth or time spent in 
the G0 phase of the cell cycle. Cells transitioning into the exponential phase of growth 
represent actively proliferating cells which in our culture conditions cells preferentially use 
glucose to generate energy by fermentation and suppression of oxidative phosphorylation, 
the so called Crabtree effect [214].  
The diauxic shifts represent a shift from glucose utilisation to the use of ethanol produced 
during fermentation and marks a period of glucose de-repression and upregulation of 
mitochondrial biogenesis to support the necessary oxidative phosphorylation.  The stationary 
phase of cell growth represents a commitment to cell cycle exit and accumulation of storage 
carbohydrates [215]. The limited growth that can be detected during stationary phase 
requires a functional mitochondrial electron transport chain [215].    
3.6.1 Overexpression of RAS2S225A or RAS2S225E in yeast cells leads to growth 
defects 
 
The growth of S. cerevisiae can be influenced by several factors such as temperature, pH, and 
the availability of nutrients. To analyse the growth of yeast strains overexpressing RAS2, 
RAS2S225A, RAS2S225E or an empty plasmid control, a growth assay was performed as described 
in Materials and Methods, Section 2.9.1. The growth of both a wild type strain and a Δras2 
strain expressing the RAS2 mutant alleles were analysed to determine whether the 




In the presence of endogenous Ras2p the overexpression of either RAS2S225A or RAS2S225E led 
to a lower final OD, early transition into the post-diauxic phase of cell growth and extended 
lag phase when compared to the control strain (Figure 27). Furthermore, In the presence of 
endogenous Ras2p the overexpression of RAS2S225A or RAS2S225E led to a decrease in the 
exponential growth rate when compared to the control strain (Figure 28). The doubling times 
(growth rates) for a wild type control strain and a wild type strain overexpressing RAS2 was 
approximately 180 minutes (Figure 28). Wild type cells expressing either RAS2S225A or 
RAS2S225E displayed a significant increase in doubling time to approximately 200 minutes 










Figure 27. Growth analysis of S. cerevisiae wild type cells overexpressing RAS2, RAS2S225A, 
RAS2S225E or empty plasmid control.  
 The growth analysis was carried out in SD –URA media as described in Materials and Methods 
(Section 2.9.1). This data represents an average of three biological repeats and error bars 














Figure 28. Growth rate analysis of S. cerevisiae wild type cells overexpressing RAS2 or 
RAS2S225A or RAS2S225E  
The growth rate analysis was carried out as described in Materials and Methods (Section 
2.9.1). The data represents an average of three biological repeats and error bars represents 
the standard deviation. A One-way ANOVA using a Dunnetts multiple comparison test was 
used to determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 
and *** = adjusted p value ≤ 0.001. 
 
The alleles RAS2, RAS2S225A or RAS2S225E were overexpressed in a Δras2 strain to determine 
whether the expression of these alleles would result in a growth phenotype in the absence of 
endogenous Ras2p. The overexpression of either RAS2S225A or RAS2S225E in a Δras2 background 
led a lower final OD, early transition into the post-diauxic phase of cell growth and extended 
lag phase when compared to the control strain (Figure 29). Without the presence of 
endogenous Ras2p the overexpression of either RAS2S225A or RAS2S225E led to a decrease in 
the exponential growth rate when compared to the control strain (Figure 30). The doubling 
times (growth rates) for a Δras2 control strain and a Δras2 strain overexpressing RAS2 was 
approximately 180 minutes (Figure 30). No significant difference in growth rate was observed 
125 
 
when RAS2 or an empty plasmid control was overexpressed in either wild type cells or a Δras2 
background. Δras2 cells overexpressing either RAS2S225A or RAS2S225E displayed a significant 
increase in doubling time when compared to the Δras2 control and RAS2 overexpression 
strain (Figure 30). In wild type cells, the overexpression of either RAS2S225A or RAS2S225E 
presented a doubling time of 200 minutes (Figure 29). In a Δras2 background, the 
overexpression of RAS2S225E presented a doubling time of also 200 minutes with a doubling of 
190 minutes observed in the RAS2S225A strain (Figure 30).  Suggesting that the growth defects 
caused by the overexpression of RAS2S225A or RAS2S225E are dominant as defects occur 













Figure 29. Growth rate analysis of a S. cerevisiae Δras2 strain overexpressing RAS2, 
RAS2S225A, RAS2S225E or an empty plasmid control.  
The growth analysis was carried out in SD –URA media as described in Materials and Methods 
(Section 2.9.1). The data represents an average of three biological repeats and error bars 












Figure 30. Growth rate analysis of S. cerevisiae Δras2 cells overexpressing RAS2, RAS2S225A, 
RAS2S225E or an empty plasmid control.   
The growth rate analysis was carried out as described in Materials and Methods (Section 
2.9.1). The data represents an average of three biological repeats and error bars represents 
the standard deviation. A One-way ANOVA using a Tukey multiple comparison test was used 
to determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** 












































































3.6.2 Overexpression of either RAS2S225A or RAS2S225E in yeast cells leads to 
decreased cell viability 
 
To determine whether the overexpression of either RAS2S225A or RAS2S225E affects viability in 
both a wild type and Δras2 background, a viability assay was conducted. An overnight culture 
was re-inoculated to 2 x 103 cells/ml and incubated for 24 hours. 200 μl (containing 300 cells) 
was plated onto selective, -URA agar plates. These were left to incubate at 30 °C for 36 hours 
and the colonies were then counted to allow quantification of colony forming units (CFUs). 
Viability of cells analysed from the inoculated culture represented the viability of cells, or cell 
death, during nutrient deprivation. Analysing viability of yeast cells under stresses such as 
nutrient deprivation can shed light on whether cells are functioning correctly.  A stationary 
phase, after 24 hours of growth, wild type strain expressing a control plasmid, had 
approximately 40 % viability when grown in SD -URA medium. 
The overexpression of RAS2 in a wild type and Δras2 background lead to an increase in cell 
viability when compared to the control strains (Figure 31). In cells overexpressing the empty 
plasmid control the loss of ras2 lead to no significant change in viability (Figure 31). The 
overexpression of either RAS2S225A or RAS2S225E in both a wild type and Δras2 background lead 
to a two-fold reduction in colony forming efficiency when compared to wild type and Δras2 
background control strains (Figure 31). We can conclude that the overexpression of RAS2S225A 
or RAS2S225E leads to both perturbed growth and a reduction in viability when compared to 










Figure 31. A colony forming efficiency assay of S. cerevisiae wild type or Δras2 cells 
overexpressing RAS2, RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA 
media  
 A) A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2, 
RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA media. A colony forming 
efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A 
One-way ANOVA using a Dunnetts multiple comparison test was used to determine statistical 
significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = adjusted p value ≤ 
0.001. B) A colony forming efficiency assay of S. cerevisiae Δras2 cells overexpressing RAS2, 
RAS2S225A, RAS2S225Eor an empty plasmid control, grown in SD –URA.  The colony forming 
efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A 
One-way ANOVA using a Tukey multiple comparison test was used to determine statistical 
significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = adjusted p value ≤ 
0.001. 
 
3.6.3 Overexpression of RAS2S225A or RAS2S225E in a yeast cells leads to a sensitivity 
to oxidative stress 
 
Ras activity has been linked to cells ability to adapt to environmental stress [216]. We 
investigated the effect of oxidative stress on wild type cells expressing RAS2, RAS2S225A, 
RAS2S225E using a spotting assay as described in Materials and Methods, Section 2.9.5. 
On the control plate a reduction in growth was observed in wild type cells overexpressing 




concordant with the phenotypes observed in the growth assay (Figure 27) and the viability 
assay (Figure 31). Interestingly, the overexpression of RAS2 in wild type cells led to an increase 
in growth when compared to the wild type control in all conditions investigated (Figure 32). 
As the concentration of hydrogen peroxide increased, the growth of wild type cells 
overexpressing RAS2S225A or RAS2S225E decreased when compared to the wild type control and 
RAS2 overexpression strains (Figure 32). At a hydrogen peroxide concentration of 3 mM, we 
observe growth in both the control strain and the RAS2 overexpression strain, but growth was 
absent in wild type cells expressing either RAS2S225A or RAS2S225E (Figure 32).  This suggests 
that the overexpression of either RAS2S225A or RAS2S225E leads to sensitivity to oxidative stress 






Figure 32. Spotting assay of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or an 
empty plasmid control.  
Cells were serially diluted from 2*10^6/ml to 2*10^3/ml and plated onto SD -URA plates 




To investigate whether the overexpression of either RAS2S225A or RAS2S225E in wild type cells 
leads to hydrogen peroxide sensitivity in liquid media, growth analysis was conducted when 
the media was supplement with 2 mM hydrogen peroxide. As previously observed,  the 
expression of RAS2S225A or RAS2S225E in wild type cells leads to growth defects when grown in 
SD –URA media (Figure 31). However wild type cells overexpressing either RAS2S225A or 
RAS2S225E and grown in 2 mM hydrogen peroxide, presented a further significant increase in 
lag time and a decrease in final OD reached when compared to cells expressing RAS2S225A or 
RAS2S225E grown without the presence of hydrogen peroxide (Figure 33).  Upon addition of 
hydrogen peroxide, we also observed a significant increase in doubling time when compared 
to wild type cells expressing RAS2S225A or RAS2S225E grown without the supplementation of 










Figure 33. Growth analysis of S. cerevisiae wild type cells overexpressing RAS2, RAS2S225A, 
RAS2S225E or an empty plasmid control.   
A growth analysis of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or an empty 
plasmid control was carried out in SD –URA or SD-URA + 2mM H2O2 media as described in 
Materials and Methods (Section 2.9.1). This data represents an average of three biological 

















Figure 34. Growth rate analysis of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E 
or an empty plasmid control.  
A growth rate analysis of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or an empty 
plasmid control grown in either SD –URA or SD –URA+ 2mM H2O2 was carried out as described 
in Materials and Methods (Section 2.9.1). The data represents an average of three biological 
repeats and error bars represents the standard deviation. A One-way ANOVA using a Tukey 
multiple comparison test was used to determine statistical significance. Non-significant = NS, 
* = adjusted p-value ≤ 0.05 and *** = adjusted p value ≤ 0.001. 
 
3.6.4 Overexpression of RAS2S225A or RAS2S225E   in yeast cells leads to copper 
sensitivity 
 
We have previously shown that the overexpression of either RAS2S225A or RAS2S225E in wild 
type cells leads to oxidative stress sensitivity. We sought to investigate whether the 
overexpression of either RAS2S225A or RAS2S225E in wild type cells resulted in other 
environmental stress sensitivities, such as heavy metal ion stress. Here we supplemented 
copper sulphate (CuS04) at varying concentrations to the growth media and investigated the 
effect of heavy metal ion stress on the growth of wild type cells overexpressing RAS2, 
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RAS2S225A, RAS2S225E or an empty plasmid control using a spotting assay as described in 
Materials and Methods, Section 2.9.6.   
On the control plate a reduction in growth was observed in wild type cells overexpressing 
either RAS2S225A or RAS2S225 when compared to the control strain (Figure 35). As the 
concentration of CuS04 increased, the growth of wild type cells overexpressing RAS2S225A or 
RAS2S225E decreased when compared to the wild type control and RAS2 overexpression strains 
(Figure 35). At a CuS04 concentration of 3 mM, we observe growth in both the control strain 
and the RAS2 overexpression strain, but no growth was observed in wild type cells expressing 
either RAS2S225A or RAS2S225E (Figure 35).  This suggests that the overexpression of either 
RAS2S225A or RAS2S225E leads to sensitivity to CuS04 in wild type cells.  
 
Figure 35. Spotting assay of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or an 
empty plasmid control.  
Cells were serially diluted from 2*10^6/ml to 2*10^3/ml and plated onto SD -URA plates 
supplemented with increasing concentrations of copper sulphate. This experiment was 




3.7 Chronological ageing analysis of S. cerevisiae cells overexpressing 
RAS2S225A 
 
3.7.1 Overexpression of RAS2S225A in wild type cells reduces chronological life 
span 
 
To further investigate the effects of the overexpression of the RAS2S225A on both growth and 
viability a chronological ageing assay was conducted. Overnight cultures of wild type cells 
overexpressing the empty plasmid backbone control or RAS2S225A mutant allele were grown 
and sub-cultured to a calculated OD600 of 0.1 in SD –URA media. After 24 hours of incubation, 
an aliquot of the culture was taken to calculate the colony forming units (Materials and 
Methods, Section 2.9.9) and for flow cytometry analysis to measure levels of propidium iodide 
(Materials and Methods, Section 2.9.12) and dihydroethidium fluorescence (Materials and 
Methods, Section 2.9.11) to assess necrosis and superoxide production respectively.  Aliquots 
of cells were taken from the same culture sequentially at 24-hour intervals for 6 days and 
colony forming unit counts and flow cytometry analysis were undertaken. The final 
























Figure 36. A chronological ageing assay of wild type cells over expressing RAS2S225A or an 
empty plasmid control grown in SD –URA.  
The chronological ageing assay was conducted as described in materials and method (Section 
2.9.8). The data represents an average of three technical repeats and error bars represents 
the standard error of the mean. 
 
After 24 hours of incubation the wild type control shows ~40 % viability compared to ~20 % 
in wild type cells overexpressing RAS2S225A (Figure 36). At day 2 we see an unexpected increase 
in viability in the wild type control but see a decrease in viability in cells overexpressing 
RAS2S225A. Over time we observed an overall decrease in viability when compared to the first 
time point in both strains. At day 12, the RAS2S225A mutant was unable to form viable colonies 
whereas the control strain had a colony forming efficiency of ~18 %. Thus, under the 
conditions used the overexpression of RAS2S225A leads to a complete loss of viability after 12 
days of incubation which was not observed in the wild type control (Figure 36). 
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3.7.2 Flow cytometry to analyse the levels of ROS in wild type cells expressing 
RAS2S225A 
 
To investigate the levels of cell death in cells overexpressing RAS2S225A, fluorescence-activated 
cell sorting (FACS) was utilised. This flow cytometry-based technique was used to determine 
whether the overexpression of RAS2S225A results in an increase in ROS. Increased levels of ROS 
within cells is indicative of cell stress or programmed cell death [217][155][218]. The dye 
dihydroethidium (DHE) was used to analyse ROS levels within cells. DHE is oxidised by 
superoxide radicals (O2˙¯). The reaction between superoxide and DHE leads to a fluorescence 
output that can be detected using a flow cytometer.  ROS accumulation was measured using 
flow cytometry as described in Materials and Methods, Sections 2.9.11. A marker (M1) was 
set to incorporate the standard peak for the comparison of samples to a control sample grown 
without any ROS indicator dye. The M1 marker was set at the same fluorescence intensity 
position on the x axis of all subsequent samples. The second marker (M2) was set to the right-
hand side of the M1 marker and incorporated any peaks that represented an increase in 




















Figure 37. A bar chart presenting the percentage of DHE positive cells in wild type cells 
overexpressing RAS2S225A or an empty plasmid control.  
Strains were grown in SD-URA and measurements were taken over a 12-day period of 
continuous incubation. Cells were incubated with DHE in a 96 well plate for 15 minutes to 
measure superoxide production. The data displayed is an average of three biological repeats 
and error bars represent standard deviation 
 
In both the wild type control and the RAS2S225A strain there was a very low percentage of DHE 
positive cells after the first day of growth suggesting a small proportion of ROS producing cells 
(Figure 37). Between days 2 to 6 there was an increase in the percentage of DHE positive in 
both strains. At day 6, the percentage of DHE positive cells rose to ~20% in both strains. At 
day 12 the percentage of DHE positive cells in the wild type control increased to 50 % and 55 
% in wild type cells overexpressing RAS2S225A, respectively (Figure 37). This data set suggests 
that the overexpression of the RAS2S225A mutant does not lead to a loss of viability that 
correlates with an increase in ROS production, a phenotype commonly linked to forms of cell 




3.7.3 Flow Cytometry to analyse the levels of necrosis in wild type cells expressing 
RAS2S225A 
 
To investigate the levels of necrosis in the wild type control and wild type cells overexpressing 
RAS2S225A propidium iodide was used. Propidium iodide (PI) intercalates into double stranded 
nucleic acids when the cell membrane is compromised. PI can therefore only penetrate 
necrotic cells and is excluded by viable cells and so its uptake is a useful marker of this mode 
of cell death. A marker (M1) was set to incorporate the standard peak for the comparison of 
samples to a control sample grown without any Propidium Iodide. The M1 marker was set at 
the same fluorescence intensity position on the x axis of all subsequent samples. The second 
marker (M2) was set to the right-hand side of the M1 marker and incorporated any peaks that 
represented an increase in fluorescence intensity. The control had no value for the M2 marker 
as there was no increase fluorescence detected. 
In both the wild type control and wild type cells overexpressing RAS2S225A the percentage of 
PI positive cells was negligible at day 1 (Figure 38). Between days 1-4 there was a small 
increase in the percentage of PI positive cells from 1 to 10% in both strains. This was again 
expected, as the number of days of continuous growth increases the population of ageing 
cells in the culture will increase leading to an increase in cell death and hence an increase in 
the percentage of PI positive cells. At day 6 we observed a further increase in the percentage 
of PI positive cells in both strains, with the percentage of PI positive cells in the wild type 
control marginally exceeding that of the RAS2S225A mutant strain. At day 12 a significant 
increase in PI positive cells is observed in the wild type control strain when compared to the 
RAS2S225A strain. In the wild type control the percentage of PI positive cells reaches 50 % of 
the population with wild type cells overexpressing RAS2S225A showing 40 % of the population 
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being PI positive (Figure 38). This data suggests that the overexpression of RAS2S225A in wild 












Figure 38. A bar chart presenting the percentage of PI positive cells in wild type cells 
overexpressing RAS2S225A or an empty plasmid control.  
Strains were grown in SD-URA and measurements were taken over a 12-day period of 
continuous incubation Cells were incubated with PI in a 96 well plate for 15 minutes to 
measure cell death. The data displayed is an average of three technical repeats and error bars 
represent standard deviation. 
 
3.8 The overexpression of either RAS2S225A or RAS2S225E in wild type cells 
presents no significant abnormalities in cells ability to regulate autophagy  
 
In S. cerevisiae, Ras proteins mediate autophagy through the activity of PKA [219][167]. The 
RAS/cAMP/PKA pathway has been shown to be highly interconnected with the TOR pathways 
which is also involved in the regulation of autophagy in yeast [219][167][166]. Both Tor and 
Ras often control overlapping effectors, including effectors involved in autophagy. We aim to 
investigate whether the overexpression of either RAS2, RAS2S225A or RAS2S225E in a GFP-ATG8 
strain leads to changes in cells ability to regulate autophagy. Here we analyse the autophagy-
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related ubiquitin-like protein Atg8 as a tool for monitoring and quantifying autophagy upon 
the overexpression RAS2, RAS2S225A or RAS2S225E in yeast cells (Figure 39).   
Atg8 most commonly exists conjugated to the lipid phosphatidylethanolamine (PE). In S. 
cerevisiae, Atg8-PE conjugation is regulated by the nutritional status of the cells. During 
nutrient-rich conditions, Atg8 mainly exists in the unconjugated form but upon nitrogen 
starvation most of the Atg8 population conjugates to PE [220]. During nitrogen starvation 
Atg8-PE is recruited to the phagophore assembly site and localizes to both the inner and outer 
phagophore membranes, but is generally not detected on the surface of completed 
autophagosomes [220]. Upon autophagosome  completion, Atg8-PE localised to the inner-
autophagosome membrane is transported to the vacuole where it is degraded by vacuolar 
proteases as part of the autophagic body [220]. The population of Atg8 present on the outer 
membrane of the autophagosome is released via the deconjugation of the Atg8-PE by a Atg4-
dependent cleave step [221]. GFP-Atg8 shows the same behaviour as Atg8, and autophagic 
flux can be followed by monitoring the vacuolar delivery and subsequent breakdown of GFP-
Atg8. When autophagic flux is normal, GFP-Atg8 that is present inside the autophagosome is 
cleaved after the autophagic body membrane is lysed and the contents are exposed to the 
vascular hydrolases. The proteolysis of GFP-Atg8 liberates an intact GFP moiety, which 
accumulates in the vacuole as autophagy proceeds. The increase in free GFP levels can be 
detected and quantified by western blot analysis and correlated with the autophagic rate 
[222][223].  
We transformed plasmids overexpressing either RAS2, RAS2S225A or RAS2S225E into a GFP-ATG8 
background to assess autophagic rate. An empty plasmid backbone was transformed into a 
GFP-ATG8 background as a control. ATG8–GFP cells overexpressing either RAS2, RAS2S225A, 
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RAS2S225E, or an empty plasmid control were grown in SD-URA for 24 hours to stationary 
phase. Following this, 1ml of culture was transferred to nitrogen starvation media (Materials 
and Methods, Section 2.1.4) to induce autophagy, and incubated at 30 °C with 200 rpm 
shaking for 6 hours (Materials and Methods, Section 2.9.7). Total protein was extracted from 
cells pre- and post-induction of autophagy and subjected to western blotting (Materials and 
Methods Section 2.8). We did not observe any significant differences in autophagic flux in 
GFP-ATG8 strains overexpressing RAS2, RAS2S225A or RAS2S225E when compared to the control 
(Figure 39). In the absence of nitrogen starvation, no significant differences in the detection 
of GFP-ATG8 or GFP were observed between strains (Figure 39). In the presence of nitrogen 
starvation, a significant increase in GFP detection was detected in all strains but no significant 
difference in free GFP detection was noted between strains (Figure 39). As no significant 
differences in GFP liberation upon nitrogen starvation was observed when compared to the 
control strain, we propose that the overexpression of RAS2, RAS2S225A or RAS2S225E does not 


















Figure 39. A western blot showing the detection of GFP in GFP-ATG8 cells overexpressing 
RAS2, RAS2S225A, RAS2S225E or an empty plasmid control.  
Cells were grown in SD –URA media for 24 hours. 1ml of culture was transferred to nitrogen 
starvation media to induce autophagy via nitrogen starvation and incubated at 30°C with 200 
RPM shaking for 6 hours. Total protein was extracted from cells pre- and post-induction of 
autophagy and subjected to western blotting. To ensure uniform protein loading, the levels of 
Pgk1p were detected after probing for Ras2p. This experiment was repeated three times and 









3.9 Analysis of the effects of the overexpression of RAS2S225A or RAS2S225E 
upon mitochondria morphology 
 
3.9.1 Microscopic analysis of wild type cells overexpressing RAS2S225A, RAS2S225E or 
an empty plasmid control and co-expressed with a GFP-mitochondria probe 
 
Ras activity has been linked to the regulation of mitochondrial function[224][218] [225]. To 
investigate the effect of the modification of Ras2S225 upon mitochondria morphology, wild 
type cells expressing either RAS2S225A, RAS2S225E or an empty plasmid control were 
transformed with a GFP-mitochondria probe. During stationary phase of growth, no 
significant differences in mitochondrial inheritance or morphology was observed in wild type 















































Figure 40. Images taken using fluorescence microscopy of wild type strains overexpressing 
RAS2S225A, RAS2S225E or an empty plasmid control co-expressed with a GFP-mitochondria 
probe during stationary phase of growth.  
Fluorescence signal represents the presence of mitochondria within cells. The GFP 
mitochondria probe contains the first 69 amino acids of subunit 9 of the F0 ATPase of 
Neurospora crassa [Su9(1–69)] which is a mitochondrial matrix targeting sequence and 
includes a processing site for the mitochondrial matrix processing peptidase (Westermann & 
Neupert 2000). Cells were cultured in SD –URA/-LEU growth media. This experiment was 








3.10 Respirometry to assess mitochondrial function in wild type cells 
overexpressing RAS2S225A or RAS2S225E  
 
Our results indicate that the overexpression of either RAS2S225A or RAS2S225E in both a wild 
type and Δras2 background can lead to a loss in viability that is not accompanied by an 
increase in either ROS accumulation or PI staining. One possibility is that cells overexpressing 
either RAS2S225A or RAS2S225E are in fact senescent or quiescent and that the loss of viability 
does not represent cell death, but rather an inability to divide. We noted no significant 
abnormalities in mitochondrial inheritance or morphology in cells overexpressing either 
RAS2S225A or RAS2S225E, however we did not investigate mitochondrial activity. To address this, 
we measured respiration within wild type cells overexpressing RAS2S225A or RAS2S225E.  
A high-resolution respirometer was used to measure respiration by analysing the oxygen 
consumption of wild type cells overexpressing either RAS2S225A, RAS2S225E or an empty plasmid 
control. The oxygen consumption was measured as O2 flow per cell (Figure 41). The drugs 
Triethiltyn bromide (TET), Carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP), and 
Antimycin A (AntA) were used to investigate the functioning of individual components of the 










Figure 41. A typical respirometry profile generated from the Oroboros oxygraph-2k. 
 The blue line shows oxygen concentration and the red line represents the oxygen flux per cell 
(pmol/s*Mill). The black arrows indicate the steady state oxygen flux (Routine), the induced 
mitochondrial resting state (Leak), the maximal capacity of the electron transport system (ETS) 
and the non-mitochondrial oxygen flux (nmt). For the analyses of individual components of 
the respiratory chain specific drugs were added to the chambers. The drug TET was used to 
induce leak respiration, FCCP was used to inhibit ATP synthase and therefore allow maximal 
electron transport through the ETS and AntA was used to inhibit the ETS. 
 
To measure ‘Leak’ respiration we used the drug TET, which inhibits ATP synthase complex V. 
ATP synthase produces energy in the form of ATP through the pumping of protons across the 
mitochondrial inner-membrane space (IMS) into the mitochondrial matrix. Inhibition of ATP 
synthase results in the accumulation of protons within the IMS, leading to an inhibition of the 
movement of electrons through the electron transport chain. The activity of ATP synthase 
therefore represents an integral control mechanism. Upon the addition of TET, any 
respiration that is detected when ATP synthase is inhibited does so because of protons 
moving freely across the IMM independently of the pump, and thus called leak respiration. If 
the leak respiration of a strain is higher than that of the control strain, we can conclude that 
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more respiration has been detected that is occurring independently of ATP synthase proton 
pumping activity and by association, ATP synthesis.   
Mitochondrial membrane potential is a major regulator of electron passage, if the membrane 
potential is too high electrons cannot passage along the ETC as this requires proton pumping 
into the IMS, which becomes more difficult as the membrane potential is increased. The 
inhibition of ATP synthase stops election movement as the resulting affect is an increase in 
membrane potential. When a TET induced drop in respiration is not observed, it suggests that 
oxygen consumption and electron movement occurs independently of ATP synthase and 
therefor ATP is not synthesized as it requires the movement of protons through the pump; 
this is termed uncoupled respiration.    
To measure the maximal capacity of the electron transport system (ETS) the drug FCCP was 
used. FCCP is a proton ionophore that forms pores in the IMM rendering it permeable and 
permitting the free flow of protons across it. The resulting effect if the disruption of the 
membrane potential provided by the proton gradient allowing the ETC to function at its 
maximal potential. As such, the higher the ETS detected, the higher the capacity of the ETC.    
To measure the non-mitochondrial (nmt) origin of respiration the drug Antimycin A (AntA) 
was used. AntA inhibits cytochrome C reductase (complex III) through binding to the Qi site 
and preventing the transfer of electrons. Complex III is the third phase in the ETC and is 
oxidised at the Qi site, therefor inhibition of this site prevents re-oxidation by oxygen. As a 






Figure 42. A bar chart showing the routine, leak, ETS and NMT O2 flux values for wild type 
cells overexpressing RAS2S225A, RAS2S225E or an empty plasmid backbone control.  
The data shown represents one experiment. 
 
A significant reduction in routine respiration was observed upon the overexpression of 
RAS2S225A or RAS2S225E in wild type cells when compared to the control strain (Figure 42). The 
overexpression of RAS2S225E presented the most notable reduction, with a routine respiration 
of 0.2 (mt)[pmol/(s*Mill)], compared to 13.1 (mt)[pmol/(s*Mill)] in the wild type control 
(Figure 42). Our results indicate that the overexpression of either RAS2S225A or RAS2S225E in 
wild type cells results in a significant decrease in routine respiration when compared to the 
control strain. A significant decrease in leak respiration was also noted upon the 
overexpression of RAS2S225A or RAS2S225E when compared to the wild type control (Figure 42). 
Interestingly, leak respiration was not detected in wild type cells overexpressing RAS2S225E. As 
the leak respiration of strains overexpressing RAS2S225A or RAS2S225E is lower than that of the 
control strain, we can conclude that the respiration detected in these strains is not occurring 
independently of ATP synthase proton pumping activity.  
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A significant decrease was observed in the maximal capacity of the electron transport system 
(ETS) in wild type cells overexpressing RAS2S225A or RAS2S225E when compared to the wild type 
control, therefor suggesting that the overexpression of either RAS2S225A or RAS2S225E causes a 
reduction in the overall capacity of the ETS (Figure 42).  
Individual components of the ETC were further analysed to identify whether a component 
was affected by the overexpression of either RAS2S225A or RAS2S225E. This was completed by 
comparing the oxygen flux ratios between the Routine and ETS (R/E) and the Leak and ETS 
(L/E). The oxygen flux ratios from each strain were compared to the wild type expressing an 
empty plasmid backbone. 
The ratio obtained from dividing the Routine respiration rate by the ETS respiration rate (R/E) 
defines how close to the maximal capacity the mitochondria are functioning during Routine 
respiration. The closer to 1 the R/E ratio is, the closer to maximum capacity the ETS is working 
in that strain. A higher R/E ratio could suggest more uncoupling of the ETC, an increase in ADP 
driven respiration or a limitation of the ETC components.  
The ratio obtained from dividing the Leak respiration rate by the ETS respiration rate (L/E) 
was analysed to determine whether the ETC is uncoupled. The closer to 1 the L/E ratio is, the 
higher the levels of uncoupled respiration that are occurring independently of ATP synthase. 









Figure 43. The oxygen flux ratios between the Routine and ETS (R/E) and the Leak and ETS 
(L/E) are shown for wild type cells overexpressing RAS2S225A, RAS2S225E or an empty plasmid 
backbone control.  
The data shown represents one experiment. 
 
The increase in the R/E ratio observed in wild type cells overexpressing RAS2S225A suggests 
that the mitochondria in these cells are working closer to the maximal capacity when 
compared to the wild type control (Figure 43). To determine whether the increase in R/E was 
due to uncoupled respiration, the ratio for L/E was analysed. The L/E ratio was decreased in 
wild type cells overexpressing RAS2S225A, which suggests a decrease in uncoupled respiration, 
when compared to wild type control (Figure 43). As the mitochondria in wild type cells 
overexpressing RAS2S225A are functioning close to their maximal capacity, we can conclude 
that wild type cells overexpressing RAS2S225A are neither necrotic nor apoptotic.  
The decrease in the R/E ratio observed in wild type cells overexpressing RAS2S225E suggests 
that the mitochondria in these cells are not functioning close to the maximal capacity when 
compared to the wild type control (Figure 43).  To determine whether there is an increase in 
uncoupled respiration when compared to the control strain, the ratio for L/E was analysed. 
The L/E ratio was 0 in wild type cells overexpressing RAS2S225E, which suggests there is no 
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uncoupled respiration present (Figure 43). We suggest that the overexpression of RAS2S225E 
in wild type cells results in severe mitochondrial dysfunction, as opposed to repression. From 
the data generated in this study, we see no evidence of cell death markers even when 
respiration is minimal. We therefor conclude that the overexpression of either RAS2S225A or 
RAS2S225E results in a deficit of growth resumption that accounts for the loss of viability 
observed. 
3.11 Sequence alignment between Ras2 and human N-Ras suggests that 
Serine225 is conserved in human N-Ras at Serine173 
 
We have shown that the Serine225 residue of the Ras2 protein is important for growth, 
viability, and the localisation of Ras. We hypothesized that this residue may be conserved in 
higher eukaryotes. To address this, sequence alignment between the Ras2 protein and the 
human N-Ras protein was performed (Figure 44). Remarkably, although significant sequence 
divergence between the yeast and human Ras proteins outside of the GTPase domain and C 
terminal CAAX box, we discovered that Ras2 Serine225 was conserved in human N-Ras at 
Serine173 (Figure 44). The conservation of this serine residue in human Ras proteins may 
suggest an important role of this residue in higher eukaryotic systems. Plasmids 
overexpressing the wild type NRAS gene or plasmids containing the NRAS gene mutated at 
SerineS173, where the serine was either substituted with alanine to produce a non-
phosphoryatable residue or glutamate to produce phosphomimetic residue, were 




Figure 44. Sequence alignment of the Ras2 protein and human N-Ras shows that Serine225 
of Ras2p (circled) is conserved in N-Ras at Serine173. 
 
3.11.1 The expression of NRAS, NRASS173A or NRASS173E induces growth defects in 
wild type cells  
 
As sequence alignment revealed conservation of the yeast Ras2S225 phosphorylation site in 
the human Nras protein, constructs expressing human NRAS or human NRAS mutations at the 
equivalent phosphorylation site (Ser173) were transformed into wild type cells. To analyse the 
growth of yeast strains overexpressing NRAS, NRASS173A, NRASS173E or an empty plasmid 
control, a growth assay was performed as described in Materials and Methods, Section 2.9.1. 
Overexpression of either NRAS, NRASS173A or NRASS173E in wild type cells resulted in severe 
growth defects when compared to the wild type control (Figure 45). The expression of either 
wild-type or mutated human NRAS led to an increase in lag time, early transition to diauxic 
growth and overall lower final biomass when compared to the control strain (Figure 45). The 
mutated forms of human NRAS were seen to perturb growth to a greater extent when 
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compared to the wild-type Human NRAS expressing strain. A significant increase in doubling 
time was observed upon the overexpression NRAS, NRASS173A, NRASS173E in wild type cells 















Figure 45. Growth analysis of S. cerevisiae wild type cells overexpressing RAS2, RAS2S225A, 
RAS2S225E or empty plasmid control.   
The growth analysis was carried out in SD –URA media as described in Materials and Methods 
(Section 2.9.1). This data represents an average of three biological repeats and error bars 


















Figure 46. Growth rate analysis of S. cerevisiae wild type cells overexpressing RAS2 or 
RAS2S225A or RAS2S225E.   
The growth rate analysis was carried out as described in Materials and Methods (Section 
2.9.1). The data represents an average of three biological repeats and error bars represents 
the standard deviation. A One-way ANOVA using a Dunnets multiple comparison test was used 
to determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** 
= adjusted p value ≤ 0.001. 
 
3.11.2 Expression of NRAS, NRASS173A or NRASS173E in yeast cells leads to a 
reduction in viability 
 
To determine whether the overexpression of either NRAS, NRASS173A or NRAS173E led to 
changes in viability in wild type cells we performed a colony forming efficiency assay, as 
described in Materials and Methods, Section 2.9.3. The overexpression of either NRAS, 
NRASS173A or NRASS173E in wild type cells resulted in a significant reduction in viability when 
compared to the plasmid control in the wild type (Figure 47). Our data suggests that the 
overexpression of Human NRAS in yeast cells leads to a significant decrease in viability 
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regardless of the status of Ser173. This data alone, therefor does not allow us to determine the 











Figure 47. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing 
NRAS, NRASS173A, NRASS173E or an empty plasmid control grown in SD –URA media. 
  A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). This data represents three biological repeats and the error bars represent the 
standard deviation. A One-way ANOVA using a Dunnets multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 




















































































3.12 Discussion of Results 
 
Ras proteins are small GTPases that act as molecular switches within cells that link 
extracellular stimuli to intracellular effectors. Ras proteins play a conserved role in the control 
of both cell growth and proliferation [211]. As a result, mutations that induce the constitutive 
activation of Ras proteins are often associated with changes in cell behaviour that can lead to 
disease, such as human cancer [41]. The localisation of Ras proteins are reported to be 
predominantly to the inner cytoplasmic surface of the plasma membrane, but they can also 
be observed on endomembranes, such as the endoplasmic reticulum, and the mitochondrial 
outer membrane [65][57][212]. It has been shown that Ras undergoes a series of 
posttranslational modifications that dictate its subcellular localisation.  Surprisingly, the 
phosphorylation of Ras2p in S. cerevisiae has not been studied in regards to its regulation of 
intracellular localisation, despite significant evidence existing linking phosphorylation to Ras 
localisation in humans [50][77]. While phosphorylation is an important posttranslational 
modification, little is known on its effect on Ras2 protein activation and localisation. Previous 
studies conducted by the Kent Fungal Lab, under the supervision of Dr Campbell Gourlay have 
identified the residue Ser225 of Ras2p as a potential phosphorylation site within the Ras2 
protein of S. cerevisiae. The present study investigates further whether Ras2p 
phosphorylation provides a mechanism that regulates Ras2p trafficking inside the cell.  
The data presented in this chapter suggests that the modification of the Ser225 residue of 
Ras2p is important for both localisation and activity of Ras proteins. We have shown that 
during both log and stationary phases of growth, the overexpression of either RAS2S225A or 
RAS2S225E in wild type cells results in significant changes in the localisation of active Ras 
populations when compared to the RAS2 overexpression strain and wild type control. Actively 
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growing wild type cells localise GTP-bound Ras to the plasma membrane and nucleus. In wild 
type cells, such localisation results in the activation of the cAMP/PKA pathway, which signals 
to the cell to initiate both growth and proliferation. We suggest that during exponential 
growth, wild type cells overexpressing either RAS2S225A or RAS2S225E sequester active Ras to 
the nuclear envelope with reduced activity seen at the plasma membrane and nucleus. We 
hypothesize that the miss-localisation and inappropriate activation of Ras at the nuclear 
envelope results in aberrant activation of the cAMP/PKA pathway. 
Upon nutrient depletion, GTP-bound Ras populations present a widespread/diffused signal 
with a faint nuclear localisation within wild type cells. Interestingly, we show that the 
overexpression of RAS2S225A or RAS2S225E presents a nuclear envelope localisation of GTP-
bound Ras which was not observed in either the control or RAS2 overexpression strains. We 
suggest that the overexpression of RAS2S225A or RAS2S225E leads to the miss localisation of 
active Ras to the nuclear envelope and an inappropriate activity during nutrient depletion, a 
time in which Ras activity should be minimal. We hypothesize that the resulting localisation 
of GTP-bound Ras caused by the overexpression of RAS2S225A or RAS2S225E, results in the 
inappropriate activation of PKA during a period of growth where its activity should be 
reduced.  
The localisation of GFP-Ras2p, GFP-Ras2pS225A or GFP-Ras2pS225E was investigated using 
fluorescent microscopy. Surprisingly, no significant changes in the localisation of fluorescently 
labelled Ras2p was observed between wild type cells overexpressing RAS2, RAS2S225A or 
RAS2S225E. The predominant localisation of GFP-Ras2p was observed at the plasma membrane 
in both stationary and exponential phase of cell growth. As previously mentioned, the 
overexpression of RAS2S225A or RAS2S225E resulted in significant differences in the localisation 
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of active Ras population when compared to the control and RAS2 overexpression strain. 
Therefor it was surprising that the overexpression of the mutant RAS2 alleles failed to result 
in changes in GFP-Ras2p localisation. As the RBD domain binds to Ras proteins only in their 
GTP-bound state and does not differentiate between Ras1 and Ras2, we hypothesize that the 
modification of Ser225 results in the miss localisation of both Ras proteins when only in their 
GTP-bound state. 
 In the current study, the localisation of both active Ras and GFP-Ras2p was investigated 
exclusively in wild type cells. For future investigations, we believe it would be useful to study 
the localisation of active Ras populations and GFP-Ras2p in a Δras2 background.  Such 
investigations will reveal the effects of the overexpression of either RAS2, RAS2S225A or 
RAS2S225E on the localisation of active Ras populations in the absence of endogenous wild-type 
Ras2p. Similarly, we would like to investigate the localisation of GFP-Ras2p, GFP-Ras2pS225A or 
GFP-Ras2pS225E in a Δras2 background to identify whether the presence of endogenous wild 
type Ras2p affects the localisation of GFP-Ras2p, GFP-Ras2pS225A or GFP-Ras2pS225E.  
Western blot analysis confirmed that Ras2, Ras2pS225A and Ras2pS225E are being overexpressed 
in both a wild type and Δras2 background. The overexpression of RAS2S225A or RAS2S225E in wild 
type cells during exponential phase of cell growth led to an increase in Ras2p protein 
expression when compared to the control and RAS2 overexpression strain. We hypothesize 
that this could be the result of an increase in the stability of the Ras2 protein, although it is 
not known whether this is due to an increase in mRNA levels, translation, or the stability of 
the protein itself. The overexpression of either RAS2S225A or RAS2S225E in a wild type 
background led to an increase Ras2p expression during stationary phase when compared to 
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the control and RAS2 strain. Suggesting a putative role of Ser225 in the regulation of Ras2 
protein expression or protein stability.  
The overexpression of RAS2S225A or RAS2S225E resulted in significant growth defects when 
compared to the empty plasmid control in both wild type and Δras2 backgrounds. Our 
findings show that Ras2S225 is important for Ras function and furthermore that the growth 
defects induced by the overexpression of RAS2S225A or RAS2S225E are in fact dominant as 
growth defects manifest irrespective of whether endogenous Ras2p is present. Furthermore, 
we have identified the importance of Ras2S225 in the maintenance of chronological lifespan. 
We show that the overexpression of RAS2S225A in wild type cells leads to a significant decrease 
in chronological life span when compared to the wild type, providing further evidence that 
the Ser225 residue is important for Ras function.  
As Ras2p is involved in the regulation of antioxidant defences, we investigated whether the 
substitution of Ser225 of yeast Ras2 with glutamate or alanine led to changes in the cells ability 
to tolerate the addition of hydrogen peroxide to both liquid and solid media. The addition of 
H2O2 to liquid media resulted in significant growth defects in cells overexpressing RAS2 
mutant alleles when compared to the control strain. This effect was also recapitulated on 
solid media, with an increased sensitivity to peroxide observed in wild type cells 
overexpressing RAS2S225A or RAS2S225E when compared to the control strain. The inability of 
wild type cells overexpressing RAS2S225A or RAS2S225E to recover from this stress response is 
an indication that overexpression of either RAS2S225A or RAS2S225E alters the signalling 
properties of Ras and leads to a suppression of the oxidative stress response.  
To investigate whether perturbed growth was accompanied by changes in culture viability a 
colony forming efficiency assay was performed. The expression of RAS2S225A or RAS2S225E in 
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both a wild type and Δras2 background leads to a significant reduction in viability when 
compared to the control strain. The expression of RAS2 did not appear to reduce viability in 
the Δras2 background but interestingly increased viability when expressed in wild type cells. 
This reduction in viability only observed in cells overexpressing RAS2S225A or RAS2S225E suggests 
that the Ser225 of Ras2 is important for Ras function. 
The findings within this chapter suggest that the modification of ser225 residue of Ras2 leads 
to growth defects, changes in the oxidative stress response and leads to a reduction in viability 
in wild type cells. We therefore investigate whether the overexpression of either RAS2S225A in 
a wild type background leads to an increase in markers of cell death, such as ROS. Increased 
levels of ROS within cells is indicative of cell stress or programmed cell death [217][155][218]. 
Using FACS analysis with the dye dihydroethidium (DHE) we measured ROS levels in cells 
overexpressing RAS2S225A. Interestingly our data indicated the overexpression of RAS2S225A 
presented no significant increase in the percentage of DHE positive cells when compared to 
the wild type control. This data set suggests that the overexpression of the RAS2S225A mutant 
does not lead to a loss of viability that correlates with an increase in ROS production, a 
phenotype commonly linked to forms of cell death in yeast [217]. 
With no significant elevation in cellular ROS levels in strains assayed, we performed a FACS 
analysis using the dye propidium iodide to determine whether wild type cells overexpressing 
RAS2S225A showed increased levels of necrosis when compared to the wild type control. Our 
data suggests that the overexpression of RAS2S225A presented no significant increase in the 
percentage of necrotic cells when compared to the wild type control. This data suggests that 
the overexpression of RAS2S225A in wild type cells does not lead to a loss of viability that can 
be explained by an increase in necrosis.   
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In S. cerevisiae, Ras proteins mediate autophagy through the activity of PKA [219][167]. The 
RAS/cAMP/PKA pathway has been shown to be highly interconnected with the TOR pathways 
which is also involved in the regulation of autophagy in yeast [219][167][166]. Both Tor and 
Ras often control overlapping effectors, including effectors involved in autophagy. We 
investigated whether the overexpression of either RAS2, RAS2S225A or RAS2S225E led to changes 
in cells ability to regulate autophagy. We observed no significant differences in autophagic 
flux upon the overexpression of RAS2S225A or RAS2S225E when compared to the control strain, 
indicating that the overexpression of either RAS2S225A or RAS2S225E does not result in 
autophagic flux abnormalities.  
We show that the expression of RAS2S225A or RAS2S225E, in both a wild type and Δras2 
background results in a loss of viability but is not accompanied by elevated DHE or PI staining. 
An explanation is that cells expressing the mutant RAS2 alleles are in fact senescent or 
quiescent and that the loss of viability does not represent cell death, but rather an inability to 
divide. To address this, we investigated levels of respiration within wild type cells 
overexpressing RAS2S225A or RAS2S225E.  We can confirm that wild type cells overexpressing 
RAS2S225A or RAS2S225E are respiring suggesting these cells are not dead but have an inability 
to divide.  
The findings in this chapter clearly suggest an important role of the Ser225 residue of Ras2 for 
both protein localisation and function. We hypothesized that this residue may be conserved 
in higher eukaryotes. To address this, sequence alignment between the Ras2 protein and the 
human N-Ras protein was performed. Interestingly, although significant sequence divergence 
between the yeast and human Ras proteins outside of the GTPase domain and C terminal 
CAAX box, we discovered that Ras2 SerineS225 was conserved in human N-Ras at Serine173.  As 
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sequence alignment revealed conservation of the yeast Ras2S225 phosphorylation site in the 
human Nras protein, constructs expressing human NRAS or human NRAS mutations at the 
equivalent phosphorylation site (Ser173) were transformed into wild type cells. Growth 
analysis revealed that the overexpression of either NRAS, NRASS173A or NRASS173E in wild type 
cells resulted in severe growth defects and reduced viability when compared to the wild type 
control. However, it appears that the overexpression of human NRAS in the yeast system is 
inherently toxic and therefor the importance of the NRASS173 is unknown and requires further 
investigation.  
In this study we observed a loss in viability upon the overexpression of RAS2S225A or RAS2S225E 
that cannot be explained by cell death. We therefor propose that the loss of viability observed 
in these cells is not attributable to cell death but rather a cessation of cell growth. Future 
investigations will focus on determining the nature of the growth arrest driven by the miss 
localisation of active Ras and to determine under which conditions cells can re-engage in the 




















The Ras/cAMP/PKA pathway in S. cerevisiae plays a major role in the control of growth and 
metabolism in response to nutrients. The main positive regulator of the pathway is Cdc25, 
which in response to nutrients, activates the redundant small GTPases Ras1 and Ras2 [78]. 
GTP-bound Ras activates adenylate cyclase, stimulating the production of cAMP. An increase 
in cAMP results in the activation of Protein Kinase A (PKA) via the dissociation of the PKA 
regulatory subunit Bcy1 from the PKA catalytic subunit(s) encoded by TPK1, TPK2 and TPK3 
[81][192]. Upon activation, PKA controls a number of essential cellular and physiological 
processes such as growth, resting state, glycogen and trehalose content, carbohydrate and 
nitrogen metabolism, stress tolerance and the expression of genes that are controlled by 
STRE-boxes in their promotors [226][154][216].   
The production of cAMP plays an integral role in the transmission and coordination of nutrient 
signals into the cell. Extracellular glucose levels in the growth medium are coupled to 
intracellular cAMP concentrations that regulate appropriate responses [227][228]. Control of 
cAMP levels is essential for yeast cell adaption, for example the regulation has been shown 
to mediate glycogen storage, oxidative metabolism, response to heat shock as well as a 
commitment to cell death [228][229][230][147]. Ras activity and cAMP levels are also tightly 
linked to growth, for example the expression of ribosomal protein genes is increased upon 
cAMP elevation to support cell division [119]. The production of intracellular cAMP is tightly 
regulated through feedback loops and the action of the phosphodiesterases, which catalyse 
the degradation of cAMP [86][85]. S. cerevisiae contains two cAMP phosphodiesterases, PDE1 
and PDE2, which encode a low-affinity (Pde1) and a high-affinity cAMP phosphodiesterase 
(Pde2) [86][85]. Pde2 is an Mg2+ requiring, zinc-binding enzyme which controls the basal 
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cAMP levels in the cell and thereby protects it from changes in the extracellular environment 
[88].  
 Mutations that inhibit the production of cAMP, such as seen in Δcdc25 mutants, prevent 
progression through the cell cycle check point in late G1 called start, rendering cells arrested 
in G1 in a manner closely resembling the cell cycle arrest promoted by nutrient depletion 
[231][232]. While mutations that activate the Ras/cAMP pathway, such as activating 
mutations in the RAS2 gene and BCY1 mutations appear to present the opposite phenotype. 
Wild type cells perform G1 arrest in response to nutrient depletion [233], where cells carrying 
activating mutations in the Ras/cAMP pathway fail to accumulate as G1-arrested cells upon 
nutrient deprived conditions [115]. Cells with constitutive Ras/cAMP signalling, such as the 
rasval19 mutant, fail to adapt to nutrient depletion and rapidly lose viability [98].  
We have shown that the overexpression of RAS2S225A or RAS2S225E in wild type cells lead to 
growth defects, reduced viability, sensitivity to both reactive oxygen species and copper and 
reduced respiration. We show that the overexpression of RAS2S225A or RAS2S225E results in the 
miss localisation of active Ras populations to the nuclear envelope during both log and 
stationary phases of growth. We hypothesize that such defects are a result of an early 
transition into a post-diauxic growth because of the miss localisation of active Ras populations 
to nuclear envelope. Previous studies have established a correlation between post-
translational processing of Ras, its membrane localization, and its biological activity 
[234][235][61]. In S. cerevisiae, Ras proteins are localised predominantly in the cell in a 
membrane compartment, as are other components of the signal transduction pathway with 
which Ras interacts, including adenylyl cyclase and Cdc25 [236][237]. Mutation of the site of 
farnesylation in Ras blocks all post-translational processing, abolishes its biological activity, 
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and renders the protein predominantly cytoplasmic [78]. This has prompted models 
suggesting that post-translational modification of Ras is essential for its biological activity 
because it allows co-localization of Ras with other components of the signal transduction 
apparatus.  
 As the predominant plasma membrane localisation of active Ras during log phase growth was 
not observed in cells overexpressing either RAS2S225A or RAS2S225E, we sought to investigate 
whether the premature transition into reduced growth was induced through aberrant 
Ras/cAMP signalling. To address this, RAS2S225A or RAS2S225E mutant alleles were 
overexpressed in strains lacking different components of the RAS/cAMP/PKA pathway and 




4.2 Growth analysis of the overexpression of RAS2S225A or RAS2S225E in a Δpde2 
background 
 
Pde2 is a high-affinity cAMP phosphodiesterase which catalyses the degradation of cAMP  
[86]. The deletion of PDE2 leads to an elevation in intracellular cAMP, resulting in the over 
activation of PKA [238][165]. To investigate whether an increase in activation of the 
Ras/cAMP/PKA pathway in cells overexpressing RAS2S225A or RAS2S225E resulted in further 
changes in growth and viability, we overexpressed either RAS2S225A or RAS2S225E in a Δpde2 
background and conducted both growth and viability assays. 
4.2.1 Over expression of RAS2S225A or RAS2S225E in a Δpde2 background leads to 
growth defects  
 
The growth of cells overexpressing RAS2S225A, RAS2S225E or containing an empty plasmid 
control in a Δpde2 background was analysed using the growth assay described in Materials 
and Methods, Section 2.9.1. The growth of Δpde2 strains was compared to a wild type strain 
expressing an empty plasmid control.  The overexpression of RAS2S225A or RAS2S225E in a Δpde2 
background lead to a significant increase in lag time and reached a lower final biomass when 
compared to the control strain in both the wild type and pde2 deletion background (Figure 
48). When compared to the wild type control, Δpde2 strains expressing an empty plasmid 
control displayed an early transition into the post-diauxic phase of cell growth and reached a 
lower final biomass after 24 hours of growth (Figure 48). When compared to the 
overexpression of either RAS2S225A or RAS2S225E in a wild type background (Figure 28), a 
significant increase in lag time and decrease in overall biomass was observed after 24 hours 
of growth when either RAS2S225A or RAS2S225E was overexpressed in a Δpde2 background 
(Figure 48).  
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No significant difference in growth rates was observed between wild type cells or Δpde2 cells 
expressing an empty plasmid control (Figure 49). Although, a significant decrease in growth 
rate was observed in strains overexpressing RAS2S225A or RAS2S225E in a pde2 deletion 
background when compared the wild type and Δpde2 control strain (Figure 49). When 
compared to the growth rate of wild type cells overexpressing either RAS2S225A or RAS2S225E 
(Figure 29), we observed a 60-minute decrease in growth rate when overexpressing RAS2S225A 
or RAS2S225E in a Δpde2 background. Our results imply that a loss in the ability to control the 
activation of the Ras/cAMP/PKA results in a further loss in fitness upon the overexpression of 
either RAS2S225A or RAS2S225E, as supported by previous published observations, Leadsham et 








Figure 48. Growth analysis of cells overexpressing RAS2S225A, RAS2S225E or empty plasmid 
control in Δpde2 background.  
Wild type cells expressing an empty plasmid control was assayed as an additional control.  The 
growth analysis was carried out in SD –URA media as described in Materials and Methods 
(Section 2.9.1). The experiment was repeated three times and representative data set is 
shown. This data represents an average of three technical repeats and error bars represent 














Figure 49. Growth rate analysis of cells overexpressing RAS2S225A, RAS2S225E or an empty 
plasmid backbone control in Δpde2 background. 
 Wild type cells expressing an empty plasmid control was assayed as an additional control. The 
growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). 
The experiment was repeated three times and representative data set is shown. The data 
represents an average of three technical repeats and error bars represents the standard 
deviation. A One-way ANOVA using a Dunnets multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 
adjusted p value ≤ 0.001. 
 
4.2.2 The Overexpression of either RAS2S225A or RAS2S225E in a Δpde2 background 
leads to a further decrease in viability when compared to the overexpression of 
RAS2 mutants in wild type cells 
 
To determine whether the overexpression of either RAS2S225A or RAS2S225E in a Δpde2 
background lead to a reduction in viability, a viability assay was conducted as described in 
























































RAS2S225E in a Δpde2 background was compared to wild type cells expressing the RAS2S225A or 
RAS2S225E to attest whether the deletion of pde2 further attenuated viability.    
An overnight culture was re-inoculated to 2 x 103 cells/ml and incubated for 24 hours. 300 
cells were plated onto selective, -URA agar plates. These were left to incubate at 30 °C for 36 
hours and the colonies were then counted to allow quantification of colony forming units 
(CFUs). Viability of cells analysed from the inoculated culture represented the viability of cells, 
or cell death, during nutrient deprivation.  
A wild type strain expressing a control plasmid grown for 24 hours, had approximately 40 % 
viability when grown on SD -URA medium. The expression of an empty plasmid control in a 
Δpde2 background lead to no significant change in viability when compared to the wild type 
control strain (Figure 50). The overexpression of RAS2S225A or RAS2S225E in a Δpde2 background 
presented a significant reduction in viability when compared to the wild type and Δpde2 
control strains (Figure 50). Upon the deletion of PDE2, cells overexpressing either RAS2S225A 
or RAS2S225E presented a significant decrease in viability when compared to wild type cells 
overexpressing RAS2S225A or RAS2S225E (Figure 50). Indicating that the deletion of pde2 in wild 




















Figure 50. A colony forming efficiency assay of S. cerevisiae wild type and Δpde2 cells 
overexpressing RAS2S225A, RAS2S225Eor an empty plasmid control, grown in SD –URA.   
The colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). The data presented is the average of three biological repeats and error bars 
represent standard deviation. A One-way ANOVA using a Tukey multiple comparison test was 
used to determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 
and *** = adjusted p value ≤ 0.001. 
 
4.3 Growth analysis of wild type cells co-expressing PDE2 and the RAS2 
mutant alleles 
 
4.3.1 The co-expression of PDE2 in wild type cells overexpressing RAS2S225E 
rescues growth defects 
 
We have previously observed that the overexpression of either RAS2S225A or RAS2S225E in a 
Δpde2 background further attenuates growth and viability when compared to the 
overexpression of RAS2S225A or RAS2S225E in wild type cells. We hypothesize that such 
observations are a result of an elevation in the activity of the Ras/cAMP/PKA pathway which 
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is further increased due to the cells inability to degrade cAMP in the absence of PDE2. We 
investigate whether reducing the activation of the Ras/cAMP/PKA through the 
overexpression of PDE2, will lead to differences in growth and viability in cells overexpressing 
either RAS2S225A or RAS2S225E mutant alleles. To analyse the growth of wild type cells co-
expressing PDE2 with RAS2S225A, RAS2S225E or an empty plasmid backbone, a growth assay was 
performed as described in Materials and Methods, Section 2.9.1. The growth of these strains 
was compared to a wild type strain expressing an empty plasmid control.  
All strains overexpressing PDE2 presented an early transition into post diauxic growth and 
reached a lower final biomass after 24 hours of growth when compared to the wild type 
control (Figure 51). Interestingly, the overexpression of PDE2 in wild type cells overexpressing 
RAS2S225E lead to no observable growth defects when compared to wild type cells co-
expressing PDE2 with the empty plasmid control. Wild type cells co-expressing PDE2 with 
RAS2S225A presented significant growth defects when compared to the wild type cells co-
expressing PDE2 with the empty plasmid control (Figure 51).  
A decreased growth rate when compared to the wild type control was observed in all PDE2 
overexpression strains. An increase in growth rate was observed when PDE2 was co-
expressed with RAS2S225E when compared to the PDE2 overexpression control strain (Figure 
52). However, no significant differences in growth rate were observed when PDE2 was co-
expressed with RAS2S225A in wild type cells when compared to the PDE2 overexpression 
control strain (Figure 52). Our data indicates that the overexpression of PDE2 in wild type cells 












Figure 51. Growth analysis of wild type cells co-expressing PDE2 with either RAS2S225A, 
RAS2S225E or empty plasmid control.  
Wild type cells expressing an empty plasmid control was assayed as an additional control. The 
growth analysis was carried out in SD -URA/-LEU media as described in Materials and Methods 
(Section 2.9.1). The experiment was repeated three times and representative data set is 
shown. This data represents an average of three technical repeats and error bars represent 

















Figure 52. Growth rate analysis of wild type cells overexpressing RAS2S225A, RAS2S225E or an 
empty plasmid backbone co-expressed with PDE2.  
Wild type cells expressing an empty plasmid control was assayed as an additional control. The 
growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). 
The experiment was repeated three times and representative data set is shown. The data 
represents an average of three technical repeats and error bars represents the standard 
deviation. A One-way ANOVA using a Tukey multiple comparison test was used to determine 
statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = adjusted p 
















































































4.3.2 The expression of PDE2 in wild type cells overexpressing RAS2S225A or 
RAS2S225E rescues viability 
 
To determine whether the overexpression of PDE2 in wild type cells overexpressing RAS2S225A, 
RAS2S225E or an empty plasmid control resulted in a change in viability, a viability assay was 
conducted as described in Materials and Methods, Section 2.9.3.  
The viability of wild type cells overexpressing RAS2S225A or RAS2S225E and PDE2 was compared 
to wild type cells expressing the RAS2 mutant alleles without PDE2 overexpression. When 
compared to the wild type control, no significant differences in viability was observed when 
PDE2 was overexpressed in wild type cells overexpressing RAS2S225A or RAS2S225E (Figure 53).  
Suggesting that overexpression of PDE2 rescues viability when co-expressed with either 
RAS2S225A or RAS2S225E. In wild type cells overexpressing RAS2S225A or RAS2S225E only, the 
percentage of viable cells was significantly lower than when PDE2 was co-overexpressed with 




























Figure 53. A colony forming efficiency assay of wild type cells overexpressing RAS2S225A, 
RAS2S225E or an empty plasmid backbone co-expressed with PDE2. 
 Cells were grown in SD-URA/-LEU or -URA.  The colony forming efficiency analysis was carried 
out as described in Materials and Methods (Section 2.9.3). The data presented is the average 
of three biological repeats and error bars represent standard deviation. A One-way ANOVA 
using a Tukey multiple comparison test was used to determine statistical significance. Non-












4.4 Growth analysis of the effects of the deletion of TPK1, TPK2 or TPK3 on 
wild type cells overexpressing RAS2S225A or RAS2S225E  
 
4.4.1 Deletion of TPK2 or TPK3 reduces growth defects in cells overexpressing 
RAS2S225A or RAS2S225E 
 
PKA is a heterotetramer comprised of two regulatory subunits and two catalytic subunits 
[239]. In S. cerevisiae, BCY1 encodes the regulatory subunit and the catalytic subunits are 
encoded by TPK1, TPK2 and TPK3. [81][78]. The binding of two cAMP molecules to each 
regulatory subunit in the holoenzyme triggers the release of the catalytic subunits and their 
activation. The PKA subunits Tpk1, 2 and 3 share overlapping functions but also have been 
shown to be involved in the regulation of several separable processes. Tpk1 has been 
identified to play a role in the branched chain amino acid biosynthesis pathway, mitochondrial 
DNA stability and mitochondrial iron homeostasis [82]. Whereas Tpk2 has been shown to 
impact iron uptake, trehalase synthesis and water homeostasis [82][83]. However, 
constitutive PKA activity can prove deleterious, with the overexpression of TPK3 shown to 
inhibit growth [84]. 
We have previously shown that the viability of wild type cells overexpressing either RAS2S225A 
or RAS2S225E can be significantly altered though either the deletion or overexpression of PDE2. 
Our results indicate that the overexpression of RAS2 mutant alleles results in an inability of 
cells to appropriately regulate the Ras/cAMP/PKA pathway. We sort to investigate whether 
the deletion of one or more of the TPK subunits in strains overexpressing RAS2S225A or 
RAS2S225E results in any significant changes in growth and viability.  
To analyse the growth of cells overexpressing RAS2S225A, RAS2S225E or an empty plasmid 
backbone control in a Δtpk1, Δtpk2 or Δtpk3 background, a growth assay was performed as 
176 
 
described in Materials and Methods, Section 2.9.1. The growth of Δtpk1, Δtpk2 or Δtpk3 
strains was compared to a wild type strain containing an empty plasmid (Figure 54).  
The overexpression of either RAS2S225A or RAS2S225E in a Δtpk1, Δtpk2 or Δtpk3 background 
presented an early transition into post diauxic growth and reached a lower final biomass after 
24 hours of growth when compared to all strains expressing an empty plasmid control (Figure 
54). Strains expressing either RAS2S225A or RAS2S225E in a Δtpk1 background presented the 
most severe growth defects when compared to control strains (Figure 54). When compared 
to the overexpression of RAS2S225A or RAS2S225E in wild type cells, the expression of RAS2 
mutant alleles in a Δtpk2 or Δtpk3 background presented a reduction in the severity of the 
growth defects (Figure 54). In both a Δtpk2 or Δtpk3 background, the overexpression of either 
RAS2S225A or RAS2S225E displayed no significant changes in growth rate when compared to the 
wild type control (Figure 55). Whereas expression in a Δtpk1 background led to a decrease in 
growth rate when compared to the wild type control strain (Figure 55).  This data suggests 
that the loss of either TPK2 or TPK3 in cells overexpressing RAS2S225A or RAS2S225E leads to a 
rescue of growth rate defects, indicating an involvement of the function of Tpk2 and Tpk3 in 
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Figure 54. Growth analysis of cells overexpressing RAS2S225A, RAS2S225E or empty plasmid 
control in Δtpk1 (A), Δtpk2 (B) or Δtpk3 (C) 
Wild type cells expressing an empty plasmid control was assayed as an additional control.  The 
growth analysis was carried out in SD –URA media as described in Materials and Methods 
(Section 2.9.1). The experiment was repeated three times and representative data set is 
shown. This data represents an average of three technical repeats and error bars represent 





Figure 55. Growth rate analysis of wild type cells overexpressing RAS2S225A, RAS2S225E or an 
empty plasmid backbone in Δtpk1 (A), Δtpke2 (B) or Δtpk3 background (C). 
 Wild type cells expressing an empty plasmid control was assayed as an additional control. The 
growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). 
The experiment was repeated three times and representative data set is shown. The data 
represents an average of three technical repeats and error bars represents the standard 
deviation. A One-way ANOVA using a Dunnetts multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 







4.4.2 Analysis of viability in Δtpk1, Δtpk2 or Δtpk3 cells overexpressing RAS2S225A 
or RAS2S225E 
 
To determine whether the overexpression of either RAS2S225A or RAS2S225E in a Δtpk1, Δtpk2 
or Δtpk3 background led to changes in viability, a viability assay was conducted as described 
in Materials and Methods, Section 2.9.3. The viability of cells overexpressing RAS2S225A or 
RAS2S225E in a tpk1, tpk2 or tpk3 single deletion background was compared to wild type or 
tpk1-3 deletion strains expressing an empty plasmid control. The viability of wild type cells 
overexpressing RAS2S225A or RAS2S225E was also compared to the viability observed upon the 
overexpression of RAS2S225A or RAS2S225E in a tpk1, tpk2 or tpk3 single deletion background. 
An overnight culture was re-inoculated to 2 x 103 cells/ml and incubated for 24 hours. 300 
cells were plated onto selective, -URA agar plates. These were left to incubate at 30 °C for 36 
hours and the colonies were then counted to allow quantification of colony forming units 
(CFUs). Viability of cells analysed from the inoculated culture represented the viability of cells, 
or cell death, during nutrient deprivation. After 24 hours of growth, a wild type strain 
expressing a control plasmid, had approximately 40 % viability when grown on SD -URA 
medium.  
Upon the deletion of tpk1 in all strains, a reduction in viability was observed when compared 
to the wild type control (Figure 56). Δtpk1 cells expressing an empty plasmid control 
presented a significant decrease in viability when compared to the wild type control, 
suggesting a putative function of Tpk1 in the maintenance of viability under the growth 
conditions used. Interestingly, the expression of RAS2S225A in a Δtpk1 background lead to an 
increase in viability when compared to Δtpk1 cells expressing an empty plasmid control 
(Figure 56). However, no significant change in viability was observed when compared to wild 
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type cells overexpressing RAS2S225A (Figure 56). No significant changes in viability was 
observed when RAS2S225E was expressed in a Δtpk1 background when compared to the Δtpk1 
control strain (Figure 56). A decrease in viability was seen in cells overexpressing RAS2S225E in 
a Δtpk1 background when compared to wild type strains overexpressing RAS2S225E (Figure 56). 
Our data suggests that Tpk1p and the Ras2pS225A mutants are acting within different 
pathways, as loss of TPK1 leads to a loss in viability which can be improved upon the 
overexpression of RAS2S225A. However, the loss of TPK1 increases the toxic effects on viability 
upon the overexpression of RAS2S225E when compared to the expression of RAS2S225E in wild 
type cells but not when compared to the Δtpk1 control, providing further evidence to suggest 
that Tpk1 and RAS2 mutant alleles are functioning independently. This observation aligns with 
the data shown in Figure 54, suggesting that the toxic effects induced by the overexpression 
of RAS2S225A or RAS2S225E are not mediated through Tpk1.    
Upon the overexpression of RAS2S225A or RAS2S225E in a Δtpk2 background a decrease in 
viability was observed when compared to the wild type control and the Δtpk2 control strain 
(Figure 56). Interestingly, an increase in viability is observed in Δtpk2 cells expressing an 
empty plasmid control when compared to the wild type control suggesting that TPK2 has a 
putative function in reducing viability during the post diauxic shift under the growth 
conditions used (Figure 56). The overexpression of RAS2S225A or RAS2S225E in a Δtpk2 
background results in no further decrease in viability when compared to the overexpression 
of RAS2S225A or RAS2S225E in a wild type background (Figure 56). We therefore propose that the 
loss in viability induced by the overexpression of RAS2 mutant alleles in cells does not depend 
on Tpk2 alone. Therefor the role of Tpk2 in exponential growth is separable from the observed 
loss of viability during stationary phase growth.  
181 
 
Upon the overexpression of RAS2S225A or RAS2S225E in Δtpk3 cells a significant decrease in 
viability is observed when compared to the wild type and Δtpk3 control strains (Figure 56). 
No significant difference in viability was observed between the wild type and Δtpk3 control 
strain (Figure 56). Indicating the deletion of tpk3 does not play an important function in 
maintenance of cell viability under the conditions used. Our data suggests that the deletion 
of tpk3 in cells overexpressing RAS2S225A or RAS2S225E does not rescue viability to wild type 
levels. However, a significant decrease in viability was observed upon the deletion of tpk3 in 
cells overexpressing RAS2S225E when compared to wild type cells overexpressing either 
RAS2S225E. However, no significant difference in viability was observed between the 
overexpression of RAS2S225A in a Δtpk3 or wild type background.  Our data indicates that the 
loss of tpk3 in cells overexpressing RAS2S225E results in a further attenuation of viability. 
However, the loss of tpk3 in cells overexpressing RAS2S225A does not present any changes in 
viability when compared to expression of RAS2S225A in wild type cells. Overall, we show the 
loss viability observed upon expression of the RAS mutant alleles used here cannot be 













Figure 56. A colony forming efficiency assay of S. cerevisiae wild type, Δtpk1 (A), Δtpk2 (B) 
or Δtpk3 (C) cells overexpressing RAS2S225A, RAS2S225Eor an empty plasmid control, grown in 
SD –URA.   
The colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). The data presented is the average of three biological repeats and error bars 
represent standard deviation. A One-way ANOVA using a Tukey multiple comparison test was 
used to determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 








4.5 Growth analysis of the double deletion of tpk1/tpk2, tpk3/tpk2 or 
tpk1/tpk3 on wild type cells overexpressing RAS2 mutant alleles 
 
4.5.1 Overexpression of RAS2 mutant alleles in tpk1-3 double deletion 
backgrounds leads to no rescue of growth defects 
 
The deletion of TPK1, TPK2 or TPK3 in cells overexpressing RAS2S225A or RAS2S225E failed to 
result in a complete rescue of viability or growth. We hypothesized that the double deletion 
of different Tpk subunits in cells overexpressing the RAS2 mutant alleles may result in a full 
restoration of viability to that of the wild type control.  
To analyse the growth of cells overexpressing RAS2S225A, RAS2S225E or an empty plasmid 
backbone control in a Δtpk1/ Δtpk2, Δtpk2/ Δtpk3 or Δtpk1/ Δtpk3 background, a growth 
assay was performed as described in Materials and Methods, Section 2.9.1. The growth of 
mutant strains was compared to a wild type strain expressing an empty plasmid control.  
The overexpression of RAS2S225A or RAS2S225E in all backgrounds presented an early transition 
into post diauxic growth and reached a lower final biomass after 24 hours of growth when 
compared to all strains expressing an empty plasmid control (Figure 57). When compared to 
the overexpression of RAS2S225A or RAS2S225E in wild type cells, the expression of RAS2 mutant 
alleles in a Δtpk1/ Δtpk2 background presented a reduction in the severity of the growth 
defects previously observed when expressed in wild type cells (Figure 57). Strains expressing 
RAS2S225A or RAS2S225E in a Δtpk3/ Δtpk2 background presented the most severe growth 
defects when compared to control strains (Figure 57). We observed a marginal decrease in 
growth rate when RAS2S225A was overexpressed in a tpk1/tpk2 when compared to the wild 
type control (Figure 58). No significant changes in growth rate were observed upon the 
overexpression of RAS2S225A or RAS2S225E in a Δtpk1/ Δtpk3 background when compared to the 
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wild type control (Figure 58). However, a significant decrease in growth rate was observed 
upon the overexpression of RAS2S225A or RAS2S225E in Δtpk2/ Δtpk3 background when 
compared to the wild type control (Figure 58). We suggest that the overlapping functions of 
either Tpk1 and Tpk2 or Tpk1 and Tpk3 is either responsible for the reduced growth rate or 
that the combined loss of these subunits can compensate for the toxic effects of the 











Figure 57. Growth analysis of cells overexpressing RAS2S225A, RAS2S225E or empty plasmid 
control in a Δtpk1/ Δtpk2 (A), Δtpk1/ Δtpk3 (B), or Δtpk1/ Δtpk3 (C).  
Wild type cells expressing an empty plasmid control was assayed as an additional control.  The 
growth analysis was carried out in SD –URA media as described in Materials and Methods 
(Section 2.9.1). The experiment was repeated three times and representative data set is 
shown. This data represents an average of three technical repeats and error bars represent 
























Figure 58. Growth rate analysis of yeast cells overexpressing RAS2S225A, RAS2S225E or an 
empty plasmid backbone in a Δtpk1/ Δtpk2 (A), Δtpk1/ Δtpk3 (B) or Δtpk1/ Δtpk3 (C) 
background.  
Wild type cells expressing an empty plasmid control was assayed as an additional control. The 
growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). 
The experiment was repeated three times and representative data set is shown. The data 
represents an average of three technical repeats and error bars represents the standard 
deviation. A One-way ANOVA using a Dunnets multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 







4.5.2 Analysis of viability in cells overexpressing RAS2S225A or RAS2S225E in a Δtpk1/ 
Δtpk2, Δtpk1/ Δtpk3 or Δtpk1/ Δtpk3 background 
 
As the overexpression of either RAS2S225A or RAS2S225E in a Δtpk1, Δtpk2 or Δtpk3 background 
did not result in a full rescue of viability to wild type levels, the RAS2 mutant alleles were 
expressed in backgrounds containing the double deletion of the genes encoding the Tpk 
subunits to investigate whether the combination of Tpk subunit deletions restored viability in 
wild type cells overexpressing the RAS2 mutant alleles. To determine whether the 
overexpression of either RAS2S225A or RAS2S225E in a Δtpk1/ Δtpk2, Δtpk1/ Δtpk3 or Δtpk1/ 
Δtpk3 background lead to a change in viability, a viability assay was conducted as described 
in Materials and Methods, Section 2.9.3. The viability of cells overexpressing RAS2S225A or 
RAS2S225E in Tpk subunit double deletion strains was compared to wild type and tpk1-3 double 
deletion strains expressing an empty plasmid as a control.  
Cells overexpressing an empty plasmid control in a Δtpk1/ Δtpk2 background presented no 
significant changes in viability when compared to the wild type control (Figure 59). The 
overexpression of RAS2S225A or RAS2S225E in a Δtpk1/ Δtpk2 background showed a decrease in 
viability when compared to the wild type and Δtpk1/ Δtpk2 control (Figure 59). However, no 
significant change in viability was observed when compared to wild type cells overexpressing 
RAS2 mutant alleles. Our data suggests that deletion of both Tpk1 and Tpk2 in wild type cells 
expressing the mutant RAS2 alleles does not result in the rescue of viability to wild type levels. 
This suggests that the toxicity observed through either the overexpression of RAS2S225A or 
RAS2S225E is not mediated through the combined functions of Tpk1 and Tpk2.  
Cells expressing the control plasmid in a Δtpk1/ Δtpk3 background showed a significant 
reduction in viability when compared to the wild type control with cells eliciting less than 5% 
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viability (Figure 59). This result suggests a putative role for both subunits in the maintenance 
of viability in stationary phase of growth under the conditions used. The expression of either 
RAS2S225A or RAS2S225E in a Δtpk1/ Δtpk3 background did not lead to the formation of viable 
colonies, thus indicating that the deletion of both Δtpk1 and Δtpk3 in wild type cells 
overexpressing RAS2S225A or RAS2S225E prevents the formation of viable colonies (Figure 59).  
 Upon the expression of an empty plasmid in a Δtpk3/ Δtpk2 background, a small decrease in 
viability is observed when compared to the wild type control (Figure 59). Upon the expression 
of either RAS2S225A or RAS2S225E mutant alleles in a Δtpk3/ Δtpk2 background, we see a 
significant decrease in viability when compared to the Δtpk3/ Δtpk2 control strain (Figures 
59). When compared to wild type cells expressing either RAS2S225A or RAS2S225E, the deletion 
of Δtpk3/ Δtpk2 in these strains leads to a further decrease in viability (Figure 59). Suggesting 
that the deletion of both tpk3 and tpk2 is important for the maintenance of viability in wild 




























Figure 59. A colony forming efficiency assay of wild type, Δtpk1/ Δtpk2 (A), Δtpk1/ Δtpk3 
(B) or Δtpk3/ Δtpk2 (C) cells overexpressing RAS2S225A, RAS2S225Eor an empty plasmid control, 
grown in SD –URA.   
The colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). The data presented is the average of three biological repeats and error bars 
represent standard deviation. A One-way ANOVA using a Tukey multiple comparison test was 
used to determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 
and *** = adjusted p value ≤ 0.001. 
 
4.6 Microscopic analysis of GFP-Tpk1p, GFP-Tpk2p or GFP-Tpk3p cells 
overexpressing RAS2S225A, RAS2S225E or an empty plasmid control 
 
In the mammalian system, PKA anchor proteins (AKAPs) localise PKA holoenzymes to distinct 
subcellular localisations. Such targeting facilitates the spatio-temporal control of PKA 
signalling in order to phosphorylate specific localized effectors [240]. Considering the wide 
variety of PKA-controlled targets in S. cerevisiae, it is therefore not surprising that subcellular 
localisation of PKA subunits, as in multicellular organisms, occurs in the yeast system.  
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In S. cerevisiae,  wild type cells grown on glucose localise Byc1 almost exclusively in the 
nucleus during exponential growth, while in stationary phase Bcy1 is distributed in both 
nuclear and cytoplasmic compartments [241]. In wild type yeast growing on glucose, GFP-
Tpk1, GFP-Tpk2 and GFP-Tpk3 present a predominated localisation in the nucleus [242][241]. 
GFP-Tpk2 presents the strongest nuclear localisation with GFP-Tpk1 and GFP-Tpk3 showing a 
more even distribution over both the nuclear and cytoplasmic compartments. It was shown 
by Portela et al (2009), that wild type yeast cells grown to stationary phase showed a 
pronounced decrease in nuclear accumulation of all PKA subunits with GFP-Tpk2 and GFP-
Tpk3 concentrated in extra-nuclear foci [242]. As it has been shown that PKA subunit 
localisation has been correlated to intracellular cAMP levels we sought to investigate whether 
the overexpression of RAS2S225A or RAS2S225E in wild type cells resulted in changes to the 
localisation of GFP-Tpk1, GFP-Tpk2 or GFP-Tpk3.  
To attest whether the overexpression of RAS2S225A or RAS2S225E influenced the localisation of 
either GFP-Tpk1, GFP-Tpk2 or GFP-Tpk3, fluorescent microscopy was conducted as described 
in Methods and Materials (Section 2.10). The localisation of fluorescently labelled Tpk 
subunits was examined during both stationary and exponential phases of cell growth (Figure 
60). An empty plasmid control was introduced to all fluorescently tagged strains as a control.  
In wild type cells grown on glucose, GFP-Tpk1 is reported to be mainly accumulated in the 
nucleus during exponential growth [242][241]. Our findings are concordant with literature 
and show that a GFP-Tpk1 strain expressing an empty plasmid control also presents a 
predominant nuclear localisation (4.14A). Such localisation of GFP-Tpk1 was also observed in 
cells overexpressing either RAS2S225A or RAS2S225E (Figure 60/61). No significant changes in the 
percentage of cells presenting nuclear localisation was observed upon the overexpression of 
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either RAS2S225A or RAS2S225E in a GFP-Tpk1 background when compared to the control strain 
(Figure 60/61). Our results suggest that the overexpression of either RAS2S225A or RAS2S225E 
does not affect GFP-Tpk1p localisation during exponential growth.  
It has been shown that during stationary phase growth, a pronounced decrease in nuclear 
accumulation of all PKA subunit is observed. Our results are not in keeping with such an 
observation as the localisation of GFP-Tpk1 still presented a predominant nuclear localisation 
with no significant loss of nuclear accumulation of GFP-Tpk1 observed between log and 
stationary phases of growth in all strains (Figure 60/61). Portela et al (2009), assayed cells 
after 7 days of growth, whereas in this study our definition of stationary phase is growth after 
24 hours. One explanation is that the 6-day time difference between the experiments 
conducted in this study and those conducted by Portela et al (2009), is the cause in the 
differences in localisation observed. The predominant localisation of GFP-Tpk1 in all strains 
assayed is a nuclear localisation with no significant differences in the percentage of cells 
presenting a nuclear localisation of GFP-Tpk1 observed upon the overexpression of RAS2 
mutant alleles when compared to the control (Figure 60/61). Our results indicate that the 
overexpression of either RAS2S225A or RAS2S225E does not affect GFP-Tpk1 localisation during 






Figure 60. Images taken by fluorescent microscopy of GFP-Tpk1p cells overexpressing either 
RAS2S225A, RAS2S225E or an empty plasmid vector control during exponential and stationary 
phase of cell growth.  
The fluorescent signal represents the presence of GFP-Tpk1 within cells. Cells were cultured in 
SD – URA growth media. This experiment was repeated three times and a representative data 
















Figure 61. Graphical representation of the localisation of GFP-Tpk1p in cells expressing 
either RAS2S225A, RAS2S225E or an empty plasmid control during the logarithmic (A) or 
stationary (B) phase of cell growth.  
Cells were cultured in SD –URA growth media. To quantify the localisation of GFP-Tpk1, 100 
cells for each strain were counted on three separate days with a total 300 cells being counted 
and the number of cells displaying the different phenotypes observed was calculated and 
represented as a percentage of the total number of cells counted. The data represents an 
average of three biological repeats and error bars represents the standard deviation.  
 
In wild type cells, GFP-Tpk2 is localised in the nucleus during logarithmic growth. Our data 
reflects current literature and presents GFP-Tpk2 localised to the nucleus in the GFP-Tpk2p 
control strain during log phase growth (Figure 62/63). We observed no significant change in 
GFP-Tpk2 localisation in cells expressing RAS2S225A or RAS2S225E when compared to the control, 
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suggesting that expression of either RAS2S225A or RAS2S225E does not affect GFP-Tpk2p 
localisation in actively growing cells (Figure 62/63).  
It has been reported that during stationary phase of growth in wild type cells, GFP-Tpk2 
presents a pronounced reduction in nuclear accumulation and GFP-Tpk2 localises to extra-
nuclear foci. In this study we see a predominant nuclear localisation of GFP-Tpk2 in all strains 
examined (Figure 62/63), however we infrequently noted the presence of extra-nuclear foci. 
No significant difference in the percentage of cells presenting nuclear localisation of GFP-Tpk2 
or the percentage extra-nuclear foci was observed upon the overexpression of either 
RAS2S225A or RAS2S225E in a GFP-Tpk2 background when compared to the control strain (Figure 
62/63). We therefore propose that the overexpression of RAS2S225A or RAS2S225E does not 








Figure 62. Images taken by fluorescent microscopy of GFP-Tpk2p cells overexpressing either 
RAS2S225A, RAS2S225E or an empty plasmid vector control during exponential and stationary 
phase of cell growth.  
The fluorescent signal represents the presence of GFP-Tpk2p within cells. Cells were cultured 
in SD – URA growth media. This experiment was repeated three times and a representative 


























Figure 63. Graphical representation of the localisation of GFP-Tpk2p in cells expressing 
either RAS2S225A, RAS2S225E or an empty plasmid control during the logarithmic (A) or 
stationary (B) phase of cell growth.  
Cells were cultured in SD –URA growth media. To quantify the localisation of GFP-Tpk2, 100 
cells for each strain were counted on three separate days with a total 300 cells being counted 
and the number of cells displaying the different phenotypes observed was calculated and 
represented as a percentage of the total number of cells counted. The data represents an 
average three biological repeats and error bars represents the standard deviation.  
 
In wild type yeast cells grown on glucose, GFP-Tpk3 accumulates in the nucleus during 
exponential growth and sequesters in extra-nuclear foci in stationary phase. During 
exponential growth, a predominant nuclear localisation of GFP-Tpk3 was observed in all 
strains examined with no difference in GFP-Tpk3p localisation upon the overexpression of 
RAS2S225A or RAS2S225E when compared to the control strain (Figure 64/65). We therefor 
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propose that the overexpression of either RAS2S225A or RAS2S225E does not lead to changes in 
GFP-Tpk3 localisation during exponential growth.  
During stationary phase, all strains examined show a pronounced reduction in the percentage 
of cells with a nuclear localisation of GFP-Tpk3 and an increase in GFP-Tpk3 localising to the 
cytoplasmic compartment was observed (Figure 64/65). GFP-Tpk3 was seen to localise to 
extra-nuclear foci but again this was noted infrequently (Figure 64/65). The predominant 
localisation of GFP-Tpk3 in all strains was cytoplasmic with no significant differences in GFP-
Tpk3 localisation observed upon the overexpression of RAS2S225A or RAS2S225E when compared 
to control strain noted (4.18B). We propose that the overexpression of RAS2S225A or RAS2S225E 











Figure 64. Images taken by fluorescent microscopy of GFP-Tpk3p cells overexpressing either 
RAS2S225A, RAS2S225E or an empty plasmid vector control during exponential and stationary 
phase of cell growth.  
The fluorescent signal represents the presence of GFP-Tpk3p within cells. Cells were cultured 
in SD – URA growth media. This experiment was repeated three times and a representative 































Figure 65. Graphical representation of the localisation of GFP-Tpk3p in cells expressing 
either RAS2S225A, RAS2S225E or an empty plasmid control during the logarithmic (A) or 
stationary (B) phase of cell growth. 
 Cells were cultured in SD –URA growth media. To quantify the localisation of GFP-Tpk3, 100 
cells for each strain were counted on three separate days with a total 300 cells being counted 
and the number of cells displaying the different phenotypes observed was calculated and 
represented as a percentage of the total number of cells counted. The data represents an 






S. cerevisiae tolerates diverse environmental conditions through the coordinated regulation 
of growth, cell cycle progression and metabolic activities. The Ras/cAMP pathway is 
fundamental for the regulation and integration of these processes [147][136][243][216]. The 
reprogramming of cell metabolism at the diauxic shift, as well as adaptions during both the 
post-diauxic phase and entry into stationary phase, are negatively regulated by the 
Ras/cAMP/PKA pathway [216][154][244][153]. Therefore, mutations that activate the 
Ras/cAMP pathway, such as activating mutations in the RAS2 gene and BCY1 mutations fail to 
undergo correct diauxic reprogramming during nutrient depletion [233][115]. Cells with 
elevated cAMP levels rapidly lose viability in stationary phase as they fail to activate gene 
expression programmes that facilitate storage of carbohydrates, oxidative phosphorylation 
and upregulation of stress response mechanisms [233][115]. Conversely, cells with lower 
cAMP/PKA activity, such as seen in Δcdc25 mutants, exhibit physiological changes associated 
with nutrient limitation, including G1 cell cycle arrest, accumulation of storage carbohydrates 
and increased resistance towards heat and depleted oxidative stress responses [231][232].  
We have previously shown that the overexpression of RAS2S225A or RAS2S225E in wild type cells 
results in the miss localisation of active Ras populations to the nuclear envelope, resulting in 
significant defects in both growth and viability. We hypothesize that such defects are a result 
of the dysregulation of the cell cycle . We sought to investigate whether cessation of growth 
was caused through the aberrant signalling of Ras/cAMP/PKA pathway. To address this, 
RAS2S225A or RAS2S225E mutant alleles were overexpressed in strains lacking different 
components of the Ras/cAMP/PKA pathway.  
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The loss of PDE2 in cells overexpressing RAS2S225A or RAS2S225E resulted in a further 
attenuation of viability and growth defects when compared to the overexpression of RAS2 
mutant alleles in wild type cells. Our results imply that a loss in the ability to control 
intracellular cAMP levels and Ras/cAMP/PKA pathway activation, results in a further loss in 
fitness upon the overexpression of either RAS2S225A or RAS2S225E, as supported by previous 
published observations, Leadsham et al 2010 [224]. We hypothesize that such observations 
can be explained through an elevation in intracellular cAMP levels and increased activity of 
the Ras/cAMP/PKA pathway, which is further increased due to the cells inability to degrade 
cAMP in the absence of PDE2. To reduce the levels of intracellular cAMP and Ras/cAMP/PKA 
activation in wild type cells overexpressing RAS2S225A or RAS2S225E we co-expressed PDE2 and 
performed both a growth and viability assay. The overexpression of PDE2 in cells expressing 
either RAS2S225A or RAS2S225E resulted in a complete rescue of viability and growth rate to that 
of wild type levels. We suggest that the growth and viability defects observed are a result of 
increased levels of cAMP, and thus activation of PKA, which can be repressed via reducing 
cAMP levels via the co-expression of PDE2.  
We hypothesize that the overexpression of either RAS2S225A or RAS2S225E in wild type cells 
results in an increase in the activation of the Ras/cAMP/PKA pathway. We therefore sought 
to investigate whether the deletion of the genes encoding downstream targets of cAMP, such 
as the PKA catalytic subunits TPK1, TPK2 and TPK3 in wild cells overexpressing RAS2S225A or 
RAS2S225E resulted in changes in growth and viability in a manner analogous to the deletion or 
overexpression of PDE2. Our results suggest that TPK1 is epistatic with the expression of 
the RAS2S225A mutant allele with respect to viability. We conclude this as expression of 
RAS2S225A rescues viability defects upon loss of TPK1 in wild type cells. Tpk2 function is 
responsible for the reduction in viability observed in the wild type but is not involved in the 
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loss of viability observed upon the overexpression of either RAS2S225A or RAS2S225E in wild type 
cells. We propose that Tpk3 contributes to the maintenance of viability in cells overexpressing 
RAS2S225A or RAS2S225E as loss of Tpk3 results in a further loss in viability. We suggest that the 
loss in viability upon the overexpression of RAS2 mutant alleles cannot be attributed to the 
activity of any single Tpk, as the deletion of single Tpk subunits does not rescue the viability 
phenotype. We therefor investigated the effect of deleting combinations of the Tpk subunits 
in wild type cells overexpressing RAS2S225A or RAS2S225E. We suggest that the overlapping 
functions of either Tpk1 and Tpk2 or Tpk1 and Tpk3 is either responsible for the reduced 
growth rate or that the combined loss of these subunits can compensate for the toxic effects 
of the overexpression of RAS2S225A or RAS2S225E in wild type cells.  
We conclude that the deletion of PKA subunits in wild type cells overexpressing RAS2S225A or 
RAS2S225E has pronounced effects on the growth rate but not viability. A possible explanation 
is that all three subunits contribute to the loss of viability, but the more likely explanation is 
that the complexity of PKA function means that the deletion of multiple subunits results in 
pleiotropic effects and the loss of viability observed upon the combined deletion of Tpk 
subunits are additive to the toxic effects of the overexpression RAS2S225A or RAS2S225E. The 
single or double deletion of the genes encoding the downstream targets of cAMP, such as the 
PKA catalytic subunits TPK1, TPK2 and TPK3 in wild cells overexpressing RAS2S225A or RAS2S225E 
did not result in changes in growth and viability analogous to the overexpression of PDE2. This 
observation does not wholly support our hypothesis that the effects of RAS2S225A or RAS2S225E 
overexpression are mediated via the PKA pathway. But as the overexpression of PDE2 was 
sufficient to rescue viability in wild type cells overexpressing RAS2 mutant alleles, we propose 
that the reduced growth phenotype is mediated by the dysregulated activation of PKA. 
However, the genetic approach of deleting Tpk subunits could not dissect the control of PKA 
202 
 
on the slow growth phenotype observed. We propose the following model (Figure 66) to 
explain the control of PKA on the phenotypes observed upon the overexpression of RAS2S225A 
or RAS2S225E in wild type cells. Further investigations will focus on whether there any 
environmental conditions, such as growth in nutrient rich media, which rescue cells 










Figure 66. A schematic demonstrating how the miss localisation of Ras2pS225 to the nuclear 
envelope effects PKA activity.  
The modification of RAS2S225 results in the miss localisation of active-Ras to the nuclear 
envelope during both log and stationary phase of growth. Miss localization of Ras to the 
nuclear envelope leads to an increased activation of PKA. The redundant functions of Tpk1 and 
Tpk2 or Tpk1 and Tpk3 are responsible for the reduction in growth rate defects and increased 
PKA activity drives a loss in viability that is attributed to a state of cell cycle dysregulation. 
Viability can be rescue upon the overexpression of PDE2 demonstrating that viability defects 
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In previous chapters we show that the overexpression of either RAS2S225A or RAS2S225E leads 
to Ras miss localisation and activation at the nuclear envelope. Such localisation results in 
growth defects and a loss of viability that we propose is attributable to a dysregulation of the 
cell cycle. We established that the slow growth phenotype observed is linked to elevated PKA 
activity, as overexpression of PDE2 in strains overexpressing RAS2S225A or RAS2S225E rescued 
viability.  
Investigations thus far involved the culturing of cells in minimal media to allow for the 
selection of plasmids used in this study. We consistently observed that overnight cultures of 
wild type cells exhibited a viability between 40-50 % suggesting that the media used is 
limiting. However, overexpression of RAS2 led to an increase in viability in minimal media, 
suggesting that the media itself may not be limiting. It may be the case that the wild type 
strain used in this study is unable to access or forage for certain metabolites, leading to 
reduced viability, which can be corrected upon the overexpression of RAS2. This finding 
suggests an interplay between Ras activity, utilisation of available nutrition and cell fate. We 
sought to investigate whether changing the nutritional composition of growth media would 
enable cells overexpressing RAS2 mutant alleles to resume growth in a manner analogous to 
the co-expression with PDE2. 
In this chapter we focus on the effects of di/tri-peptide availability and uptake on cell fate 
within the context of Ras activation. Peptides are composed of sequences of amino acids and 
once catabolized provide the essential building blocks required for protein synthesis. In 
addition, certain peptides and amino acids can be utilized as a nitrogen source and can act as 
signalling molecules that alter cell behaviour. For example, the branched-chain amino acid 
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leucine, has been shown to control TORC1 activity [171][172]. TORC1 senses and responds to 
nutrients to promote cell growth and the inhibition of catabolic processes, such as autophagy. 
Branched-chain amino acids such as leucine function by affecting the ‘nucleotide binding 
status of the Exit from G 0 Complex’ (EGOC) GTPase subunits Gtr1 and Gtr2 in Saccharomyces 
cerevisiae, promoting growth[173][174].  
In mammals, amino acids exert a major role on the regulation of protein synthesis through 
the control of the kinases mTOR and Gcn2 [172][177]. The regulation of Gcn2 activity by 
amino acid availability relies on the capacity of Gcn2 to sense the increased levels of 
uncharged tRNAs upon amino acid scarcity [177]. Upon low levels of essential amino acids, 
Gcn2 phosphorylates the α-subunit of eukaryotic initiation factor 2 alpha (eIF2α), resulting in 
the inhibition of protein synthesis. [178].  
Due to the multifaceted role of amino acids and peptides in biological systems, it is therefore 
not surprising that microbes have evolved a multitude of mechanisms to facilitate peptide 
and amino acid uptake. The study of such mechanisms has been extensively examined in 
yeast, with amino acid uptake mechanisms presenting high conservation in mammals.  
Saccharomyces cerevisiae has two distinct peptide transport mechanisms, a di-/tripeptides 
(the PTR system) and a tetra-/pentapeptides (the OPT) transport system [245][246][180]. The 
PTR family of peptide transporters transport a number of substrates, including amino acids, 
nitrates and di/tri-peptides [179]. PTR2 encodes an integral membrane protein (Ptr2p) 
involved in the physical translocation of peptides across the plasma membrane by the means 
of proton-motive force [180]. The transporter is specific for di-/tripeptides, with a preference 
for peptides containing hydrophobic amino acids. In S. cerevisiae the regulation 
of PTR2 expression is strongly affected by the composition of the extracellular environment. 
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In the absence of the preferred nitrogen sources PTR2 expression is induced [181] [182].The 
import of di/tripeptides composed of basic or bulky hydrophobic N-terminal residues 
increases PTR2 expression via reducing cellular levels of Cup9p, the homeodomain-containing 
transcriptional repressor of PTR2. Specific di/tri-peptides function as both as ligands and 
regulators of the E3 ubiquitin ligase Ubr1p. Ubr1p mediates the Cup9p degradation system 
that is governed by the identity of N-terminal amino acids [183][184]. Most di/tripeptides are 
too small to be degraded by the proteasome and are assimilated as nutrients by intracellular 
peptidases. However, di/tripeptides with basic (Type 1: His, Lys, or Arg) and bulky (Type 2: Ile, 
Trp, Leu, Tyr, or Phe) N-terminal residues can compete with larger protein substrates and bind 
at the Type 1 and Type 2 Ubr1p substrate-binding sites. Once bound, Ubr1p-mediated 
degradation of Cup9p is allosterically activated via the release of the Ubr1p auto inhibitory 
domain, revealing a substrate-binding domain that binds an internal degron in Cup9p [185]. 
Relief of Cup9p repression of PTR2 results in enhanced PTR2 expression. A positive regulatory 
feedback loop is created where di/tripeptide uptake perpetuates Ubr1p-mediated Cup9p 
degradation, upregulating PTR2 expression and thus increased di/tripeptide uptake. 
Although Ptr2p is the major transporter of di/tripeptides in S. cerevisiae, di/tripeptides can 
also be imported with a low efficacy by Dal5p, whose primary function is the import of 
nitrogen sources, such as allantoate and ureidosuccinate [186]. As aforementioned, the 
peptide transporters Opt1 and Opt2, which have partially overlapping functions, import 
peptides of 4–5 residues. In addition, Opt1 is a high affinity importer of glutathione, a 
“noncanonical” tripeptide [187]. In the same way as the Ptr2 transporter of di/tripeptides, 
the expression of OTP2 is down-regulated by Cup9p, whereas the expression of OPT1 is 
independent of Cup9p [187]. In addition to PTR2 and OPT2, the N-end rule pathway also 
controls the expression of DAL5, but in a manner contrary to that of the other two 
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transporters: whereas Cup9p is a transcriptional repressor of PTR2 and OPT2, Cup9p up-
regulates the expression of DAL5 [179][187].  
In this chapter we investigate how the availability and uptake of di/tripeptides interplays with 





5.2 Growth on nutrient rich media rescues viability in wild type cells 
overexpressing RAS2S225A or RAS2S225E 
 
In Chapter 3, we show that the viability of wild type cells overexpressing either RAS2S225A or 
RAS2S225E is significantly reduced after 24 hours of growth in minimal media. We sought to 
investigate whether growth on nutrient rich media, such as YPD, rescued viability in cells 
overexpressing RAS2S225A or RAS2S225E. To address this, a colony forming efficiency assay was 
performed. An overnight culture was re-inoculated to 2 x 103 cells/ml and incubated for 24 
hours. 300 cells were plated onto either selective -URA agar plates or YPD agar plates. These 
were left to incubate at 30 °C for 36 hours and the colonies were then counted to allow 
quantification of colony forming units (CFUs).  
All strains re-plated onto YPD media presented a significant increase in viability when 
compared to strains grown on SD –URA (Figure 67).  When compared to wild type cells 
overexpressing RAS2S225A or RAS2S225E grown on SD-URA, the re-plating of RAS2S225A or 
RAS2S225E strains onto nutrient rich agar resulted in a significant increase in colony forming 
efficiency (Figure 67). No significant differences in viability were observed between wild type 
cells overexpressing RAS2S225A, RAS2S225E or an empty plasmid control when grown on YPD 
(Figure 67).  This data indicates that overexpression of either RAS2S225A or RAS2S225E in wild 
type cells does not lead to cell death but rather a cessation of proliferation. Cells were able 
to re-proliferate upon re-plating on nutrient rich agar, providing further evidence to suggest 
that overexpression of RAS2S225A or RAS2S225E leads to a cessation of growth as opposed to cell 













Figure 67. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing 
RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA media and plated on 
either SD-URA or YPD.  
 A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 
adjusted p value ≤ 0.001 
 
5.3 Determination of the component of YPD that allows RAS2S225A or RAS2S225E 
to escape growth cessation 
 
5.3.1 Supplementation of Yeast Extract to minimal media rescues viability in wild 
type cells expressing RAS2S225A or RAS2S225E 
 
In order to determine which component of the nutrient rich media results in the exit from the 
reduced growth phenotype observed in cells overexpressing RAS2S225A or RAS2S225E, YPD was 
broken down into its constituent parts and these were individually added to the SD –URA agar 
at the same concentration as seen in YPD. A colony forming efficiency assay was performed 
as described in Materials and Methods Section 2.9.3, and after 24 hours of incubation in SD –
URA media cells were plated onto either SD-URA or SD –URA + Yeast Extract solid media and 
the colony forming efficiency for each condition was calculated. 
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Upon growth on SD-URA media supplemented with yeast extract, a significant increase in 
viability was observed in all strains when compared to strains grown on SD-URA (Figure 68). 
Again, no significant changes in viability were observed in wild type cells overexpressing 
RAS2S225A or RAS2S225E alleles compared to the wild type control grown in SD –URA plus yeast 
extract (Figure 68). We therefor suggest that the supplementation of yeast extract to SD-URA 
media rescues viability in wild type cells overexpressing RAS2S225A or RAS2S225E mutant alleles 













Figure 68. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing 
RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA media and plated on 
either SD-URA or SD-URA + Yeast Extract.  
 A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 
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5.3.2 Increasing the glucose concentration in the growth media does not rescue 
viability in wild type cells overexpressing RAS2S225A or RAS2S225E 
 
It has previously been established that the addition of glucose to nutrient starved cultures 
provides the stimulus for cells to exit a quiescent state and re-proliferate [247] 
[149][226][150]. To attest whether increasing the glucose concentration in the growth media 
would result in an increase in viability in cells overexpressing either RAS2S225A or RAS2S225E in 
a manner resembling that of the re-plating of cells on YPD, a colony forming efficiency assay 
was conducted. After 24 hours of growth in SD –URA, cells were plated on either SD-URA (2 
% glucose) or SD-URA (4 % glucose). We observed no significant difference in colony forming 
efficiency in the wild type control when re-plated on SD-URA containing 4 % glucose (Figure 
69). No rescue in the viability to that of the wild type control was observed in RAS2S225A or 
RAS2S225E mutants when plated on media containing 4 % glucose (Figure 69). We therefor 
conclude that increasing the availability of glucose in the growth media does not rescue 
viability in a manner resembling that of growth on YPD. We therefor conclude that the 


















Figure 69. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing 
RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA media and plated on 
either SD-URA (2 % glucose) or SD-URA (4 % glucose).   
A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 
adjusted p value ≤ 0.001 
 
5.3.3 Supplementation of Peptone to minimal media increases viability of wild 
type cells overexpressing RAS2S225A or RAS2S225E 
 
As we have observed that the supplementation of yeast extract to SD-URA was sufficient to 
rescue the toxic effects on viability of expressing either RAS2S225A or RAS2S255E in wild type 
cells. We sort to investigate whether the supplementation of peptone, at the same 
concentration seen in YPD, to SD-URA media allow cells overexpressing RAS2 mutant alleles 
to re-engage the cell cycle. To address this question, a colony forming efficiency assay was 
conducted as previously described and cells were plated on either SD-URA or SD-URA 
supplemented with peptone. 
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Upon growth on SD-URA media supplemented with peptone, a significant increase in viability 
was observed in all strains when compared to growth on SD-URA (Figure 70). Again, no 
significant changes in viability were observed in wild type cells overexpressing RAS2S225A or 
RAS2S225E mutant alleles when compared to the wild type control grown in SD –URA with the 
supplementation of peptone (Figure 70). We therefor propose that the supplementation of 
peptone to SD-URA media rescues viability in wild type cells overexpressing RAS2S225A or 









Figure 70. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing 
RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA media and plated on 
either SD-URA or SD-URA + Peptone.   
A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 







5.4 Supplementation of Peptone to minimal media increases chronological 
life span of wild type cells overexpressing RAS2S225A 
 
We have previously shown that the overexpression of RAS2S225A in wild type cells lead to a 
decrease in chronological life span. As the supplementation of peptone to the growth media 
was shown to rescue viability in wild type cells overexpressing RAS2S225A, we sought to 
investigate whether supplementation of peptone to SD-URA media, at the same 
concentration found in YPD, would lead to an increase in the chronological lifespan of cells 
overexpressing RAS2S225A. To test this hypothesis, a chronological life span assay was 
conducted as described in Materials and Methods, Section 2.9.8.  Cells were grown in and 
then plated on SD-URA media or grown in SD-URA + Peptone and then plated on media 
containing SD-URA + Peptone.  
All strains grown in the presence of peptone presented a significant increase in chronological 
lifespan when compared to strains grown without peptone supplementation (Figure 71). On 
day 1, the wild type control strain grown in the presence of peptone presented a significant 
increase in viability when compared to the control strain grown in SD-URA only (Figure 71). 
At day 12, the wild type control grown with peptone supplementation showed ~40 % of the 
culture still being able to form viable colonies compared to only ~20 % in the wild type control 
grown without peptone (Figure 71).  
Wild type cells overexpressing RAS2S225A grown in SD-URA + peptone, presented a significant 
increase in viability after day 1 when compared to the RAS2S225A mutant grown in –URA media 
(Figure 71).  After day 12, wild type cells overexpressing RAS2S225A were unable to form viable 
colonies, however when grown in media supplemented with peptone, ~20 % of cells were 
able to form viable colonies (Figure 71). We therefor propose that peptone supplementation 
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increases chronological lifespan in all strains and reduces the detrimental effects of the 







Figure 71. A chronological ageing assay of wild type cells over expressing RAS2S225A or an 
empty plasmid control grown in SD –URA and plated on SD-URA or grown in SD-URA + 
Peptone and plated on SD-URA + Peptone. 
 The chronological ageing assay was conducted as describe in materials and method (Section 
2.9.8). The data represents an average of three biological repeats and error bars represents 















5.5 Supplementation of peptone to minimal media protects cells from 
necrosis 
 
We have shown that the supplementation of peptone to SD –URA increases the chronological 
lifespan of all strains examined. We aimed to attest whether an increase in chronological 
lifespan was coupled with a decrease in cell death. To address this question, fluorescence-
activated cell sorting (FACS) was employed to analyse the levels of cell death markers in wild 
type cells overexpressing RAS2S225A or an empty plasmid control when grown in either SD –
URA or SD –URA + peptone. To investigate the levels of necrosis in the wild type control and 
wild type cells overexpressing RAS2S225A propidium iodide was used.  
The supplementation of peptone to SD –URA significantly decreased the percentage of PI 
positive cells in all strains (Figure 72). No significant difference in the percentage of PI positive 
cells between wild type and the RAS2S225A overexpression strain were observed after 12 days 
(Figures 5.6B). On day 12, cells grown without peptone supplementation presented ~40% of 
the cells being PI positive, whereas cells grown in the presence of peptone presented less 
than 2 % of the population being PI positive (Figure 72). After 12 days of growth in peptone 
supplemented media, no significant elevation in cell death was observed (Figure 72). We 
therefor conclude that peptone addition protects all strains examined from necrosis and that 
necrosis cannot explain the loss of viability observed in wild type or RAS2S225A expressing cells 
during the chronological lifespan assay. However, we conclude that necrosis does account for 
a significant proportion of dead cells after day 6 of the chronological ageing assay and that 










Figure 72. A bar chart presenting the percentage of PI positive cells in wild type cells 
overexpressing RAS2S225A or an empty plasmid control grown in -URA (A) or -URA + Peptone 
(B) 
(A) A bar chart presenting the percentage of PI positive cells in wild type cells overexpressing 
RAS2S225A or an empty plasmid control. Strains were grown in SD-URA and measurements were 
taken over a 12-day period of continuous incubation. Cells were incubated with PI in a 96 well 
plate for 15 minutes to measure cell death. The data displayed is an average of three biological 
repeats. (B) A bar chart presenting the percentage of PI positive cells in wild type cells 
overexpressing RAS2S225A or an empty plasmid control. Strains were grown in SD-URA + 
Peptone and measurements were taken over a 12-day period of continuous incubation. Cells 
were incubated with PI in a 96 well plate for 15 minutes to measure cell death. The data 
displayed is an average of three biological repeats and error represent standard deviation. 
 
5.6 Supplementation of peptone to minimal media retards ROS accumulation 
in cells  
 
The supplementation of peptone to the growth media increased the chronological life span 
of all strains examined and reduced the levels of necrosis within the population. We therefor 
sort to attest whether the supplementation of peptone reduced the accumulation of ROS, a 
marker attributed to cell death, in all strains examined. To investigate the levels of cell death 
in cells overexpressing RAS2S225A or an empty plasmid control, fluorescence-activated cell 
sorting (FACS) was utilised. This flow cytometry-based technique was used to determine 
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whether the overexpression of RAS2S225A results in an increase in ROS. The dye 
dihydroethidium (DHE) was used to analyse superoxide levels within cells. During the first six 
days of incubation, the addition of peptone to the growth media reduced the percentage of 
DHE positive cells in all strains examined when compared to cells grown in SD –URA (Figure 
73). Between days 1 and 4 in strains grown in the presence of peptone, less than 1 % of the 
cell population tested positive for elevated DHE (Figure 73). However, at day 12, the 
supplementation of peptone did not reduce the percentage of DHE positive cells when 
compared to the strains grown in SD –URA only (Figure 73). We propose that the addition of 
peptone to the growth media protects all strains examined from ROS accumulation during 
the first 6 days of incubation. We suggest that ROS accumulation cannot explain the loss in 
viability of cells until the last two time points of the chronological ageing assay, where 











Figure 73. A bar chart presenting the percentage of DHE positive cells in wild type cells 
overexpressing RAS2S225A or an empty plasmid control grown in -URA (A) or -URA + Peptone 
(B) 
A) A bar chart presenting the percentage of DHE positive cells in wild type cells overexpressing 
RAS2S225A or an empty plasmid control. Strains were grown in SD-URA and measurements were 
taken over a 12-day period of continuous incubation. Cells were incubated with DHE in a 96 
well plate for 15 minutes to measure superoxide production. The data displayed is an average 
of three biological repeats. (B) A bar chart presenting the percentage of DHE positive cells in 
wild type cells overexpressing RAS2S225A or an empty plasmid control. Strains were grown in 
SD-URA + peptone and measurements were taken over a 12-day period of continuous 
incubation. Cells were incubated with DHE in a 96 well plate for 15 minutes to measure 
superoxide production. The data displayed is an average of three biological repeats and error 
bars represent standard deviation. 
 
5.7 Supplementation of Peptone to minimal media protects cells from 
oxidative stress 
 
We have previously shown that the overexpression of either RAS2S225A or RAS2S225E in wild 
type cells leads to an increase in hydrogen peroxide sensitivity when compared to the wild 
type control and RAS2 overexpression strain. We have shown that the supplementation of 
peptone to minimal media resulted in increased chronological life span and overall decrease 
in cell death and stress in all strains examined. We sought to investigate whether the 
supplementation of peptone to SD –URA media containing different concentrations of 
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hydrogen peroxide would rescue the hydrogen peroxide sensitivity previously observed upon 
the overexpression of RAS2S225A or RAS2S225E in wild type cells. To investigate the effect of 
oxidative stress on wild type cells expressing RAS2, RAS2S225A, RAS2S225E or an empty plasmid 
control, a blotting assay was conducted as described in Materials and Methods, Section 2.9.5. 
On the SD -URA control plate, which did not contain H2O2 or peptone, a reduction in growth 
can be observed in cells expressing RAS2S225A or RAS2S225E when compared to the control 
strain (Figure 74). Upon the supplementation of peptone to the control plate, the reduced 
growth observed in cells overexpressing RAS2S225A or RAS2S225E is rescued (Figure 74). In the 
absence of peptone, as the concentration of hydrogen peroxide is increased, the growth of 
the wild type cells overexpressing RAS2S225A or RAS2S225E decreases (Figure 74). At a hydrogen 
peroxide concentration of 3 mM, we observed growth in both the control strain and the RAS2 
overexpression strain, but growth was absent in wild type cells overexpressing either 
RAS2S225A or RAS2S225E (Figure 74). However, in the presence of peptone, all strains assayed 
grew on all concentrations of hydrogen peroxide (Figure 74). As the concentration of 
hydrogen peroxide was increased, we observed no significant decrease in growth across all 
strains (Figure 74). We therefor propose that peptone supplementation is protective against 
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peroxide stress in wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or an empty 




Figure 74. Spotting assay of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or an 
empty plasmid control grown on -URA (A) or -URA + Peptone (B) in the presence of hydrogen 
peroxide. 
(A) Spotting assay of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or an empty 
plasmid control. Cells were serially diluted from 2*10^6/ml to 2*10^3/ml and plated onto SD 
-URA plates supplemented with increasing concentrations of hydrogen peroxide. (B) Spotting 
assay of wild type cells overexpressing RAS2, RAS2S225A, RAS2S225E or an empty plasmid control. 
Cells were serially diluted from 2*10^6/ml to 2*10^3/ml and plated onto SD -URA plates 
containing peptone and supplemented with increasing concentrations of hydrogen peroxide. 
 
5.8 Leucine supplementation does not rescue viability in wild type cells 
overexpressing RAS2S225A or RAS2S225E 
 
Certain peptides and amino acids can be utilized as a nitrogen source and can act as signalling 
molecules that alter cell behaviour. For example, the branched-chain amino acid leucine, has 
been shown to control TORC1 activity [171][172]. TORC1 senses and responds to nutrients to 
promote cell growth and the inhibition of catabolic processes, such as autophagy. Branched-
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chain amino acids such as leucine function by affecting the ‘nucleotide binding status of 
the Exit from G 0 Complex’ (EGOC) GTPase subunits Gtr1 and Gtr2 in Saccharomyces 
cerevisiae [173][174].  
We hypothesize that growth on YPD and supplementation of either yeast extract or peptone 
to SD –URA media increases the concentration of amino acids within the media. As leucine 
concentrations have been positively correlated with cell growth, we investigated whether 
increasing the concentration of leucine in the media rescues viability in wild type cells 
overexpressing RAS2S225A or RAS2S225E. A colony forming efficiency assay was conducted as 
previously described in methods and materials, Section 2.9.3. Cells were plated on either SD-
URA or SD-URA supplemented with 150 μg/ml of leucine. The normal levels of leucine 
required in the medium for the growth of S. cerevisiae are 30 μg/ml. A synthetic complete 
(SC) URA drop out mixture of amino acids from Formedium however contains 380 μg/ml 
leucine. We increased the levels of leucine further by adding an additional 150 μg/ml of 
leucine to the SD –URA media and investigated whether additional leucine supplementation 
resulted in pronounced changes in viability of wild type cells overexpressing RAS2S225A or 
RAS2S225E (Figure 75). 
We observed no significant difference in colony forming efficiency in the wild type control 
when re-plated on SD-URA supplemented with 150 μg/ml of leucine (Figure 75). No rescue in 
the viability to that of the wild type control was observed in RAS2S225A or RAS2S225E mutants 
when plated on media containing additional leucine (Figure 75). We therefor conclude that 
increasing the availability of leucine in the growth media does not rescue viability in a manner 
resembling that of growth on YPD. We therefor conclude that the exit from growth cessation 











Figure 75. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing 
RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA media and plated on 
either SD-URA or SD-URA + 150 μg/ml of leucine.  
 A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 
adjusted p value ≤ 0.001 
 
5.9 Deletion of the di/tri-peptide transporter PTR2 does not further 
attenuate viability in wild type cells overexpressing RAS2S225Aor RAS2S225E 
mutant alleles 
 
We suggest that the supplementation of either yeast extract or peptone to minimal media is 
sufficient to allow wild type cells expressing RAS2S225A or RAS2S225E to re-engage the cell cycle. 
We hypothesized that both peptone and yeast extract may share a common metabolite(s) to 
which the increase in the viability observed can be attributed to.   
Peptone is produced by the enzymatic digest of proteins, producing water-soluble, protein 
hydrolysates of non-chemically defined nature, containing peptides, amino acids, and 
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inorganic salts, but devoid of lipids and sugars. Whereas yeast extract consists of the 
intracellular content of yeast cells upon removal of the cell wall. Upon the analysis of the two 
ingredients, we observed that both ingredients provide a source of di/tripeptides to the cells. 
We hypothesized that the increase in viability observed in wild type cells overexpressing the 
RAS2S225A or RAS2S225E mutant alleles upon the supplementation of either yeast extract or 
peptone to the media is a result of elevated intracellular levels of di/tri-peptides within cells. 
In S. cerevisiae, the uptake of di/tripeptides is predominantly performed by the 
transmembrane peptide transporter Ptr2p.  We hypothesized that the deletion of PTR2 in 
wild type cells overexpressing RAS2S225A or RAS2S225E would further attenuate viability. To 
attest this hypothesis, plasmids overexpressing RAS2S225A, RAS2S225E or an empty plasmid 
control were introduced into a Δptr2 background and a colony forming efficiency assay was 
performed as described in Materials and Methods, Section 2.9.3. The deletion of PTR2 in wild 
type cells expressing the empty plasmid control presented no significant changes in viability 
when compared to the wild type control (Figure 76). In wild type strains expressing either 
RAS2S225A or RAS2S225E the deletion of PTR2 resulted in ~20 % of cells within the population 
being able to form colony forming units (Figure 76), presenting no difference in viability when 
compared wild type cells overexpressing RAS2S225A or RAS2S225E mutant alleles (Figure 76). We 
therefor propose that the deletion of PTR2 does not further attenuate viability in wild type 



















Figure 76. A colony forming efficiency assay of S. cerevisiae wild type or Δptr2 cells 
overexpressing RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA media. 
 A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). A One-way ANOVA using a Dunnetts multiple comparison test was used to 
determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = 
adjusted p value ≤ 0.001 
 
5.10 Deletion of CUP9 in wild type cells overexpressing RAS2S225A or RAS2S225E 
rescues growth defects  
 
Expression of the PTR2 peptide transporter is induced by dipeptides with destabilizing N-
terminal residues. These dipeptides bind to Ubr1p, the ubiquitin ligase of the N-end rule 
pathway, and allosterically accelerate the Ubr1-dependent degradation of Cup9p, a 
transcriptional repressor of PTR2. Ubr1p targets Cup9p through its internal degron [185]. We 
have previously shown that deletion of PTR2 presented no significant changes in viability in 
wild type cells overexpressing RAS2S225A or RAS2S225E mutant alleles. We hypothesized that 
increasing PTR2 expression and thus increasing di/tri-peptide transport in wild type cells 
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overexpressing either RAS2S225A or RAS2S225E may enhance viability. To increase PTR2 
expression, we deleted the gene encoding for the transcriptional repressor of PTR2, CUP9. 
Plasmids encoding either RAS2S225A or RAS2S225E or an empty plasmid control were introduced 
into a Δcup9 background and a growth analysis was conducted as described in Materials and 
Methods, Section 2.9.1.  
We observed no significant growth defects in Δcup9 strains overexpressing RAS2S225A or 
RAS2S225E mutant alleles when compared to the wild type control (Figure 77) with no 
significant differences in growth rate observed (Figure 78). Deletion of CUP9 in wild type cells 
rescues the growth defects previously observed when overexpressing RAS2S225A or RAS2S225E 


































Figure 77. Growth analysis of S. cerevisiae wild type and Δcup9 cells overexpressing 
RAS2S225A, RAS2S225E or empty plasmid control.   
The growth analysis was carried out in SD –URA media as described in Materials and Methods 
(Section 2.9.1). This data represents an average of three biological repeats and error bars 










Figure 78. Growth rate analysis of S. cerevisiae wild type or Δcup9 cells overexpressing 
RAS2S225A, RAS2S225E or an empty plasmid control.   
The growth rate analysis was carried out as described in Materials and Methods (Section 
2.9.1). The data represents an average of three biological repeats and error bars represents 
the standard deviation. A One-way ANOVA using a Dunnets multiple comparison test was used 
to determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** 




5.11 Deletion of CUP9 in wild type cells expressing RAS2 mutant alleles 
rescues viability  
 
To determine whether the overexpression of either RAS2S225A or RAS2S225E affects viability in 
a Δcup9 background, a viability assay was conducted as described in Materials and Methods, 
Section 2.9.3 The deletion of CUP9 in wild type cells expressing a plasmid control presented 
no significant change in viability when compared to the wild type control (Figure 79). 
Interestingly, the overexpression of RAS2S225E in a Δcup9 background lead to a significant 
increase in viability when compared to the wild type control (Figure 79). Furthermore, the 
overexpression of RAS2S225A in a Δcup9 background lead to no significant changes in viability 
when compared to the wild type control (Figure 79). Our data suggests that the deletion of 
CUP9 in wild type cells overexpressing RAS2S225A or RAS2S225E prevents the toxic gain of 
function of the overexpression of either RAS2S225A or RAS2S225E in wild type cells and prevents 






























Figure 79. A colony forming efficiency assay of S. cerevisiae wild type or Δcup9 cells 
overexpressing RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA media.   
A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). The data represents an average of three biological repeats and error bars 
represents the standard deviation. A One-way ANOVA using a Dunnetts multiple comparison 
test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value 
≤ 0.05 and *** = adjusted p value ≤ 0.001. 
 
5.12 Deletion of UBR1 does not further attenuate viability in wild type cells 
overexpressing RAS2S225A or RAS2S225E  
 
We have previously shown that the deletion of CUP9 rescues the growth defects induced by 
the overexpression of either RAS2S225A or RAS2S225E in wild type cells. We hypothesize that 
deletion of CUP9, increases PTR2 expression thus increasing the transportation of di-
tripeptides into the cell and restoring viability. As Ubr1p degrades cellular Cup9p, we 
hypothesize that the deletion of UBR1 in wild type cells will increase the levels of cellular 
Cup9p and thus decrease the expression of PTR2 which may further decrease viability in wild 
type cells overexpressing either RAS2S225A or RAS2S225E. To attest this hypothesis, plasmids 
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encoding RAS2S225A, RAS2S25E or an empty plasmid control were introduced into a Δubr1 strain 
and a colony forming efficiency assay was conducted as described in Materials and Methods, 
Section 2.9.3).  
The expression of an empty plasmid control in a Δubr1 background lead to no significant 
changes in viability when compared to the wild type control (Figure 80). The overexpression 
of either RAS2S225A or RAS2S225E in a UBR1 deletion strain lead to a decrease in viability when 
compared to the control strains (Figure 80). The viability of Δubr1 strains expressing either 
RAS2S225A or RAS2S225E was ~20%, which mirrors that seen in wild type cells overexpressing the 
RAS2S225Aor RAS2S225E mutant alleles (Figure 30). We therefor propose that the deletion of 
UBR1 in wild type cells overexpressing RAS2S225A or RAS2S225E does not lead to a further 










Figure 80. A colony forming efficiency assay of S. cerevisiae wild type or Δubr1 cells 
overexpressing RAS2S225A, RAS2S225Eor an empty plasmid control grown in SD –URA media.  
 A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.3). The data represents an average of three biological repeats and error bars 
represents the standard deviation. A One-way ANOVA using a Dunnetts multiple comparison 
test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value 
≤ 0.05 and *** = adjusted p value ≤ 0.001. 
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5.13 The effects of di-peptide supplementation on the viability of wild type 
cells overexpressing the RAS2 mutant alleles 
 
We have shown that the deletion of CUP9 in wild type cells overexpressing either RAS2S225A 
or RAS2S225E rescues both growth and viability. We hypothesize that the deletion of CUP9, 
relieves PTR2 from repression and increases its expression. We propose that increased PTR2 
expression will lead to elevate di/tri-peptide uptake into cells which may result in the rescue 
of the growth defects observed in wild type cells overexpressing RAS2S225A or RAS2S225E. 
It has been previously revealed that the regulation of PTR2 expression in S. cerevisiae is also 
influenced by the extracellular environment. In particular di/tri-peptides have been identified 
to induce PTR2 expression [185][182][179]. Furthermore, the import of di/tri-peptides 
comprised of basic or bulky hydrophobic N-terminal residues have also been shown to 
increase PTR2 expression via the reduction of cellular levels of the PTR2 repressor Cup9p 
[185].  
In order to increase PTR2 expression without the deletion of its repressor CUP9 in wild type 
cells overexpressing RAS2S225A, we proposed to utilize the positive regulatory feedback loop 
mediated by di/tri-peptide uptake by the supplementation of peptides containing bulky and 
basic N-terminal residues to the –URA growth media. We hypothesize that the 
supplementation of these specific di/tripeptides will upregulate PTR2 expression and thus 
increase di/tri-peptide uptake and enable wild type cells overexpressing RAS2S225A to exit 
growth cessation. To attest this hypothesis, a colony forming efficiency assay was performed 
as described in (Materials and Methods, Section 2.9.4) and after 24 hours of incubation in SD 
–URA media, cells were plated onto either SD-URA or SD –URA with the addition of a specific 
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di-peptide at a 1 mM concentration. After 36 hours of incubation the colony forming 
efficiency for each condition was calculated. 
Surprisingly, no significant difference in viability was observed in all strains grown in the 
presence of any of the supplemented di-peptides (Figure 81). No increase in viability to that 
of the wild type was observed in the RAS2S225A mutant upon supplementation of any of the 
di/tripeptides to the minimal media (Figure 81). We therefor conclude that the presence of 
either Leu-Leu, Ala-Leu, Tyro-Ala or His-Leu at a 1 mM concentration does increase viability 











Figure 81. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing 
RAS2S225A or an empty plasmid control grown in SD –URA media and plated on SD-URA 
supplemented with a di-peptide at a 1 mM concentration. 
 A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.4). The data represents an average of three biological repeats and error bars 
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The supplementation of either Leucine-Leucine, Alaline-Leucine, Tyrosine-Alaline or 
Histadine-Leucine dipeptides to the growth media at a 1 mM concentration did not rescue 
viability in wild type cells overexpressing RAS2S225A. We hypothesized that combining all the 
previously examined dipeptides together in the growth media may present changes in 
viability of the RAS2S225A mutant, which were not observed previously when dipeptides were 
supplemented to the growth media singularly. To attest this hypothesis, a colony forming 
efficiency assay was conducted as previously described in Materials and Methods, Section 
2.9.4. Cells were plated onto SD –URA media containing the following dipeptides at a 1 mM 
concentration, Leucine-Leucine, Alaline-Leucine, Tyrosine-Alaline and Histadine-Leucine. The 
supplementation of the dipeptide mix did not result in a rescue of viability in wild type cells 
overexpressing RAS2S225A when compared to the wild type control (Figure 82). We conclude 
that the supplementation of the dipeptides examined in this study, either added singularly or 
combined together, failed to produce any significant changes in the viability of either the wild 





























Figure 82. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing 
RAS2S225A or an empty plasmid control grown in SD –URA media and plated on SD-URA 
supplemented with the di-peptides; Leucine-Leucine, Alaline-Leucine, Tyrosine-Alaline and 
Histadine-Leucine at a 1 mM concentration.  
A colony forming efficiency analysis was carried out as described in Materials and Methods 
(Section 2.9.1). The data represents an average of three biological repeats and error bars 
represents the standard deviation. A One-way ANOVA using a Dunnetts multiple comparison 
test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value 




In previous chapters we suggest that the overexpression of either RAS2S225A or RAS2S225E leads 
to the miss localisation of active Ras to the nuclear envelope. Such localisation results in 
growth defects and a loss of viability that we believe to be attributable to deregulation in the 
cell cycle. We established that the slow growth phenotype observed is linked to elevated PKA 
activity, as overexpression of PDE2 in strains overexpressing RAS2S225A or RAS2S225E rescued 
viability. We sought to investigate whether changing the nutrition availability would enable 
cells overexpressing RAS2 mutant alleles to restore growth and viability in manner analogous 
to the co-expression with PDE2. 
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We show that the growth of wild type cells overexpressing RAS2S225A or RAS2S225E on nutrient 
rich media, such as YPD, rescued viability.  We therefore propose that the overexpression of 
either RAS2S225A or RAS2S225E in wild type cells does not lead to cell death but rather a cessation 
of proliferation, as cells were able to re-proliferate upon re-plating on nutrient rich agar. This 
provides further evidence to suggest that the overexpression of RAS2S225A or RAS2S225E leads 
to a cessation of growth in the yeast system opposed to cell death. To determine which 
component of the nutrient rich media results in the reengaging of the cell cycle, YPD was 
broken down into its constituent parts and these were individually added to the SD –URA agar 
at the same concentration as seen in YPD. Viability assays were conducted and the 
supplementation of both yeast extract or peptone to SD –URA media resulted in a rescue of 
viability in wild type cells overexpressing RAS2S225A or RAS2S225E. Interestingly, increasing the 
availability of either glucose or leucine to cells overexpressing RAS2S225A or RAS2S225E did not 
lead to any changes in viability. This indicates that the nature of the slow growth phenotype 
seen upon overexpression of RAS2 mutant alleles is not mediated through glucose and leucine 
levels.  
The effects of peptone supplementation were investigated further with regards to its effect 
on chronological life span, cell death and oxidative stress sensitivity. In wild type cells 
overexpressing RAS2S225A or RAS2S225A, the supplementation of peptone increased the 
chronological life span of cells and decreased the levels of both necrosis and ROS in the cell 
population.  
We show that the supplementation of either yeast extract or peptone to minimal media is 
sufficient to allow wild type cells expressing RAS2S225A or RAS2S225E to restore growth. We 
hypothesized that both peptone and yeast extract may share a common metabolite(s) to 
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which the increase in the viability observed can be attributed to.  Upon the analysis of the 
two ingredients, we observed that both ingredients provide a source of di/tripeptides to the 
cells. We hypothesized that the increase in viability observed in wild type cells overexpressing 
the RAS2S225A or RAS2S225E mutant alleles upon the supplementation of either yeast extract or 
peptone to the media is a result of elevated intracellular levels of di/tri-peptides within cells.  
In S. cerevisiae, the uptake of di/tripeptides is predominantly performed by the 
transmembrane peptide transporter Ptr2p. To reduce the intracellular levels of di/tripeptides, 
PTR2 was deleted in cells overexpressing RAS2 mutant alleles. Surprisingly, the deletion of 
PTR2 presents no significant changes in viability. However, the deletion of CUP9, the 
transcriptional repressor of PTR2, rescued both growth and viability defects. We propose that 
the deletion of CUP9 increases PTR2 expression, increases peptide uptake and allowing cells 
to reengage in the cell cycle. This data indicates an interplay between Ras activity, utilisation 
of available nutrition and cell fate. 
To further investigate the effects of di/tri-peptide uptake on the viability of cells 
overexpressing either RAS2S225A or RAS2S225E, the dipeptides; Leu-Leu, Ala-Leu, Tyro-Ala or His-
Leu were supplemented to the growth media and viability assays conducted. However, no 
significant effects on cell viability were observed upon the addition of any of the di-peptides. 
We then hypothesised that the rescue of viability observed in cells overexpressing RAS2S225A 
or RAS2S225E may not be mediated by a single di-peptide but rather a combination. To attest 
this the dipeptides previously examined were added together in the growth media and 
viability assays were conducted. However, no change in viability was recorded in wild type 
cells overexpressing RAS2 mutant alleles. We therefor propose that the rescue in viability 
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observed from growth on YPD, supplementation of either peptone or yeast and deletion of 
CUP9 is not wholly attributable to an increase in di/tripeptide uptake.  
Although unlikely, it is possible that the growth of wild type cells in nutrient rich media may 
result in a reduction of plasmid copy number. In this scenario, a reduction in copy number of 
either the plasmids expressing RAS2S225A or RAS2S225E in wild type cells could explain the 
increase in viability observed when grown in YPD media when compared to cells grown in SD 
–URA media.  This is an important considerations and further investigations must be 
conducted to address this question. In the next chapter we investigate the global effects of 























Chapter 6  
Transcriptome analysis of 























Quiescence in yeast cells is defined as a temporary non-proliferating cellular state. In S. 
cerevisiae, quiescent cells display a number of specific characteristics that differentiate them 
from proliferating cells: the overall transcription rate is substantially reduced [215]; the rate 
of overall protein synthesis is reduced to approximately 0.3 % of that observed in exponential 
cultures [248]; the expression of specific gene sets is severely downregulated e.g. genes 
encoding ribosomal proteins[249]; and chromosomes are condensed [250].  
In previous chapters we suggest that the overexpression of either RAS2S225A or RAS2S225E in 
wild type cells leads to growth defects and a loss of viability that we propose to be attributable 
to a dysregulation in the cell cycle. We suggest that the slow growth phenotype is mediated 
through the Ras/cAMP/PKA pathway as suppression of this pathway, through the 
overexpression of PDE2, leads to a complete rescue of viability and growth. In addition, we 
show that increasing the nutrient availability to cells overexpressing RAS2 mutant alleles, 
either through growth on nutrient rich media or through deletion of CUP9, also results in a 
rescue of the loss of viability phenotype. We therefore sought to investigate the gene 
expression patterns that govern the reduced growth phenotype observed using an RNA 
sequencing approach.  
6.2 Illumina library preparation and RNA sequencing  
 
After 24 hours of growth, total RNA was extracted in biological triplicate from wild type cells 
overexpressing RAS2S225A, RAS2S225E or containing an empty plasmid using the E.Z.N.A.TM Yeast 
RNA Kit as detailed in Materials and Methods, Section 2.7.4. After extraction, RNA purity was 
estimated using a NanoDrop ND-1000 spectrophotometer and sent to the Centre for Genome 
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Enabled Biology and Medicine (Aberdeen, UK) for library preparation and sequencing. 
Sequencing was performed on the Illumina NextSeq500 platform, producing 75bp single end 
reads.  
Prior to library preparation the quality and quantification of RNA samples were evaluated 
with TapeStation (Agilent) and Qubit (Thermal Fisher) by Dr Jin Pu from the Centre for 
Genome Enabled Biology and Medicine (Aberdeen, UK). The samples with the minimum RIN 
of 8.0 were proceeded. The mRNA-Seq libraries were prepared using TruSeq™ Stranded 
mRNA Sample Preparation Kit (Ilumina) according to the manufacturer’s instructions. Briefly, 
Poly-A RNA were purified from 500ng of total RNA with 1ul (1:100) ERCC spike (Thermal 
Fisher) as an internal control using RNA purification oligo(dT) beads, fragmented and 
retrotranscribed using random primers. Complementary-DNAs were end-repaired, and 3-
adenylated, indexed adapters were then ligated. 15 cycles of PCR amplification were 
performed, and the PCR products were cleaned up with AMPure beads (Beckman Coulter).  
Libraries were validated for quality on Agilent DNA1000 Kit and quantified with the qPCR NGS 
Library Quantification kit (Roche). The final libraries were equimolar pooling and sequenced 
using the High Output 1X75 kit on the Illumina NextSeq 500 platform producing 75 bp single 
end reads. For each library a depth 20-30M reads were generated. 
6.3 Quality control analysis of RNA-Seq reads 
 
The analysis of RNA–Seq samples was performed using the Galaxy web platform 
(www.usegalaxy.org) [202].  The quality of the RNA sequencing reads was checked using the 
FASTQC v0.11.5 plug-in, using the default settings [203]. The FastQC plug-in provides a 
simplistic platform to perform quality control checks on raw sequencing data sourced from 
high throughput sequencing pipelines. FastQC delivers visual readouts of the quality of raw 
241 
 
sequencing data, providing information on basic statistics including the average sequence 
length, number of sequences and the number of poor-quality sequences. Importantly, FastQC 
produces a Phred score for each sample, providing information on the probability of a base 
being erroneous and provides an adapter content score, indicating the level of adapter 
contamination within the reads.  
After the completion of the FastQC analysis, the information obtained was used to determine 
whether any trimming of the sequencing was necessary before deeper analysis. All samples 
with low quality ends (Phred score < 20) and adapter sequences were trimmed using the 
TrimGalore v0.4.3 plug-in [204]. After trimming, 98.8% of initial reads remained and FastQC 
v0.11.5 [203] was run again to confirm the quality. There were no Poly-A reads (more than 
90% of the bases equal A), ambiguous reads (containing N) or low-quality reads (more than 
50% of the bases with a Phred score < 20). After processing, the mean Phred score per read 
was 37. 
6.4 FastQC output  
 
6.4.1 Basic Statistics 
 
The basic statistics output generated from the FastQC analysis indicated that there were no 
sequences flagged as poor quality after trimming across all samples (Table 6.1). The sequence 
length of the reads after trimming was between 40-52 bases and the average sequencing 








Table 13. Basic statistics output from FastQC analysis of the RNA sequencing reads 
generated from RNA isolated from wild type cells overexpressing RAS2S225A (replicate 1). 












6.4.2 Phred Score 
 
A Phred quality score is a measure of the quality of identification of the nucleobases 
generated by automated DNA sequencing [251]. The Phred scores provides an insight into the 
probability that a base within a sequencing read has been wrongly assigned, thereby 
providing an estimation of the quality of the sequencing reaction, and hence resulting reads.  
A phred score resides on a logarithmic scale ranging from 1-40 where the higher the Phred 
score the lower the probability of the base being erroneous. A nucleotide base Phred score 
of 30 indicates a 1 in 1000 probability that the base was assigned incorrectly during the 
sequencing reaction. This translates to an accuracy of 99.9 % and therefore reads with a Phred 
score greater than 30 are considered good quality reads and progressed to next-generation 
sequencing applications such as RNA-Seq [251]. For the 9 samples investigated in this study, 





Figure 83. The average Phred score for each base across the length of the sequencing read.  
This read was generated from the RNA isolated from wild type cells overexpressing RAS2S225A 
(replicate 1). This graph is representative of all samples investigated.  
 
6.4.3 N content 
 
The N content indicates the number of ambiguous reads within a sample, i.e. the number of 
reads containing at least one base which was not assigned and hence denoted as N. There 






Figure 84. N content across all bases within the reads from RNA isolated from wild type 
cells overexpressing RAS2S225A (Sample 1). 
 This graph is representative of all samples. 
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6.4.4 Adapter Content 
 
The adapter content value provides a quantification of any contamination in reads caused by 
the presence of sequences originating from the library preparation. Contaminations caused 
by the presence of adapter sequences can result in alignment errors when aligning the reads 
to a reference genome since the adaptor sequences will not appear in the genome. Therefor 
trimming of reads is necessary to remove any adaptor sequences which could influence 
downstream applications. Post trimming, no adaptor sequences were detected in reads from 
all samples (Figure 85).  
 
Figure 85. Adaptor content across bases within the reads of RNA isolated from  wild type 
cells overexpressing RAS2S225A (sample 1).  






6.5 Principle Component Analysis 
 
A principle component analysis (PCA) is a statistical procedure used for the exploration of 
large data sets. PCA is a valuable method for the visualisation of large data sets and is used to 
determine the degree of similarity between biological replicates, and how different they are 
to samples from other conditions. PCA was conducted within the DESeq2 package as part of 
the differential gene expression analysis [207].  
The PCA reduces the dimensionality of the data sets by determining directions along which 
the most variation occurs thus simplifying very large data sets while retaining as much 
information as possible [252]. Within a PCA, the first principle component (PC1), is the 
direction along which most of variation occurs and the second principal component (PC2) 
covers as much of the remaining variation as possible [252]. Samples are plotted on a PCA 
graph based on the two principle components. Samples displaying clear clustering, indicates 
similarity between samples and large degrees of separation between samples indicates a low 
level of similarity.  
In this study, biological replicates of the RNA sequenced from wild type cells overexpressing 
either RAS2S225A, RAS2S225E or an empty plasmid control cluster well along both the PC1 and 
PC2 axis, indicating that within the biological repeats there is a high degree of similarity 
(Figure 86). There is also a significant degree of separation between the clusters of the 





Figure 86. Principle component analysis of the RNA-Seq data obtained from wild type cells 
overexpressing RAS2S225A, RAS2S225E or an empty plasmid control.  
6.6 Analysis of RNA-Seq reads using the Galaxy online platform 
 
Processed reads were aligned with the reference S. cerevisiae genome S288C version R64-2-
1_20150113 (SacCer3) using HISAT2 v2.1.0 with single-end reads and reverse strand settings, 
with all other settings set to default [205]. After the completion of the alignment, the number 
of mapped reads which overlapped CSD features in the genome, using the S288C version R64-
2-1_20150113_features gtf annotation file, were determined using the featureCounts plug-
in v1.6.3 with default settings [206]. Reads aligning to multiple positions or overlapping more 
than one gene were discarded, counting only reads aligning unambiguously to a single gene. 
Differential gene expression analysis between RNA extracted from wild type cells 
overexpressing RAS2S225A, RAS2S225E or an empty plasmid control were performed using 
DESeq2 v1.18.1 using default settings [207].  
Using DESeq2, the expression levels of each gene in wild type cells overexpressing either 
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RAS2S225A or RAS2S225E was compared to samples generated from wild type cells 
overexpressing an empty plasmid control. The overexpression of either RAS2S225A or RAS2S225E 
led to a global response resulting in the significant differential expression of genes when 
compared to the wild type control. The overexpression of RAS2S225A lead to the differential 
gene expression (false-discovery-rate adjusted p-value (q) ≤ 0.05) of 4133 genes, with roughly 
equal numbers of genes up- and downregulated (2054 up and 2079 down) (Figure 87). 58 
genes were strongly (log2 fold change >2) upregulated and 23 were strongly (log2 fold change 
<-1.5) downregulated. The overexpression of RAS2S225E lead to the differential gene 
expression (false-discovery-rate adjusted p-value (q) ≤ 0.05) of 5202 genes, with 2543 
upregulated and 2659 down downregulated (Figure 88). 281 genes were strongly (log2 fold 
change >2) upregulated and 644 genes were strongly (log2 fold change <-1.5) downregulated. 
To identify the cellular pathways which these differentially expressed genes are within we 
conducted Gene Set Enrichment Analysis (GSEA; Broad Institute) [208]. The GSEA is a 
computational method which determines whether a prior defined gene set data presents 
statistically significant, concordant differences between two biological states.  
 To conduct a GSEA analysis, a list of significantly (q ≤ 0.05) differentially expressed genes, 
ranked from the most upregulated to the most downregulated were uploaded into the GSEA 
database and compared to a gene set data base (S288C version R64-2-1_20150113_features 
gtf annotation file). GSEA functions to identify whether the members of each gene set are 
randomly distributed within the ranked gene list or significantly overrepresented (enriched) 
at either end of the gene list.  Gene sets are ranked using a normalised enrichment score 
(NES). A positive normalised enrichment score indicates that genes within a specific a gene 
set are located at the top of the ranked gene list whereas a negative normalised enrichment 
score indicates that genes within a specific gene set are located at the bottom of the ranked 
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gene list. From this information we can predict which biological processes or pathways are 
up- or downregulated between strains. The GSEA is a powerful form of analysis as an increase 
in the expression of 15 % of all genes associated with a pathway may have more effect than 
a single gene that has say a 10-fold increase in expression. The GSEA output provides 
enrichment profiles showing correlations with numerous overlapping gene sets, we were able 
to visualise networks of similar gene sets using the cytoscape 3.7.1 EnrichmentMap plug-in 
[253] (Figure 87).  
6.7. GSEA analysis of cellular processes differentially regulated by the 
overexpression of RAS2S225A  
 
Interestingly, the overexpression of RAS2S225A in wild type cells induced a significant 
upregulation in pathways involved in ribosomal biogenesis, transcription, translation, glucose 
transport and central metabolism (Figure 87). Such an observation was surprising as the 
pathways upregulated recapitulate those observed from exponentially growing cells 
[248][249][226][226].  
However, such an observation can be explained upon the analysis of the pathways 
downregulated by the overexpression of RAS2S225A. We observed a significant downregulation 
in cytoskeletal, microtubule and kinetochore dynamics and nuclear and cell division; 
chromosome condensation and segregation, cell cycle phase transition, mitosis and 
transcription factors associated with cell cycle phase progression (Figure 87). The resulting 
effect of the downregulation of the pathways are indicative of a cessation of proliferation. It 
may be the case that a loss of co-ordination between cytoplasmic and nuclear machinery 
occurs upon the overexpression of RAS2S225A in that cells are primed for cell division but 




















Figure 87. Global gene expression changes in wild type cells overexpressing RAS2S225A when 
compared to a wild type control.  
(A) DESeq2 was used to compare gene expression in wild type cells overexpressing RAS2S225A 
to a wild type control and a volcano plot was generated of the log2 fold change against mean 
of normalised counts for each gene; red dots = significantly differentially expressed (q≤ 0.05) 
genes, grey dots = not significant. In total there were 4133 significantly differentially expressed 
genes. Normalised counts are the number of reads a gene has and therefor the higher the 
mean of normalised count, the greater the expression of that gene. (B) Gene set cluster map 
created using the cytoscape plug in showing the most upregulated and downregulated gene 
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sets as determined by GSEA analysis along with their cellular functions. Each circle represents 
a gene set and the lines between them corresponds to how much they overlap, the thicker the 
line the greater the genes they have in common.     
 
6.7. GSEA analysis of cellular processes differentially regulated by the 
overexpression of RAS2S225E  
 
GSEA analysis revealed that the overexpression of RAS2S225E in wild type cells elicits a similar 
pattern in the cellular pathways upregulated to that observed upon the overexpression of 
RAS2S225A. We observed an upregulation in pathways involved in ribosomal biogenesis, 
transcription, translation, glucose transport and central metabolism (Figure 88). All of which 
can be attributed to an actively growing population of cells. The pathways downregulated 
mimicked those seen upon overexpression of RAS2S225A with chromosome condensation and 
segregation, cell cycle phase transition, mitosis and transcription factors associated with cell 
cycle phase progression and chromatin remodelling all downregulated (Figure 88). This data 
suggests that both RAS2S225E and RAS2S225A lead to similar changes in the regulation of cell 















Figure 88. Global gene expression changes in wild type cells overexpressing RAS2S225E when 
compared to a wild type control.  
(A) DESeq2 was used to compare gene expression in wild type cells overexpressing RAS2S225E 
to a wild type control and a volcano plot was generated of the log2 fold change against mean 
of normalised counts for each gene; red dots = significantly differentially expressed (q≤ 0.05) 
genes, grey dots = not significant. In total there were 5202 significantly differentially expressed 
genes. Normalised counts are the number of reads a gene has and therefor the higher the 
mean of normalised count, the greater the expression of that gene. (B) Gene set cluster map 
generated by cytoscape showing the most upregulated and downregulated gene sets as 
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determined by GSEA analysis along with their cellular functions. Each circle represents a gene 
set and the lines between them corresponds to how much they overlap, the thicker the line 
the greater the genes they have in common.  
 
6.8 Further analysis of the gene sets enriched upon overexpression of 
RAS2S225A in wild type cells   
 
Following GSEA analysis we sought to visualise networks of similar gene sets using the 
cytoscape plug in (Figure 89). We sought to identify which processes within these gene set 
networks were up- or downregulated. To achieve this, we used the normalised enrichment 
score (NES) to identify which processes and to what extent genes in these pathways were 
either up- or downregulated when compared to the wild type control. Upon the 
overexpression of RAS2S225A in wild type cells we observed an increase in ribosomal 
biogenesis, transcription, and translation. Here we observed that gene sets involved in; 
cytoplasmic translation (NES = 2.29), cytosolic ribosome (NES = 2.29), ribosome biogenesis 
(NES = 2.07), translation elongation (NES = 2.43), preribosome (NES = 2.19) and ribosome 
assembly (NES = 2.18) were all significantly upregulated (Figure 89). A full list of the genes 






Figure 89. Gene sets shown to be upregulated upon the overexpression of RAS2S225Awhen 
compared to the wild type control. (A), cytosolic ribosomes (B), ribosome biogenesis (6) , 
translation elongation (D) , preribosome (E) and ribosome assembly (F).  
Vertical black lines represent individual genes in the significantly differentially expressed 
ranked gene list from upregulated (left) to downregulated (right). An increase in the 
enrichment score is seen if there are many genes towards the beginning of the ranked list 
(upregulated) in the gene set. When the green line climbs rapidly and peaks near the start of 
the graph (as shown here) it can be concluded that that gene set is overall upregulated. NES 
= normalised enrichment score, positive NES shows enrichment in the upregulated group of 
genes.       
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The gene sets significantly downregulated upon the overexpression of RAS2S225A, indicated by 
a negative normalised enrichment score (NES), included condensation of chromosomes (NES 
= - 2.22), kinetochore dynamics (NES = -2.31), sister chromatid segregation (NES = -2.08), 
regulation of mitotic metaphase anaphase transition (NES = -2.08), the U2 spliceosome 
complex (NES = -2.33) and microtubule based processes (NES = -1.93) (Figure 90).  A list of the 
genes within the gene set networks that regulate the processes detailed below can be found 




Figure 90. Gene sets shown to be downregulated upon the overexpression of RAS2S225A when 
compared to the wild type control. Chromosome condensation (A), kinetochore and 
microtububle based processes (B), sister chromatid segregation (C) , the regulation of 
mitotic-metaphase-anaphase transition (D) , U2 Type splicesomal complex (E) and 
microtubule based processes (F).  
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Vertical black lines represent individual genes in the significantly differentially expressed 
ranked gene list from upregulated (left) to downregulated (right). An increase in the 
enrichment score is seen if there are many genes towards the beginning of the ranked list 
(upregulated) in the gene set. When the green line climbs rapidly and peaks near the start of 
the graph (as shown here) it can be concluded that that gene set is overall upregulated. NES 
= normalised enrichment score, positive NES shows enrichment in the upregulated group of 
genes.       
6.9 Further analysis of the gene sets enriched upon overexpression of 
RAS2S225E in wild type cells   
 
Upon the overexpression of RAS2S225E in wild type cells we observed a similar gene enrichment 
profile when compared to the RAS2S225A mutant. Here we observed gene sets involved in 
cytoplasmic translation (NES = 2.41), cytosolic ribosomes (NES = 2.67), ribosome biogenesis 
(NES = 2.76), translation elongation (NES = 2.53), preribosome (NES = 2.89) and ribosome 
assembly (NES = 2.58) were all significantly upregulated (Figure 91). When compared wild 
type cells overexpressing RAS2S225A, the normalised enrichment score for each of the above 
processes is higher in cells overexpressing RAS2S225E. A list of the genes within the gene set 









Figure 91. Gene sets shown to be upregulated upon the overexpression of RAS2S225E when 
compared to the wild type control. Cytoplasmic translation (A), cytosolic ribosomes (B), 
preribosome (C), ribosome biogenesis (D), translation elongation (E), and ribosome 
assembly (F).  
Vertical black lines represent individual genes in the significantly differentially expressed 
ranked gene list from upregulated (left) to downregulated (right). An increase in the 
enrichment score is seen if there are many genes towards the beginning of the ranked list 
(upregulated) in the gene set. When the green line climbs rapidly and peaks near the start of 
the graph (as shown here) it can be concluded that that gene set is overall upregulated. NES 
= normalised enrichment score, positive NES shows enrichment in the upregulated group of 
genes.    
    
257 
 
The gene sets significantly downregulated upon the overexpression of RAS2S225E, indicated by 
a negative normalised enrichment score (NES), included; condensation of chromosomes (NES 
= - 2.55), nuclear division (NES = -1.84), sister chromatid segregation (NES = -2.19), organelle 
fission (NES = -1.90), chromosome segregation (NES = -2.30) and microtubule based processes 




Figure 92. Gene sets shown to be downregulated upon the overexpression of RAS2S225E when 
compared to the wild type control. Chromosome segregation (A) , chromosome 
condensation (B) , organelle fission (C) , sister chromatid segregation (D) , nuclear division 
(E)  and microtubule based processes (D).  
Vertical black lines represent individual genes in the significantly differentially expressed 
ranked gene list from upregulated (left) to downregulated (right). An increase in the 
enrichment score is seen if there are many genes towards the beginning of the ranked list 
(upregulated) in the gene set. When the green line climbs rapidly and peaks near the start of 
the graph (as shown here) it can be concluded that that gene set is overall upregulated. NES 
= normalised enrichment score, positive NES shows enrichment in the upregulated group of 






In previous chapters we suggest that the overexpression of either RAS2S225A or RAS2S225E in 
wild type cells leads to growth defects and a loss of viability that we propose to be attributable 
to a dysregulation of the cell cycle. We propose that the slow growth phenotype is mediated 
through the Ras/cAMP/PKA pathway and that nutrient availability, or indeed the cells ability 
to acquire nutrition, appears to play an important role.  
Through genome-wide transcriptome analysis of wild type cells overexpressing either 
RAS2S225A or RAS2S225E we sought to investigate the gene expression patterns that may govern 
the slower growth phenotype. Of particular interest was to ascertain whether mutant Ras2 
expression led to changes in gene expression patterns that might be regarded as hallmarks of 
cell quiescence. Quiescence in yeast cells is typically defined as a temporary non-proliferating 
cellular state characterised by reduced protein synthesis and chromosome condensation. In 
addition, a number of phenotypes have been described within quiescent yeast cells such as 
fragmented mitochondria, presence of actin bodies, chromosome condensation, formation 
of P-bodies, stress granules and proteasome storage granules and nuclear localisation of heat-
shock proteins [254]. Crucially however, quiescent cells are capable of responding to 
environmental signals such as the presence of carbon and quickly re-engage the cell cycle 
[109].  
Upon the transition of cells into the quiescent state, the coordinated downregulation of 
ribosome synthesis contributes to a dramatic ~300-fold reduction in protein synthesis rates 
[255][256]. Ribosomal protein synthesis represents 15 % of total translation and ribosome 
RNA transcription represents 60 % of the total transcription. It is therefore not surprising that 
the first global downregulation of genes upon transition into quiescence is the shutdown of 
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the transcription of genes encoding for the proteins in both subunits of the ribosome [255]. 
As protein synthesis requires a significant amount of energy such down regulation may be 
crucial for the survival of non-dividing or quiescent cell populations. 
Unexpectedly, the overexpression of either RAS2S225A or RAS2S225E in wild type cells resulted 
in a significant upregulation of transcription, translation, and ribosomal biogenesis. Such an 
observation was unexpected as the pathways upregulated recapitulate those observed within 
exponentially growing cells. We suggest that the overexpression of RAS2S225A in wild type cells 
results in a transition into a quiescence like phenotype. However, quiescence is not 
hallmarked by an upregulation in either transcriptional or translational machinery 
[215][151][254]. So, does the expression of RAS2S225A or RAS2S225E lead to quiescence at all?  
The cell-based assays conducted in this study show that overexpression of RAS2S225A or 
RAS2S225A leads to both a significant reduction in viability and a reduced level of respiration. 
This is not concordant with the status of an actively growing population. However, upon 
analysis of the pathways downregulated upon the overexpression of these RAS2 alleles we 
observe the downregulation of processes that govern cell division such as chromosome 
condensation and segregation, cell cycle phase transition, mitosis and transcription factors 
associated with cell cycle phase progression. The resulting effect of the downregulation of the 
pathways represent the fact that these cells are not engaged in the cell cycle and may provide 
an explanation for the loss in viability observed. But can a reduction in these pathways explain 
the inability of cells to resume normal growth upon exposure to fresh growth media? 
We hypothesize that the upregulation of transcription, translation and ribosomal biogenesis 
may be a result of increased PKA activity, as cells with enhanced PKA functions fail to undergo 
transcriptional reprogramming upon entry in diauxic growth [257]. However, constitutive PKA 
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activity is usually correlated with a significant loss of viability that is attributed to cell death, 
as in seen cells expressing the rasval19 mutant [98]. The overexpression of either RAS2S225A or 
RAS2S225E also results in a loss of viability but which is accompanied by cell death. We 
therefore propose that the overexpression of either RAS2S225A or RAS2S225E in wild type cells 
leads to an unreported slow growth phenotype that is characterized by an upregulation of 











































Ras proteins are small GTPases that act as molecular switches within cells that link 
extracellular stimuli to intracellular effectors. Ras proteins play a conserved role in the control 
of both cell growth and proliferation [211]. As a result, mutations that induce the constitutive 
activation of Ras proteins are often associated with changes in cell behaviour that can lead to 
disease, such as human cancer [41]. The localisation of Ras proteins are reported to be 
predominantly to the inner cytoplasmic surface of the plasma membrane, but they can also 
be observed on endomembrane’s, such as the endoplasmic reticulum, and the mitochondrial 
outer membrane [65][57][212]. 
 In recent years, the localisation and signalling of Ras on the plasma membrane has been 
extensively studied. It has been revealed that Ras undergoes a series of posttranslational 
modifications that dictate its subcellular localisation. Evidence exists to suggest that Ras 
proteins can undergo phosphorylation events which regulate its activity. Whistler and Rine  
identified Ser412  as an important phosphorylation site on the yeast Ras2 protein where 
substitution of serine with alanine at this residue lead to increased cAMP levels and elevated 
ration of Ras2-GTP compared to total Ras2 [74][213]. Surprisingly, the phosphorylation of 
Ras2p in S. cerevisiae has not been studied in regards to its regulation of intracellular 
localisation, despite significant evidence existing linking Ras phosphorylation to its 
localisation in humans [77]. This study aims to further investigate whether Ras2p 




7.1 Modification of the Ser225 residue of Ras2p is important for localisation, 
activity, and function of Ras proteins 
 
The data presented in this thesis suggests that the modification of the Ser225 residue of Ras2p 
is important for both localisation and activity of Ras proteins. We have shown that during 
both log and stationary phases of growth, the overexpression of either RAS2S225A or RAS2S225E 
in wild type cells results in significant changes in the localisation of active Ras populations. 
Actively growing wild type cells localise GTP-bound Ras to the plasma membrane and nucleus. 
In wild type cells, such localisation results in the activation of the cAMP/PKA pathway, which 
signals to the cell to initiate both growth and proliferation. We suggest that during 
exponential growth, wild type cells overexpressing either RAS2S225A or RAS2S225E sequester 
active Ras to the nuclear envelope with reduced activity seen at the plasma membrane and 
nucleus. Furthermore, we suggest that the overexpression of RAS2S225A or RAS2S225E also leads 
to the miss localisation of active Ras to the nuclear envelope and an inappropriate activity 
during stationary phase of growth. This finding therefor highlights the important role of Ras2 
protein phosphorylation on both the modulation of protein activity and localisation.  
The findings within this thesis propose that the modification of Ras2S225 is also important for 
Ras protein function. As modification of Ras2S225 leads to growth defects, changes in the 
oxidative stress response and leads to a reduction in viability in wild type cells. We show that 
the reduction of viability observed upon the overexpression of RAS2 mutant alleles does not 
represent cell death but rather an inability to divide. We therefor propose that the 
overexpression of RAS2 mutant alleles leads to a cessation of growth in wild type cells. Looked 
at together, we clearly suggest a novel role of the Ser225 residue of Ras2p for the localisation 
of GTP-bound Ras and propose a link between subcellular localisation of active Ras and 
growth cessation. Such findings provide important insights on how targeting phosphorylation 
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sites, such as Ras2S225, can be exploited to prevent growth in cells where uncontrolled 
proliferation leads to disease. 
7.2 Overexpression of RAS2S225A or RAS2S225E results in aberrant 
Ras/cAMP/PKA signalling and entry into state of reduced growth 
 
We suggest that the overexpression of either RAS2S225A or RAS2S225E leads to the miss 
localisation of active Ras to the nuclear envelope. Such localisation results in growth defects 
and a loss of viability that we believe to be attributable to a dysregulation in the cell cycle. 
We sought to investigate whether the dysregulation of the cell cycle was caused through the 
aberrant signalling of Ras/cAMP/PKA pathway. We established that the slow growth 
phenotype observed is linked to elevated PKA activity, as overexpression of PDE2 in strains 
overexpressing RAS2S225A or RAS2S225E rescued viability.  This observation was interesting as 
we initially hypothesized that the slow growth phenotype was a result of decreased PKA 
signalling. As mutations that inhibit the production of cAMP and thus reduce PKA activation, 
prevent progression through the cell cycle check point and render cells arrested in G1. Such 
a scenario would provide an explanation for the reduced growth phenotype observed upon 
overexpression of RAS2 mutant alleles [231][232]. Typically, mutations that activate the 
Ras/cAMP/PKA pathway, such as activating mutations in the RAS2 gene and BCY1 mutations 
fail to accumulate as G1-arrested cells upon nutrient deprived conditions resulting in a 
decrease in viability that is strongly correlated to cell death [115]. Whereas, we show that 
overexpression of RAS2S225A or RAS2S225E leads to enhanced PKA activity resulting in a 
reduction of viability that is not attributable to cell death but rather to a cessation of growth. 
We believe the answer lies within the localisation of active Ras, overexpression of RAS2 
mutant alleles sequesters active Ras to the nuclear envelope as opposed to the inner leaflet 
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of the plasma membrane. We hypothesize that Ras signalling from the nuclear envelope to 
PKA may result in the activation of effectors that elicit a change in gene expression that 
promotes a loss in co-ordination of growth control and environmental sensing that promotes 
growth cessation.  
As evidence for this we show that increasing the level of nutrition available enabled cells 
overexpressing RAS2 mutant alleles to escape quiescence in manner analogous to the co-
expression with PDE2. Such a result may suggest that such cells are either incapable of taking 
up sufficient levels of nutrition, which yeast perceives as growth factors, or indeed that cells 
do not sense available nutrition. We propose that increasing the nutrient availability to cells 
overexpressing RAS2 mutant alleles either through growth on nutrient rich media or through 
deletion of CUP9 results in a rescue of the viability phenotype. This finding would tend to 
suggest to us that Ras mutant induced growth cessation occurs because of an inability to take 
up nutrition from the environment. Evidence for a role for Ras in this respect is further 
provided by our finding that RAS2 overexpression improves viability on minimal media. 
Overall, our data suggests a link between Ras proteins, nutrient uptake, and growth cessation. 
7.3 Genome-wide transcriptome analysis of wild type cells overexpressing 
RAS2S225A or RAS2S225E 
  
We show that the overexpression of either RAS2S225A or RAS2S225E in wild type cells leads to 
growth defects and a loss of viability that we propose to be attributable to cell quiescence. 
We suggest that the slow growth phenotype is mediated through the Ras/cAMP/PKA pathway 
and that nutrient availability, or indeed the cells ability to acquire nutrition, appears to play 
an important role. Through genome-wide transcriptome analysis of wild type cells 
overexpressing either RAS2S225A or RAS2S225E we sought to investigate the gene expression 
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patterns that may govern the slow growth phenotype. Of interest was to ascertain whether 
mutant Ras2 expression led to changes in gene expression patterns that might be regarded 
as hallmarks of cell quiescence. 
Unexpectedly, the overexpression of either RAS2S225A or RAS2S225E in wild type cells resulted 
in a significant upregulation of transcription, translation, and ribosomal biogenesis. Such an 
observation was unexpected as the pathways upregulated recapitulate those observed within 
exponentially growing cells [255]. However, upon analysis of the pathways downregulated 
upon the overexpression of these RAS2 alleles we observe the downregulation of processes 
that govern cell division such as chromosome condensation and segregation, cell cycle phase 
transition, mitosis and transcription factors associated with cell cycle phase progression. The 
resulting effect of the downregulation of the pathways represent the fact that these cells are 
not engaged in the cell cycle and may provide an explanation for the loss in viability observed.  
We hypothesize that the upregulation of transcription, translation and ribosomal biogenesis 
may be a result of increased PKA activity, as cells with enhanced PKA functions fail to undergo 
transcriptional reprogramming upon entry in diauxic growth [257]. However, constitutive PKA 
activity is usually correlated with a significant loss of viability that is attributed to cell death, 
as in seen cells expressing the rasval19 mutant [98]. The overexpression of either RAS2S225A or 
RAS2S225E also results in a loss of viability but which is not accompanied by cell death. We 
therefore propose that the overexpression of either RAS2S225A or RAS2S225E in wild type cells 
leads to an unreported slow phenotype that is characterized by an upregulation of 
transcriptional and translational machinery and a downregulation of nuclear and cellular 
division at a time when nutrient levels have depleted. Why mutant Ras cells are no longer 
able to re-engage growth when given fresh media of the same composition is unclear but 
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RNA-Seq data not included in this thesis suggests the deletion of CUP9 in a RAS2S225A 
background may reinstate cellular growth via the upregulation of a number of transporters 
that facilitate nutrient uptake. 
7.4 Sequence alignment between Ras2 and human N-Ras suggests that 
Serine225 is conserved in human N-Ras at SerineS173 
 
We have shown that the Serine225 of the Ras2 protein is important for growth, viability, and 
the localisation and activity of Ras proteins. We hypothesized that this residue may be 
conserved in higher eukaryotes. To address this, sequence alignment between the Ras2 
protein and the human N-Ras protein was performed (Figure 93). Interestingly, although 
significant sequence divergence between the yeast and human Ras proteins outside of the 
GTPase domain and C terminal CAAX box, we discovered that Ras2 Serine225 was conserved 
in human N-Ras at Serine173 along with conservation of the surrounding region. The 
conservation of this serine residue in human Ras proteins may suggest an important role of 
this residue in higher eukaryotic systems, which could be exploited as a potential target for 




Figure 93. Sequence alignment of the Ras2 protein and human N-Ras shows that Serine225 
of Ras2p (circled) is conserved in N-Ras at Serine173 
Interestingly, an independent group identified the Ser226 residue in Ras1 to be an important 
residue for Ras1 phosphorylation, as mutating this residue to an alanine drastically diminishes 
the level of Ras1 phosphorylation [214]. Upon sequence alignment of yeast Ras1 and Ras2 
(Figure 13) we show little sequence similarity outside of the GTPase domain. However, the 
serine site position in both Ras1 and Ras2 is similar suggesting that serine residues located 
around this position may play a conserved regulatory role within Ras proteins.  
7.5 Targeting Ras membrane interaction as an anti-Ras cancer therapy  
 
Investigations have estimated that ~50 % of all tumours are a result of mutations involved in 
the constitutive activation of Ras signalling [26]. Intensive sequencing of the cancer genome 
has revealed that, despite the identification of over 600 validated cancer genes (COSMIC 
v80; http://cancer.sanger.ac.uk/cosmic) , Ras oncogenes still constitute the most frequently 
mutated oncogene family in human cancers [258]. Despite decades of intensive effort, a 
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clinically effective anti-Ras therapy remains elusive, prompting the widely held perception 
that Ras proteins are ‘undruggable’ [259][260].  
Initial approaches for the development of Ras inhibitors were guided by understanding the 
biochemical defects of mutant Ras proteins; HRAS, KRAS4A, KRAS4B and NRAS [261]. 
Unsuccessful attempts to develop anti-Ras drugs resulted from the misconception that the 
four Ras oncoproteins were identical in function [260]. With an ever increasing appreciation 
that different Ras proteins play unique roles in cancer, research has shifted its focus to KRAS, 
the isoform most frequently mutated in human cancer [262]. Sequence analyses have 
revealed the importance of the amino acids at positions 12, 13 and 61 in Ras proteins, 
mutations that cause the alternation of residues can lead to the over-activation of Ras via 
GAP impairment [41]. Mutations at these residues impair intrinsic and GAP-stimulated GTP 
hydrolysis rates and/or increase intrinsic exchange rates, favouring stimulus-independent 
formation of active Ras-GTP. As such, the earliest attempts of anti-Ras therapy centred on the 
formulation of small-molecule antagonists of GTP binding. Unfortunately, the picomolar 
affinity of Ras for GTP and the millimolar cellular concentrations of GTP render such attempts 
unsuccessful [262]. Small molecule mimetics of GAP activation on mutant Ras proteins was 
also unsuccessful due to the lack of well-defined hydrophobic pockets on the surface of Ras 
proteins [261]. As such many regarded Ras proteins as not tractable. This perception led to 
the pursuit of indirect strategies to target proteins that promote Ras membrane interaction.  
With the recognition that Ras oncogenic activity is dependent on its association with the inner 
leaflet of the plasma membrane, and the subsequent identification of posttranslational 
modifications that modulate this association, came the next targeted anti-Ras therapy. Ras is 
synthesized in the cytosol and undergoes a series of posttranslational modification’s that 
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promote its membrane association [263]. The initial modification is farnesyltransferase-
catalyzed covalent addition of a farnesyl moiety to the cysteine residue of the CAAX motif. 
Followed by the proteolytic removal of the last three amino acids by Rec1 [263]. Lastly, 
isoprenylcysteine carboxyl methyltransferase (ICMT) facilitates methyl transfer to the C-
terminal amino acid to negate the negative charge and prevent plasma membrane repulsion 
[263]. As the association of Ras proteins with the plasma membrane is essential for their 
function, targeting this requirement can be viewed as the functional equivalent not of turning 
off the defective switch that is oncogenic Ras, but of removing it and thereby destroying the 
circuit.  
 Due to the important role of the farnesyl lipid modification for posttranslational 
modifications and for Ras oncogenic activity, numerous farnyltransferase inhibitors were 
developed such as Ionafarnib and tipifarnib but disappointingly displayed no efficacy in the 
clinic. However, targeting other posttranslational modifications of Ras, such as 
phosphorylation, still display some promise as effective anti-Ras therapies [263][260][264]. 
Of these, phosphorylation of KRAS4B on serine181 can alter subcellular localisation of Ras, 
displacing the modified GTPase from the plasma membrane, and converting KRAS4B from 
growth-promoting to a growth-suppressing protein [77][265][266].   
Like the phosphorylation of the Serine181 of KRAS4B, the modification of the phosphorylation 
site of Serine225 of Ras2p also alters the subcellular localisation of Ras proteins, displacing 
GTP-bound Ras from the plasma membrane to the nuclear envelope. Such localisation is 
correlated with a transition into a quiescence-like state that can be viewed as growth-
supressing. We therefor hypothesize that modification of the equivalent serine residue in the 
NRAS oncoprotein, Serine173, may also alter the subcellular localisation of Ras proteins and 
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convert NRAS from growth-promoting to a growth-suppressing protein. Providing more 
promise, is that the Serine173 residue of NRAS is in the variable domain of the protein, which 
makes this putative phosphorylation site an attractive drug target due to its accessibility.  
Cosmic, the ‘Catalogue of Somatic Mutations in Cancer’ is an expert-curated database 
encompassing the wide variety of somatic mutation mechanisms causing human cancer. 
COSMIC contains details on millions of mutations across thousands of different cancer types. 
Hand-curation of key cancer genes provide in-depth detail on mutation distributions and 
effects, whilst semi-automated curation of cancer genomes provides broad somatic 
annotations toward target discovery. The COSMIC data provides details on the site and 
frequency of specific mutations.  
Here we used the COSMIC data to investigate whether mutations located at the residue Ser173 
of NRAS were recorded (Figure 94). Interestingly, we observed that mutations have been 
found around the conserved serine residues, but mutations were not recorded at Ser173. It 
would thus be interesting to investigate whether modification of the residues surrounding 






Figure 94. A graphical representation of the location and frequency of mutations 
surrounding the Ser173 of NRAS.  
Mutations at NRASS173 were absent but mutations were observed surrounding the conserved 
serine residue suggesting that these residues may be important for localisation and activity 
of Ras proteins.   
7.6 Conclusions and future investigations 
 
The work presented in this thesis suggests that the modification of the Ser225 residue of Ras2p 
is important for both localisation and activity of Ras proteins in yeast cells. We show that the 
miss localisation of active Ras proteins to the nuclear envelope of cells results in significant 
growth defects that are mediated through aberrant the Ras/cAMP/PKA signalling pathway. 
We suggest that enhanced PKA activity stimulated from active Ras populations on the nuclear 
envelope results in a decrease in viability which we attribute to premature cell cycle arrest, a 
phenotype previously not correlated with enhanced PKA activity. RNA-Seq analysis suggests 
that the slow growth phenotype does not recapitulate canonical quiescent transcription 
profiles but instead is characterised by an upregulation of transcriptional and translational 
machinery and a downregulation of nuclear and cellular division. The slow growth phenotype 
can be repressed through increasing nutrient availability to cells either through growth on 
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nutrient rich media or through deletion of CUP9.  Sequence alignment between yeast Ras2 
and human NRas, revealed that the Ser225 residue of Ras2 is conserved in human NRas at 
Serine173.  If modification of NRAS173 in human cells results in the miss localisation of activated 
oncoproteins and induction in cell growth cessation. We suggest that this mechanism could 
be exploited as a potential anti-Ras cancer therapeutic if the precise nature of the effects of 
Ras redirection can be identified. 
 
Further Work 
 In cancer, a single mutation in just one copy of a gene can be enough to induce 
tumorigenesis. Dominant genes show their effect even if there is just one mutation in 
one copy of that gene pair [267]. This thesis has shown that the overexpression of 
either RAS2S225A or RAS2S225E in the presence of wild type RAS2 resulted in a dominant 
phenotype. However, many of the experiments presented here have been conducted 
solely in a wild type background. While this thesis aimed to examine the effect of 
mutated RAS2 expression in a system closely resembling that present in the human 
condition i.e. one wild type and one mutated gene. Limitations of this experimental 
design are that the effect of mutated Ras2 protein expression alone is not known, and 
therefor whether the presence of the wild type Ras2 protein confounds the phenotype 
observed upon the overexpression of either RAS2S225A or RAS2S225E in S. cerevisiae. To 
address this, all experiments investigating the expression of either RAS2S225A or 
RAS2S225E should be conducted in both wild type and Δras2 yeast cells. 
 We have observed significant differences in viability between yeast cells 
overexpressing RAS2, RAS2S225A or RAS2S225E and NRAS, NRASS173A or NRASS173E; 
therefore, it would be interesting to investigate if similar growth defects and changes 
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in localisation of Ras and active Ras occur in a mammalian system. To address this, we 
would like to express NRAS, NRASS173A or NRASS173E in a human neuroblastoma cell line 
and conduct growth and viability assays. The human oncogene NRAS is linked to 
haematological malignancies particularly acute leukaemia [197][268]. Our data could 
therefore provide valuable information which might assist in developing new 
strategies for cancer treatment. 
 We have shown that the reduction in viability induced by the overexpression of 
RAS2S225A or RAS2S225E in wild type cells can be reversed through the co-expression of 
PDE2. As aforementioned, Pde2 is a high-affinity cAMP phosphodiesterase which 
catalyses the degradation of cAMP[86]. The resulting effect of the overexpression of 
PDE2, is a decrease in intracellular levels of cAMP. We hypothesize that the 
overexpression of RAS2S225A or RAS2S225E in wild type cells leads to increase in 
intracellular cAMP levels and increased PKA activity. To attest this hypothesis, we 
would like to measure the intracellular levels of cAMP in wild type cells overexpressing 
RAS2S225A or RAS2S225E and compare levels to a wild type control. This would be 
achieved through a metabolite extraction protocol and measuring cAMP 
concentrations within cells.  
 To investigate the global effects of the overexpression of either RAS2S225A or RAS2S225E 
in wild type cells we conducted a genome-wide transcriptome analysis. We have 
observed the global transcriptional changes induced upon the overexpression of 
RAS2S225A or RAS2S225E when compared to the wild type. It would be interesting to 
extract the RNA from wild type cells overexpressing wild type RAS2 and perform RNA-
Seq analysis to observe the changes in gene expression when the Serine225 is not 
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mutated. Such analysis would allow us to determine the genes up/downregulated and 
the gene sets enriched upon the modification of RAS2S225.  
 We observed that the overexpression of RAS2S225A or RAS2S225E in wild type cells had a 
dramatic effect on a wide array of cellular processes. By performing ribosomal 
profiling, we could observe a global profile of ribosomes in the cell allowing us to 
identify if they are being utilised for translation. In cells overexpressing either 
RAS2S225A or RAS2S225E we would anticipate that there should be an increase in 80S 
ribosomes, and polysomes if the overexpression of RAS2 mutant alleles in the system 
is contributing to translation. 
 Other lines of investigation would be to investigate whether the phosphorylation of 
Ras2S225 resulted in changes to the phosphorylation status of nearby serine residues ─ 
such as serine224. Furthermore, we would like to examine whether mutating both 
serine225 and serine224 would lead to a further attenuation of growth and viability in 
yeast cells overexpressing these mutant alleles. 
 It would be interesting to investigate why the loss of CUP9 in cells overexpressing 
either RAS2S225A or RAS2S225E restore normal cell growth. Such insight could be 
achieved through comparing RNA-Seq data from wild type cells overexpressing RAS2 
mutant alleles to the expression of RAS2 mutant alleles in a Δcup9 background.  Such 
analysis would allow us to determine the genes up/downregulated and the gene sets 
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Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
RPP0 25 2.342 0.0779 
TMA19 56 1.975 0.1413 
RPL30 121 1.675 0.1857 
RPL29 140 1.606 0.2388 
SSB1 195 1.461 0.278 
SSA1  220 1.406 0.3225 
SSB2 224 1.403 0.3721 
THS1  278 1.315 0.4062 
TMA7 311 1.265 0.4437 
RPL28 373 1.181 0.4711 
RPG1 404 1.133 0.5044 
TIF11 426 1.1 0.5387 
SSZ1 523 1.001 0.5511 
TIF35 531 0.993 0.585 
TIF3 535 0.989 0.6197 
HYP2 596 0.918 0.6379 
TRM7 771 0.778 0.6231 
TAE1 1061 0.585 0.5732 
RBG1 1112 0.558 0.5809 
PRT1 1175 0.525 0.5846 
HCR1 1262 0.483 0.5808 
FES1 1388 0.428 0.5655 
FUN12 1803 0.267 0.4736 
CLU1 1941 0.213 0.4476 
TIF34 2035 0.16 0.4305 
TMA46 2238 -0.234 0.3894 
RPM2 3373 -0.601 0.1329 
MTG2 3405 -0.614 0.1473 





Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
RPP0 25 2.342 0.0505 
ASC1  49 2.05 0.0944 
RPS12 79 1.818 0.1312 
RPS5 85 1.784 0.1731 
RPS3 120 1.677 0.2053 
RPL30 121 1.675 0.2458 
RPS31 138 1.615 0.2809 
RPL29 140 1.606 0.3195 
RPL39 179 1.513 0.3467 
RPL5 208 1.425 0.3743 
RPL3 232 1.381 0.4021 
RPL38 257 1.345 0.4287 
RPS20 279 1.313 0.4553 
RPL25 294 1.286 0.4829 
RPL32 300 1.278 0.5126 
RPS13 305 1.273 0.5424 
RLI1 318 1.253 0.5697 
SIS1 327 1.246 0.5979 
RPS2 363 1.193 0.6182 
RPL28 373 1.181 0.6445 
YEF3 378 1.174 0.6719 
RPL10 452 1.072 0.6799 
NAT1 571 0.946 0.6738 
HYP2 596 0.918 0.6901 
MAP1 605 0.909 0.7101 
SQT1  678 0.848 0.7129 
ARD1 709 0.825 0.7255 
SNL1 1030 0.605 0.6615 
FES1 1388 0.428 0.5841 
NAT5 1632 0.33 0.5323 
NMD3 1733 0.293 0.5148 
FUN12 1803 0.267 0.5043 
LSG1 1943 0.212 0.4753 
JJJ1  2216 -0.226 0.4139 
HEF3 2692 -0.367 0.3061 
RQC1 3116 -0.5 0.2142 
RRP14 3137 -0.507 0.2215 






Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
SNU13 23 2.41 0.025 
RPP0 25 2.342 0.0547 
RPS5 85 1.784 0.0627 
NOP58 100 1.74 0.0814 
KRR1 103 1.73 0.103 
RPS3 120 1.677 0.1204 
HCA4 148 1.59 0.1339 
RPL3 232 1.381 0.1308 
NIP7 242 1.365 0.146 
YVH1 249 1.355 0.1618 
EMG1 283 1.307 0.1702 
NOP13 285 1.303 0.1866 
RPS13 305 1.273 0.1981 
ENP1 317 1.256 0.2114 
RLI1 318 1.253 0.2274 
NOP56 357 1.203 0.2332 
RPS2 363 1.193 0.2472 
RPL28 373 1.181 0.2601 
MRT4 411 1.123 0.2651 
UTP13 430 1.095 0.2746 
NOP1 431 1.094 0.2886 
MAK16 498 1.034 0.2853 
NOC2 525 0.999 0.2915 
NEW1 534 0.991 0.3021 
DIM1 560 0.958 0.3081 
UTP4 564 0.953 0.3195 
HAS1 579 0.936 0.328 
IMP3 597 0.918 0.3354 
RRS1 598 0.917 0.3472 
UTP10 608 0.903 0.3564 
RPF2 629 0.886 0.3627 
CBF5 634 0.881 0.373 
NSA2 640 0.876 0.3829 
PRP43 652 0.866 0.3912 
SQT1  678 0.848 0.3958 
DBP3 696 0.833 0.4022 
299 
 
CIC1 708 0.827 0.41 
NOP7 717 0.821 0.4185 
UTP14 739 0.806 0.4235 
DBP5 759 0.787 0.4288 
NUG1 790 0.768 0.4311 
MAK21 803 0.757 0.4378 
IPI1 807 0.755 0.4466 
RRP1 832 0.737 0.45 
KRE33 847 0.727 0.4558 
ROK1 866 0.715 0.4605 
SLX9 889 0.701 0.4639 
BFR2 896 0.696 0.4713 
UTP21 925 0.677 0.4729 
CGR1 1001 0.626 0.4621 
UTP6 1031 0.605 0.4626 
SAS10  1045 0.596 0.4669 
SPB1 1072 0.578 0.4678 
FCF1  1132 0.548 0.46 
CKB2 1159 0.534 0.4604 
NOP2 1193 0.517 0.4587 
ERB1 1205 0.512 0.4625 
RIX7 1219 0.507 0.4657 
CKB1 1231 0.5 0.4693 
NSA1 1251 0.489 0.4708 
NOG1 1255 0.486 0.4763 
NOP9 1324 0.455 0.465 
RRP12 1334 0.452 0.4686 
UTP7 1366 0.441 0.4664 
RRP36 1394 0.425 0.4651 
NOP4 1422 0.413 0.4636 
NOG2 1466 0.397 0.4579 
DBP8 1488 0.388 0.4576 
CKA2 1528 0.364 0.4525 
BUD20 1536 0.361 0.4554 
RSA3 1543 0.359 0.4584 
PWP2 1566 0.351 0.4574 
UTP22 1602 0.34 0.453 
SSF1  1687 0.31 0.4359 
RRP7 1699 0.306 0.4371 
NMD3 1733 0.293 0.4326 
TIF6 1786 0.276 0.4231 
NOP6 1787 0.275 0.4266 
300 
 
FUN12 1803 0.267 0.4262 
RRP5 1819 0.261 0.4258 
UTP23 1828 0.258 0.4271 
CMS1 1839 0.254 0.4278 
SQS1 1871 0.239 0.4231 
UTP5 1885 0.235 0.4229 
RLP24 1887 0.234 0.4256 
UTP15 1906 0.227 0.424 
RRP9 1909 0.227 0.4264 
NOP15 1981 0.198 0.4111 
YTM1 2015 0.179 0.4052 
UTP18 2117 -0.189 0.3823 
RLP7 2137 -0.196 0.3801 
DIP2 2158 -0.205 0.3777 
TSR1 2162 -0.206 0.3795 
CRM1 2184 -0.215 0.377 
JJJ1  2216 -0.226 0.3722 
NOP16 2232 -0.232 0.3714 
SPB4 2319 -0.258 0.3531 
UTP20 2386 -0.28 0.3402 
ENP2 2464 -0.303 0.3248 
NOP19 2586 -0.335 0.2988 
UTP30 2642 -0.352 0.2895 
RRP15 2662 -0.358 0.2893 
UTP11 2710 -0.375 0.2823 
MRD1 2754 -0.386 0.2765 
LAS1 2803 -0.4 0.2696 
EBP2 2806 -0.4 0.2742 
LTV1 2974 -0.451 0.2381 
KRI1 2995 -0.458 0.239 
ECM1 3114 -0.5 0.2158 
DBP6 3234 -0.544 0.193 
MDN1 3321 -0.579 0.1788 
CKA1 3440 -0.627 0.1573 








Ribosome Assembly  
 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
RPP0 25 2.342 0.0885 
REX4 91 1.75 0.1433 
RPS31 138 1.615 0.1972 
IPI3 143 1.598 0.2608 
NSR1 180 1.508 0.3129 
RPL5 208 1.425 0.3638 
RPL3 232 1.381 0.414 
YVH1 249 1.355 0.4648 
RPL25 294 1.286 0.5059 
MRT4 411 1.123 0.5229 
RPL10 452 1.072 0.5564 
RPF2 629 0.886 0.549 
SQT1  678 0.848 0.5715 
MAK21 803 0.757 0.5717 
IPI1 807 0.755 0.6014 
RIA1 815 0.75 0.63 
RSA4 1222 0.505 0.5509 
RSA1 1519 0.368 0.4933 
RSA3 1543 0.359 0.5021 
SSF1  1687 0.31 0.4796 
RRP7 1699 0.306 0.4893 
FUN12 1803 0.267 0.4748 
LSG1 1943 0.212 0.4493 
SPB4 2319 -0.258 0.3678 
MRD1 2754 -0.386 0.2771 
MDN1 3321 -0.579 0.1617 
MRH4 3681 -0.753 0.1042 
 
Ribosome Biogenesis  
 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
SNU13 23 2.41 0.0107 
RPP0 25 2.342 0.0266 
RPS5 85 1.784 0.0238 
REX4 91 1.75 0.0346 
NOP58 100 1.74 0.0446 
302 
 
KRR1 103 1.73 0.056 
RPS3 120 1.677 0.0635 
RPL30 121 1.675 0.075 
RPS31 138 1.615 0.0821 
IPI3 143 1.598 0.0921 
HCA4 148 1.59 0.102 
NSR1 180 1.508 0.1045 
TSR2 194 1.463 0.1113 
SSB1 195 1.461 0.1213 
RPS15 201 1.446 0.13 
RPL5 208 1.425 0.1383 
EFG1 213 1.417 0.1471 
SSB2 224 1.403 0.1542 
RPL3 232 1.381 0.1619 
GSP1 235 1.379 0.171 
RRB1 236 1.374 0.1804 
NIP7 242 1.365 0.1886 
YVH1 249 1.355 0.1964 
RPS20 279 1.313 0.198 
EMG1 283 1.307 0.2063 
RPL25 294 1.286 0.2126 
RPS13 305 1.273 0.2188 
ENP1 317 1.256 0.2247 
RLI1 318 1.253 0.2333 
NOP56 357 1.203 0.2319 
RPS2 363 1.193 0.2388 
SRD1 400 1.139 0.2374 
GAR1 402 1.136 0.245 
MRT4 411 1.123 0.2507 
UTP13 430 1.095 0.2537 
NOP1 431 1.094 0.2612 
RPL10 452 1.072 0.2635 
ESF1 481 1.051 0.2635 
MAK5 482 1.051 0.2708 
MAK16 498 1.034 0.2741 
SSZ1 523 1.001 0.2748 
NOC2 525 0.999 0.2815 
NEW1 534 0.991 0.2863 
DIM1 560 0.958 0.2865 
UTP4 564 0.953 0.2923 
HAS1 579 0.936 0.2951 
NHP2 585 0.931 0.3003 
303 
 
SKI6 588 0.927 0.3062 
IMP3 597 0.918 0.3104 
RRS1 598 0.917 0.3168 
ZUO1 604 0.91 0.3218 
UTP10 608 0.903 0.3272 
RAI1 622 0.89 0.33 
RPF2 629 0.886 0.3346 
CBF5 634 0.881 0.3397 
NSA2 640 0.876 0.3444 
PRP43 652 0.866 0.3476 
RPP1 676 0.849 0.3476 
SQT1  678 0.848 0.3532 
RRP46 681 0.845 0.3585 
DBP3 696 0.833 0.3606 
TMA20 715 0.823 0.3617 
NOP7 717 0.821 0.3671 
PWP1 728 0.813 0.3702 
FYV7 738 0.806 0.3734 
UTP14 739 0.806 0.379 
DBP9 750 0.798 0.3819 
NUG1 790 0.768 0.3772 
FAP7 793 0.763 0.382 
MAK21 803 0.757 0.3849 
IPI1 807 0.755 0.3893 
RIA1 815 0.75 0.3927 
RRP1 832 0.737 0.3937 
KRE33 847 0.727 0.3951 
ROK1 866 0.715 0.3954 
RNT1 888 0.701 0.3949 
SLX9 889 0.701 0.3997 
RRP42 895 0.696 0.4032 
BFR2 896 0.696 0.408 
NUP85 898 0.694 0.4126 
SRM1 917 0.682 0.4127 
UTP21 925 0.677 0.4155 
RRP43 933 0.673 0.4184 
RRP40 936 0.669 0.4225 
CGR1 1001 0.626 0.4104 
UTP6 1031 0.605 0.4071 
SAS10  1045 0.596 0.4079 
YAR1 1054 0.59 0.4099 
RRP3 1070 0.579 0.4101 
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SPB1 1072 0.578 0.4138 
GRC3 1097 0.566 0.4115 
RCM1 1128 0.549 0.4076 
FCF1  1132 0.548 0.4106 
PUF6 1166 0.531 0.4058 
POP7 1178 0.524 0.4066 
NOP2 1193 0.517 0.4066 
SYO1 1204 0.512 0.4076 
ERB1 1205 0.512 0.4111 
RIX7 1219 0.507 0.4113 
RSA4 1222 0.505 0.4142 
CAM1 1226 0.5 0.4169 
MTR4 1250 0.489 0.4144 
NSA1 1251 0.489 0.4178 
NOG1 1255 0.486 0.4203 
HCR1 1262 0.483 0.4221 
MPP6 1304 0.466 0.4148 
NOP9 1324 0.455 0.4131 
RRP12 1334 0.452 0.4139 
UTP7 1366 0.441 0.409 
PUS7 1381 0.432 0.4084 
RRP36 1394 0.425 0.4082 
NOP4 1422 0.413 0.4042 
REX3 1445 0.404 0.4013 
RNA1 1448 0.403 0.4036 
NOG2 1466 0.397 0.4019 
DBP8 1488 0.388 0.3992 
RSA1 1519 0.368 0.3941 
BUD20 1536 0.361 0.3925 
RSA3 1543 0.359 0.3934 
RNH70 1555 0.356 0.393 
URB2 1565 0.352 0.3932 
PWP2 1566 0.351 0.3956 
TRM112 1598 0.341 0.39 
UTP22 1602 0.34 0.3916 
MTR3 1631 0.33 0.3867 
RRP4 1668 0.313 0.3796 
SSF1  1687 0.31 0.3771 
RRP7 1699 0.306 0.3764 
NMD3 1733 0.293 0.3699 
SDA1 1774 0.28 0.3616 
LTO1 1784 0.276 0.3612 
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TIF6 1786 0.276 0.3628 
NOP6 1787 0.275 0.3647 
FUN12 1803 0.267 0.3627 
RRP8 1816 0.262 0.3615 
RRP5 1819 0.261 0.3628 
UTP23 1828 0.258 0.3625 
SQS1 1871 0.239 0.3534 
UTP5 1885 0.235 0.3516 
RLP24 1887 0.234 0.353 
LCP5 1888 0.234 0.3546 
UTP15 1906 0.227 0.3518 
RRP9 1909 0.227 0.3529 
FCF2  1913 0.224 0.3536 
NOP53 1934 0.216 0.35 
LSG1 1943 0.212 0.3494 
NOP15 1981 0.198 0.3413 
REX2 1994 0.192 0.3395 
NGL2 2014 0.179 0.3359 
YTM1 2015 0.179 0.3371 
SEN1 2039 0.153 0.3323 
TMA23 2056 -0.159 0.3293 
NIC96 2098 -0.183 0.32 
SAC3  2115 -0.189 0.3172 
UTP18 2117 -0.189 0.3183 
RLP7 2137 -0.196 0.3147 
NUP49 2138 -0.197 0.3161 
DIP2 2158 -0.205 0.3126 
TSR1 2162 -0.206 0.3133 
PUS5 2169 -0.208 0.3132 
CRM1 2184 -0.215 0.3111 
JJJ1  2216 -0.226 0.3047 
NOP16 2232 -0.232 0.3024 
RMP1 2243 -0.236 0.3015 
POP6 2262 -0.242 0.2986 
SPB4 2319 -0.258 0.286 
YAE1 2371 -0.274 0.2748 
UTP20 2386 -0.28 0.2731 
YRB2 2408 -0.288 0.2697 
LSM7 2422 -0.293 0.2684 
MRM2 2448 -0.3 0.264 
ENP2 2464 -0.303 0.2623 
RAT1 2488 -0.309 0.2585 
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NOP19 2586 -0.335 0.2359 
UTP30 2642 -0.352 0.2242 
RRP15 2662 -0.358 0.2218 
UTP11 2710 -0.375 0.2124 
POP1 2717 -0.376 0.2134 
RIO2 2752 -0.385 0.2073 
MRD1 2754 -0.386 0.2098 
RSP5 2785 -0.393 0.2048 
LAS1 2803 -0.4 0.2032 
EBP2 2806 -0.4 0.2054 
BCP1 2807 -0.4 0.2082 
RRP6 2921 -0.435 0.1822 
LTV1 2974 -0.451 0.1719 
KRI1 2995 -0.458 0.17 
RRP17 3012 -0.465 0.1691 
HIT1 3049 -0.478 0.1631 
PAF1 3094 -0.492 0.1552 
ECM1 3114 -0.5 0.1538 
RRP14 3137 -0.507 0.1517 
TSR3 3142 -0.508 0.1541 
SNU66 3221 -0.539 0.1378 
DBP6 3234 -0.544 0.1385 
DIS3 3240 -0.546 0.141 
MDN1 3321 -0.579 0.1245 
LRP1 3332 -0.581 0.1259 
SPT5 3358 -0.591 0.1236 
NUP116 3447 -0.63 0.1053 
MOT1 3514 -0.658 0.0929 
TOR2 3521 -0.663 0.096 
RRP45 3569 -0.69 0.0887 
IMP4 3634 -0.722 0.0772 
MRH4 3681 -0.753 0.0706 
TOR1 3689 -0.757 0.0741 
NUP1 3707 -0.774 0.0751 
TOM1 3754 -0.812 0.0689 
SNM1 3878 -0.92 0.0436 
DBP7 3933 -0.984 0.0366 
NME1 4005 -1.098 0.0259 
 




Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
KIN4 938 0.667 -0.1891 
MAD2 1015 0.615 -0.1701 
HHT2 1155 0.536 -0.1714 
LTE1 1301 0.467 -0.1784 
CDC20 1424 0.413 -0.1831 
TPD3 1718 0.298 -0.2367 
BMH1 1961 0.205 -0.2835 
CTF3  2277 -0.246 -0.3456 
CDC55 2383 -0.279 -0.3543 
RTS1 2598 -0.339 -0.3861 
IPL1 2720 -0.377 -0.3927 
FIN1 2941 -0.442 -0.4196 
MPS1 3205 -0.534 -0.4514 
BUB3 3224 -0.54 -0.4228 
BUD2 3250 -0.55 -0.3953 
ULP2 3297 -0.571 -0.3717 
GAC1 3368 -0.599 -0.3522 
MAD1 3406 -0.614 -0.3238 
DOC1 3489 -0.65 -0.3042 
SWM1 3524 -0.664 -0.2719 
CEP3 3570 -0.69 -0.2408 
BFA1 3733 -0.791 -0.2322 
BIR1 3826 -0.874 -0.2013 
DMA2 3895 -0.934 -0.1609 
CDH1 3970 -1.039 -0.1155 
CHL4 3982 -1.053 -0.0539 




Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
SPO16 406 1.13 -0.0782 
RFA3 635 0.881 -0.1173 
REC104 710 0.825 -0.1192 
RFA2 765 0.783 -0.117 
MEI4 799 0.76 -0.11 
MCD1 805 0.755 -0.0962 
SMC3 965 0.646 -0.1228 
YCS4  1000 0.627 -0.1187 
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PDS5 1011 0.619 -0.1089 
MAD2 1015 0.615 -0.0973 
MCM16 1028 0.606 -0.0882 
SMC6 1179 0.524 -0.115 
SMC1 1192 0.517 -0.1077 
MTW1 1228 0.5 -0.1064 
HSK3 1229 0.5 -0.0964 
NSE5 1383 0.431 -0.1258 
DUO1 1473 0.393 -0.1401 
DAD1 1581 0.347 -0.1597 
CSM1 1622 0.333 -0.163 
YCG1 1689 0.309 -0.1732 
STU2 1741 0.29 -0.1801 
IRR1 1751 0.287 -0.1766 
SMC4 1797 0.271 -0.1824 
LRS4 1872 0.239 -0.196 
TOP2 1956 0.208 -0.2124 
NSE1 2172 -0.209 -0.2616 
CTF3  2277 -0.246 -0.2825 
ZIP1 2300 -0.252 -0.283 
KRE29 2459 -0.302 -0.3162 
CST9  2483 -0.307 -0.3158 
PLC1 2512 -0.316 -0.3164 
CBF2 2556 -0.328 -0.3205 
MEC3 2581 -0.334 -0.3198 
RTS1 2598 -0.339 -0.317 
MCM22 2600 -0.34 -0.3105 
NUF2 2644 -0.352 -0.3142 
DAM1 2698 -0.369 -0.32 
IPL1 2720 -0.377 -0.3177 
ASK1 2863 -0.419 -0.3446 
PPH3 2912 -0.432 -0.3479 
FIN1 2941 -0.442 -0.346 
CSE4 2956 -0.446 -0.3406 
REC102 2958 -0.446 -0.3319 
RED1 3163 -0.518 -0.3722 
MCM21 3166 -0.52 -0.3624 
MPS1 3205 -0.534 -0.3611 
BUB3 3224 -0.54 -0.3548 
DAD3 3225 -0.541 -0.3441 
ZIP2 3378 -0.603 -0.3698 
AME1 3445 -0.63 -0.3736 
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SCM3 3460 -0.636 -0.3644 
NNF1 3469 -0.641 -0.3536 
NSE4 3501 -0.653 -0.3482 
ECM11 3503 -0.655 -0.3354 
REC107 3531 -0.666 -0.3289 
CEP3 3570 -0.69 -0.3245 
REC114 3656 -0.741 -0.3309 
CTF13  3668 -0.748 -0.3187 
MMS21 3753 -0.812 -0.3233 
MND1 3765 -0.823 -0.3097 
RAD51 3795 -0.85 -0.2999 
REC8 3796 -0.85 -0.283 
BIR1 3826 -0.874 -0.2727 
UBC9 3861 -0.901 -0.2632 
SLK19 3917 -0.963 -0.2577 
MIF2 3925 -0.975 -0.24 
OKP1 3929 -0.979 -0.2212 
DSN1 3941 -0.998 -0.204 
SPO13 3950 -1.009 -0.1859 
DMC1 3963 -1.029 -0.1684 
CHL4 3982 -1.053 -0.1518 
NDC80 3988 -1.059 -0.132 
KRE28 4004 -1.091 -0.1139 
BRN1 4016 -1.125 -0.0942 
TFC3  4037 -1.199 -0.0753 
CTF19  4076 -1.374 -0.0573 
SPC24 4095 -1.573 -0.0304 




Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
MAD2 1015 0.615 -0.2262 
MCM16 1028 0.606 -0.206 
MTW1 1228 0.5 -0.2358 
HSK3 1229 0.5 -0.2167 
DUO1 1473 0.393 -0.2615 
DAD1 1581 0.347 -0.2745 
CSM1 1622 0.333 -0.2716 
STU2 1741 0.29 -0.2896 
LRS4 1872 0.239 -0.3124 
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CRM1 2184 -0.215 -0.3807 
CTF3  2277 -0.246 -0.3939 
PLC1 2512 -0.316 -0.4394 
CBF2 2556 -0.328 -0.4375 
RTS1 2598 -0.339 -0.4346 
MCM22 2600 -0.34 -0.4219 
WIP1 2638 -0.351 -0.4175 
NUF2 2644 -0.352 -0.4053 
DAM1 2698 -0.369 -0.4042 
IPL1 2720 -0.377 -0.395 
CNN1 2767 -0.388 -0.3914 
ASK1 2863 -0.419 -0.3988 
FIN1 2941 -0.442 -0.4008 
CSE4 2956 -0.446 -0.3872 
MCM21 3166 -0.52 -0.4188 
MPS1 3205 -0.534 -0.4077 
BUB3 3224 -0.54 -0.3914 
DAD3 3225 -0.541 -0.3708 
MAD1 3406 -0.614 -0.3916 
AME1 3445 -0.63 -0.3768 
NNF1 3469 -0.641 -0.358 
CEP3 3570 -0.69 -0.3562 
CTF13  3668 -0.748 -0.3514 
BIR1 3826 -0.874 -0.3566 
SLK19 3917 -0.963 -0.3419 
MIF2 3925 -0.975 -0.3064 
OKP1 3929 -0.979 -0.2696 
CBF1 3939 -0.996 -0.2338 
DSN1 3941 -0.998 -0.1958 
CHL4 3982 -1.053 -0.1654 
NDC80 3988 -1.059 -0.1261 
KRE28 4004 -1.091 -0.0881 
CTF19  4076 -1.374 -0.053 
SPC24 4095 -1.573 0.0027 
 
 
Microtubule based processes 
 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
ACT1  353 1.214 -0.063 
SPC29 379 1.169 -0.0455 
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SPC98 646 0.872 -0.0938 
CRN1 672 0.853 -0.0828 
CMD1 713 0.824 -0.076 
CLB4 725 0.814 -0.0622 
RHO2 769 0.78 -0.057 
TUB4 890 0.7 -0.0726 
ESP1 1022 0.61 -0.0928 
LDB18 1041 0.597 -0.0851 
CLB1 1096 0.566 -0.0871 
LIA1 1127 0.549 -0.0834 
ARP1 1191 0.517 -0.0885 
HSK3 1229 0.5 -0.0876 
TVP38 1232 0.498 -0.0779 
CDC28 1377 0.434 -0.1049 
DUO1 1473 0.393 -0.1205 
DYN2 1505 0.377 -0.1205 
NDC1 1574 0.349 -0.1304 
DAD1 1581 0.347 -0.1248 
STU2 1741 0.29 -0.1584 
BUD6 1815 0.262 -0.1712 
HCM1 1895 0.231 -0.1861 
BER1 1929 0.219 -0.1899 
DSK2 1935 0.216 -0.1868 
MYO2 1991 0.193 -0.1965 
DYN1 2157 -0.205 -0.2333 
NAP1 2164 -0.207 -0.2306 
ATS1  2341 -0.264 -0.269 
RRD1 2375 -0.274 -0.2716 
KIP3 2435 -0.297 -0.2802 
BBP1 2494 -0.311 -0.2883 
CBF2 2556 -0.328 -0.2968 
SPO1 2578 -0.333 -0.2953 
RTS1 2598 -0.339 -0.2931 
SFI1 2627 -0.347 -0.293 
NUF2 2644 -0.352 -0.2898 
CLB3 2653 -0.355 -0.2846 
DAM1 2698 -0.369 -0.288 
SPC42 2699 -0.369 -0.2805 
IPL1 2720 -0.377 -0.2779 
SHE1 2753 -0.386 -0.278 
ASK1 2863 -0.419 -0.2965 
KIP2 2866 -0.42 -0.2885 
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FIN1 2941 -0.442 -0.2979 
BNI1 2962 -0.447 -0.2938 
NIP100 2972 -0.45 -0.2869 
MLP2 2998 -0.46 -0.2838 
CDC5 3007 -0.462 -0.2764 
POM34 3090 -0.491 -0.2868 
CLB5 3092 -0.491 -0.2771 
MPS1 3205 -0.534 -0.2941 
DAD3 3225 -0.541 -0.2878 
GPA1 3229 -0.543 -0.2775 
SHP1 3235 -0.544 -0.2677 
JNM1 3246 -0.549 -0.2591 
NDL1 3262 -0.554 -0.2516 
STU1 3369 -0.599 -0.2657 
AME1 3445 -0.63 -0.2716 
NUM1 3562 -0.687 -0.2864 
CDC31 3573 -0.691 -0.2749 
CDC14 3604 -0.705 -0.268 
ASE1 3808 -0.859 -0.301 
BIR1 3826 -0.874 -0.2875 
KAR3 3828 -0.876 -0.27 
UBC9 3861 -0.901 -0.2596 
IRC15 3867 -0.91 -0.2424 
DMA2 3895 -0.934 -0.2301 
MPS2 3908 -0.953 -0.2138 
SLK19 3917 -0.963 -0.1962 
MIF2 3925 -0.975 -0.1782 
OKP1 3929 -0.979 -0.1591 
DSN1 3941 -0.998 -0.1416 
DYN3 3953 -1.012 -0.1237 
CDH1 3970 -1.039 -0.1066 
NDC80 3988 -1.059 -0.0894 
MPS3 4049 -1.261 -0.0787 
CTF19  4076 -1.374 -0.0572 
SPC24 4095 -1.573 -0.0298 








Sister Chromatid Segregation  
 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
POL30 166 1.548 -0.0072 
MCD1 805 0.755 -0.1489 
TOF1 879 0.705 -0.1516 
KIN4 938 0.667 -0.1513 
SMC3 965 0.646 -0.1436 
YCS4  1000 0.627 -0.1383 
PDS5 1011 0.619 -0.1272 
MAD2 1015 0.615 -0.1145 
ESP1 1022 0.61 -0.1026 
MCM16 1028 0.606 -0.0906 
HHT2 1155 0.536 -0.1101 
SMC1 1192 0.517 -0.1077 
CTF18  1215 0.509 -0.102 
LTE1 1301 0.467 -0.1128 
CDC20 1424 0.413 -0.1341 
CHL1 1508 0.376 -0.1464 
YCG1 1689 0.309 -0.1843 
MRC1 1708 0.304 -0.1821 
TPD3 1718 0.298 -0.1778 
IRR1 1751 0.287 -0.1794 
SMC4 1797 0.271 -0.1846 
BMH1 1961 0.205 -0.2206 
DYN1 2157 -0.205 -0.2644 
CTF3  2277 -0.246 -0.2885 
POL2 2313 -0.257 -0.2916 
APC2 2322 -0.26 -0.2879 
CDC55 2383 -0.279 -0.2967 
ELG1 2404 -0.286 -0.2954 
SGS1 2469 -0.303 -0.3046 
RTS1 2598 -0.339 -0.3289 
MCM22 2600 -0.34 -0.3217 
IPL1 2720 -0.377 -0.3429 
GPN2 2765 -0.388 -0.3454 
CTF8  2825 -0.411 -0.351 
RDH54 2843 -0.415 -0.3461 
MMS22 2888 -0.425 -0.3477 
TOP1 2931 -0.44 -0.3485 
FIN1 2941 -0.442 -0.3411 
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CSE4 2956 -0.446 -0.3348 
ESC2 3000 -0.46 -0.3353 
APC1 3076 -0.486 -0.3433 
SCC2  3095 -0.492 -0.337 
MCM21 3166 -0.52 -0.3429 
MPS1 3205 -0.534 -0.3407 
BUB3 3224 -0.54 -0.3333 
BUD2 3250 -0.55 -0.3275 
ULP2 3297 -0.571 -0.3264 
CSM3 3360 -0.594 -0.3287 
GAC1 3368 -0.599 -0.3173 
ECO1 3382 -0.605 -0.3073 
RMI1 3400 -0.613 -0.2981 
MAD1 3406 -0.614 -0.2859 
SRC1 3454 -0.635 -0.2837 
DOC1 3489 -0.65 -0.2779 
SWM1 3524 -0.664 -0.2717 
RAD30 3535 -0.667 -0.2596 
CEP3 3570 -0.69 -0.2529 
BFA1 3733 -0.791 -0.2758 
REC8 3796 -0.85 -0.2725 
SOH1 3818 -0.869 -0.2587 
BIR1 3826 -0.874 -0.2413 
KAR3 3828 -0.876 -0.2224 
IRC15 3867 -0.91 -0.2118 
SCC4  3880 -0.922 -0.1946 
DMA2 3895 -0.934 -0.1776 
TOP3 3902 -0.946 -0.1584 
DSN1 3941 -0.998 -0.146 
SPO13 3950 -1.009 -0.1258 
CDH1 3970 -1.039 -0.1078 
CHL4 3982 -1.053 -0.0875 
BRN1 4016 -1.125 -0.071 
MPS3 4049 -1.261 -0.0513 
CTF19  4076 -1.374 -0.0276 








U2 Splicesome Complex 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
PRP11 633 0.882 -0.1141 
PRP39 1358 0.443 -0.2712 
NTR2 1486 0.389 -0.2841 
CWC22  1520 0.368 -0.2749 
SMB1 1611 0.337 -0.2811 
SPP382 1710 0.302 -0.291 
PRP16 2132 -0.195 -0.3853 
SNU56 2303 -0.253 -0.4151 
CWC25  2335 -0.263 -0.4104 
CEF1 2377 -0.276 -0.4075 
CWC24  2402 -0.286 -0.3999 
LUC7 2492 -0.31 -0.4072 
SNU71 2592 -0.337 -0.4156 
SNP1 2626 -0.347 -0.4074 
CWC15  2873 -0.421 -0.448 
LEA1 2900 -0.43 -0.4341 
CWC27  2920 -0.435 -0.4183 
PRP45 2982 -0.455 -0.4119 
SYF1  3060 -0.481 -0.4082 
CUS1 3080 -0.487 -0.3899 
CLF1 3084 -0.489 -0.3676 
YHC1  3143 -0.51 -0.3578 
YJU2 3322 -0.579 -0.3743 
MUD1 3339 -0.584 -0.3507 
PRP9 3361 -0.594 -0.3279 
SLU7 3372 -0.601 -0.3021 
SNT309  3391 -0.608 -0.2778 
SMD2 3443 -0.63 -0.2607 
NAM8 3451 -0.633 -0.2326 
HSH49 3457 -0.635 -0.2039 
PRP40 3467 -0.64 -0.1759 
CWC2  3505 -0.656 -0.1541 
PRP22 3693 -0.764 -0.1641 
SMD1 3789 -0.844 -0.1477 
PRP18 3802 -0.854 -0.1104 
CWC21  3819 -0.869 -0.0734 
PRP2 3924 -0.974 -0.0531 
CWC23  3951 -1.01 -0.0119 




RAS2S225E vs EV- Cytoplasmic Translation- Upregulated 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
RPP0 17 3.703 0.0675 
RPL30 22 3.58 0.1352 
TMA19 35 3.425 0.1983 
SSB2 98 2.756 0.2387 
SSB1 100 2.735 0.2909 
SSA1  122 2.54 0.3353 
TMA7 132 2.496 0.3813 
RPL28 216 2.164 0.4062 
RPL29 236 2.101 0.4427 
THS1  274 2.01 0.4738 
TIF35 281 1.996 0.5108 
SSZ1 289 1.967 0.547 
RPG1 295 1.936 0.5831 
TIF3 410 1.68 0.5926 
TIF11 453 1.616 0.6152 
TRM7 663 1.312 0.599 
RBG1 827 1.161 0.5889 
PRT1 848 1.143 0.6068 
HYP2 858 1.134 0.6267 
CLU1 1250 0.815 0.5649 
RBG2 1444 0.68 0.5397 
FUN12 1495 0.657 0.5424 
FES1 1606 0.601 0.5321 
SLH1 1714 0.546 0.5214 
TIF34 1762 0.527 0.5222 
TAE1 1810 0.501 0.5224 
MTF2 1826 0.491 0.5289 
HCR1 2033 0.4 0.4957 
TIF5 2391 0.235 0.4296 
GIR2 2418 0.225 0.4287 
SRO9 3107 -0.451 0.3012 
MTG2 3375 -0.581 0.2594 
RPM2 3503 -0.65 0.2467 
TMA46 3726 -0.784 0.2178 
AFG3 4181 -1.13 0.1495 
RDN5-1 4548 -1.548 0.1067 
 
Cytosolic Ribosome  
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Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
RPP0 17 3.703 0.0459 
RPL30 22 3.58 0.0927 
RPS3 31 3.465 0.1372 
RPS12 42 3.291 0.179 
ASC1  53 3.165 0.2191 
RPL3 61 3.052 0.2583 
YEF3 66 3.013 0.2976 
RPS31 85 2.857 0.3321 
RPS5 95 2.81 0.3676 
RPS2 156 2.38 0.3874 
RPS13 174 2.314 0.4148 
RPL39 199 2.233 0.4397 
RPL28 216 2.164 0.4654 
RPL25 219 2.155 0.4936 
RPL29 236 2.101 0.5184 
RPL10 238 2.096 0.5461 
RPS20 256 2.061 0.5701 
RLI1 261 2.053 0.5967 
RPL32 271 2.021 0.6218 
RPL5 280 1.998 0.6468 
RPL38 284 1.984 0.6726 
NAT1 556 1.456 0.6382 
MAP1 626 1.35 0.6425 
SIS1 757 1.215 0.6328 
ARD1 765 1.207 0.6475 
ARX1 822 1.163 0.6519 
HYP2 858 1.134 0.66 
SQT1  951 1.047 0.6557 
SNL1 1081 0.935 0.6426 
NMD3 1105 0.913 0.6501 
GCN20 1362 0.735 0.6091 
CDC48 1461 0.675 0.5987 
FUN12 1495 0.657 0.6009 
NAT5 1570 0.615 0.5944 
FES1 1606 0.601 0.5954 
LSG1 1616 0.595 0.6016 
GCN1 2111 0.36 0.5084 
REI1 2132 0.353 0.5091 
YGR054W 2166 0.341 0.5071 
TIF5 2391 0.235 0.4658 
PAT1 2414 0.226 0.4644 
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RQC1 2553 -0.169 0.4393 
JJJ1  3714 -0.776 0.2196 
RRP14 4240 -1.182 0.1312 
BUD27 4246 -1.19 0.146 




Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
SNU13 11 4.043 0.0243 
RPP0 17 3.703 0.0475 
RPS3 31 3.465 0.0676 
NIP7 60 3.074 0.0821 
RPL3 61 3.052 0.1021 
NOP58 78 2.895 0.1178 
KRR1 94 2.814 0.1332 
RPS5 95 2.81 0.1516 
UTP13 130 2.504 0.1611 
NOP13 150 2.401 0.173 
RPS2 156 2.38 0.1876 
RPS13 174 2.314 0.1993 
NEW1 178 2.295 0.2138 
YVH1 204 2.212 0.2232 
EMG1 210 2.189 0.2365 
RPL28 216 2.164 0.2497 
NOP1 218 2.157 0.2636 
UTP10 250 2.068 0.2709 
ENP1 254 2.066 0.2838 
RLI1 261 2.053 0.2961 
NOP56 263 2.044 0.3093 
ROK1 292 1.959 0.3165 
NOC2 305 1.906 0.3265 
NUG1 336 1.845 0.3325 
CBF5 345 1.818 0.3428 
HAS1 356 1.804 0.3526 
NSA2 376 1.756 0.3603 
HCA4 378 1.753 0.3716 
NOG1 382 1.744 0.3824 
CIC1 394 1.708 0.3914 
KRE33 404 1.699 0.4007 
RIX7 443 1.632 0.4037 
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UTP4 469 1.593 0.4091 
PRP43 475 1.589 0.4185 
UTP14 489 1.56 0.4261 
DBP3 502 1.547 0.4338 
DIM1 504 1.544 0.4437 
MRT4 511 1.54 0.4526 
UTP21 513 1.538 0.4625 
RPF2 515 1.535 0.4723 
IPI1 540 1.484 0.4772 
MAK21 562 1.442 0.4824 
MAK16 577 1.417 0.4889 
RRP12 638 1.339 0.4855 
NOP7 644 1.332 0.4932 
SPB1 687 1.284 0.4932 
BFR2 696 1.272 0.4999 
NOP2 754 1.217 0.4964 
SAS10  779 1.198 0.4994 
UTP6 781 1.195 0.507 
RRP1 788 1.19 0.5136 
ARX1 822 1.163 0.5145 
SLX9 826 1.161 0.5215 
DBP5 850 1.14 0.5244 
IMP3 857 1.134 0.5306 
PWP2 895 1.091 0.5303 
NOG2 900 1.089 0.5366 
RRS1 947 1.054 0.5342 
ERB1 948 1.053 0.5411 
SQT1  951 1.047 0.5476 
RRP36 982 1.015 0.5482 
NSA1 984 1.012 0.5546 
RRP5 1025 0.979 0.5529 
UTP7 1033 0.976 0.5579 
TIF6 1041 0.967 0.5628 
YTM1 1045 0.964 0.5685 
NOP4 1096 0.92 0.5645 
NMD3 1105 0.913 0.5688 
NOP12 1190 0.859 0.5575 
NOP9 1193 0.857 0.5627 
CKB1 1194 0.856 0.5683 
UTP5 1264 0.804 0.5597 
BUD20 1279 0.797 0.5621 
NOP15 1285 0.794 0.5662 
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NOC4 1303 0.78 0.5679 
SSF1  1349 0.744 0.5637 
UTP15 1414 0.697 0.5554 
MPP10 1480 0.668 0.5466 
DBP8 1493 0.659 0.5485 
FUN12 1495 0.657 0.5526 
UTP22 1519 0.645 0.5522 
ARB1 1532 0.641 0.554 
ECM16 1581 0.611 0.5483 
RLP24 1719 0.542 0.5242 
NAN1 1727 0.54 0.5263 
CKB2 1736 0.536 0.5282 
RRP9 1743 0.534 0.5305 
SOF1 1776 0.521 0.5275 
BMS1 1888 0.467 0.5081 
UTP25 1981 0.42 0.4923 
SQS1 2031 0.4 0.485 
NOC3 2032 0.4 0.4877 
TSR1 2035 0.397 0.4899 
DIP2 2076 0.377 0.4843 
UTP23 2083 0.374 0.4855 
DBP10 2119 0.358 0.4808 
NOP14 2124 0.357 0.4823 
REI1 2132 0.353 0.4832 
CGR1 2146 0.348 0.4829 
FCF1  2156 0.344 0.4833 
CMS1 2184 0.328 0.48 
UTP20 2192 0.325 0.4807 
BUD21 2219 0.312 0.4775 
RSA3 2245 0.3 0.4744 
UTP9 2249 0.295 0.4758 
RRP7 2315 0.269 0.4644 
YBL028C 2332 0.264 0.4629 
HMO1 2339 0.261 0.4634 
BRX1 2361 0.251 0.4608 
RCL1 2374 0.241 0.46 
AFG2 2389 0.236 0.4587 
MRD1 2423 0.223 0.4535 
NOB1 2464 0.201 0.4467 
DRS1 2520 0.158 0.4366 
CKA2 2522 0.158 0.4375 
LAS1 2561 -0.172 0.4309 
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LOC1 2589 -0.193 0.4268 
RPF1 2636 -0.222 0.4189 
UTP30 2802 -0.303 0.3876 
BUD22 2838 -0.324 0.3827 
NOP6 2930 -0.365 0.3667 
UTP11 3076 -0.434 0.3403 
LTV1 3291 -0.541 0.3006 
ECM1 3450 -0.627 0.2728 
NOP19 3453 -0.628 0.2765 
NOP16 3659 -0.74 0.24 
IMP4 3699 -0.762 0.2371 
JJJ1  3714 -0.776 0.2394 
EBP2 3720 -0.781 0.2435 
RRP15 3808 -0.837 0.2314 
DBP6 4227 -1.172 0.1547 
KRI1 4409 -1.365 0.1272 





Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
RPP0 17 3.703 0.0826 
RPL3 61 3.052 0.145 
NSR1 64 3.03 0.215 
RPS31 85 2.857 0.2774 
REX4 147 2.407 0.3212 
IPI3 185 2.274 0.3667 
YVH1 204 2.212 0.4145 
RPL25 219 2.155 0.4618 
RPL10 238 2.096 0.507 
RPL5 280 1.998 0.5453 
RIA1 402 1.7 0.5608 
MRT4 511 1.54 0.5752 
RPF2 515 1.535 0.6103 
IPI1 540 1.484 0.64 
MAK21 562 1.442 0.6694 
RSA4 636 1.342 0.6861 
SQT1  951 1.047 0.6483 
RSA1 1223 0.832 0.614 
RIX1 1237 0.824 0.6306 
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SSF1  1349 0.744 0.6259 
FUN12 1495 0.657 0.6125 
LSG1 1616 0.595 0.6026 
BMS1 1888 0.467 0.5598 
DRS2 2081 0.375 0.5305 
RSA3 2245 0.3 0.5052 
RRP7 2315 0.269 0.4978 
MAK11 2353 0.255 0.4964 
BRX1 2361 0.251 0.5009 
TIF5 2391 0.235 0.5006 
MRD1 2423 0.223 0.4996 
DRS1 2520 0.158 0.4843 
RPF1 2636 -0.222 0.4667 





Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
SNU13 11 4.043 0.0125 
RPP0 17 3.703 0.0249 
RPL30 22 3.58 0.0371 
RPS3 31 3.465 0.0481 
NIP7 60 3.074 0.0535 
RPL3 61 3.052 0.0646 
NSR1 64 3.03 0.0753 
NOP58 78 2.895 0.0831 
RPS31 85 2.857 0.0923 
KRR1 94 2.814 0.1009 
RPS5 95 2.81 0.1111 
SSB2 98 2.756 0.1208 
SSB1 100 2.735 0.1305 
UTP13 130 2.504 0.1337 
REX4 147 2.407 0.1391 
RPS2 156 2.38 0.1461 
RPS13 174 2.314 0.1511 
RRB1 176 2.298 0.1592 
NEW1 178 2.295 0.1674 
IPI3 185 2.274 0.1744 
GSP1 202 2.229 0.1792 
YVH1 204 2.212 0.1871 
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EMG1 210 2.189 0.194 
NOP1 218 2.157 0.2004 
RPL25 219 2.155 0.2083 
RPL10 238 2.096 0.2122 
UTP10 250 2.068 0.2175 
ENP1 254 2.066 0.2244 
RPS20 256 2.061 0.2317 
RLI1 261 2.053 0.2383 
NOP56 263 2.044 0.2456 
RPL5 280 1.998 0.2496 
SSZ1 289 1.967 0.2551 
ROK1 292 1.959 0.2618 
NOC2 305 1.906 0.2663 
SKI6 308 1.903 0.2728 
TSR2 314 1.893 0.2786 
ESF1 330 1.85 0.2823 
NUG1 336 1.845 0.288 
CBF5 345 1.818 0.2929 
EFG1 349 1.814 0.2989 
HAS1 356 1.804 0.3043 
MAK5 358 1.803 0.3106 
NSA2 376 1.756 0.3135 
HCA4 378 1.753 0.3197 
NOG1 382 1.744 0.3254 
NHP2 390 1.72 0.3303 
RIA1 402 1.7 0.3342 
KRE33 404 1.699 0.3402 
GAR1 426 1.658 0.3419 
RIX7 443 1.632 0.3445 
SYO1 448 1.627 0.3496 
UTP4 469 1.593 0.3513 
RNT1 473 1.59 0.3564 
PRP43 475 1.589 0.362 
UTP14 489 1.56 0.365 
DBP3 502 1.547 0.3682 
DIM1 504 1.544 0.3736 
RPS15 506 1.544 0.379 
MRT4 511 1.54 0.3838 
UTP21 513 1.538 0.3892 
RPF2 515 1.535 0.3946 
RAI1 538 1.491 0.3955 
IPI1 540 1.484 0.4007 
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PUF6 541 1.484 0.4061 
MTR4 560 1.444 0.4076 
MAK21 562 1.442 0.4127 
MAK16 577 1.417 0.4149 
RRP3 613 1.37 0.4127 
PWP1 625 1.351 0.4153 
RSA4 636 1.342 0.4182 
RRP12 638 1.339 0.4228 
NOP7 644 1.332 0.4267 
ZUO1 676 1.292 0.425 
DBP2 678 1.292 0.4295 
BMT6 682 1.289 0.4335 
SPB1 687 1.284 0.4374 
DBP9 690 1.281 0.4417 
BFR2 696 1.272 0.4453 
PUS7 738 1.237 0.4413 
NOP2 754 1.217 0.4426 
RRP43 764 1.209 0.4452 
SAS10  779 1.198 0.4466 
UTP6 781 1.195 0.4508 
RRP1 788 1.19 0.4539 
ARX1 822 1.163 0.4513 
NUP85 825 1.161 0.4551 
SLX9 826 1.161 0.4593 
URB2 840 1.15 0.4608 
IMP3 857 1.134 0.4617 
RRP42 874 1.112 0.4624 
RCM1 893 1.094 0.4627 
PWP2 895 1.091 0.4664 
DHR2 898 1.09 0.47 
NOG2 900 1.089 0.4738 
BMT5 904 1.087 0.4771 
RPP1 907 1.086 0.4806 
RRS1 947 1.054 0.4764 
ERB1 948 1.053 0.4803 
SQT1  951 1.047 0.4837 
RRP36 982 1.015 0.4812 
NSA1 984 1.012 0.4846 
RRP5 1025 0.979 0.4799 
TMA20 1032 0.976 0.4823 
UTP7 1033 0.976 0.4858 
FAP7 1040 0.967 0.4881 
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TIF6 1041 0.967 0.4916 
YTM1 1045 0.964 0.4945 
SDA1 1047 0.96 0.4978 
NOP4 1096 0.92 0.4912 
SRD1 1104 0.913 0.4931 
NMD3 1105 0.913 0.4964 
RRP4 1130 0.892 0.4947 
RRP46 1139 0.888 0.4963 
NUP159 1144 0.886 0.4987 
RRP40 1155 0.882 0.4998 
NOP12 1190 0.859 0.4959 
NOP9 1193 0.857 0.4987 
SRM1 1222 0.834 0.4959 
RSA1 1223 0.832 0.4989 
FCF2  1232 0.827 0.5003 
RIX1 1237 0.824 0.5025 
RNH70 1259 0.806 0.5011 
UTP5 1264 0.804 0.5032 
REX3 1268 0.801 0.5055 
BUD20 1279 0.797 0.5063 
NOP15 1285 0.794 0.5082 
NOC4 1303 0.78 0.5075 
SSF1  1349 0.744 0.5009 
URB1 1397 0.707 0.4938 
TIF4631 1410 0.699 0.4938 
UTP15 1414 0.697 0.4957 
GLC7 1426 0.691 0.496 
POP7 1456 0.678 0.4925 
MPP10 1480 0.668 0.4901 
DBP8 1493 0.659 0.49 
FUN12 1495 0.657 0.4922 
YAR1 1505 0.652 0.4927 
UTP22 1519 0.645 0.4924 
ARB1 1532 0.641 0.4923 
FYV7 1547 0.633 0.4917 
ECM16 1581 0.611 0.4871 
NSP1 1582 0.61 0.4893 
SGD1 1598 0.603 0.4884 
LSG1 1616 0.595 0.4871 
RNA1 1699 0.553 0.4721 
LCP5 1711 0.547 0.4718 
RLP24 1719 0.542 0.4724 
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NAN1 1727 0.54 0.4729 
RRP9 1743 0.534 0.4717 
LSM6 1761 0.527 0.4701 
SOF1 1776 0.521 0.4691 
CAM1 1791 0.515 0.4681 
RVB2 1792 0.514 0.47 
MTR3 1803 0.504 0.4698 
MPP6 1823 0.493 0.4676 
RRP8 1829 0.491 0.4684 
TMA108 1846 0.48 0.4668 
BMS1 1888 0.467 0.46 
UTP25 1981 0.42 0.4425 
SQS1 2031 0.4 0.4339 
NOC3 2032 0.4 0.4353 
HCR1 2033 0.4 0.4368 
TSR1 2035 0.397 0.438 
NGL2 2058 0.386 0.4349 
DIP2 2076 0.377 0.4327 
DRS2 2081 0.375 0.4333 
UTP23 2083 0.374 0.4344 
GRC3 2086 0.373 0.4354 
DBP10 2119 0.358 0.4301 
NOP14 2124 0.357 0.4305 
REI1 2132 0.353 0.4304 
CGR1 2146 0.348 0.429 
FCF1  2156 0.344 0.4284 
UTP20 2192 0.325 0.4223 
BUD21 2219 0.312 0.4181 
RSA3 2245 0.3 0.414 
UTP9 2249 0.295 0.4144 
NOP8 2285 0.279 0.4082 
RRP7 2315 0.269 0.4032 
MAK11 2353 0.255 0.3965 
BRX1 2361 0.251 0.3959 
RCL1 2374 0.241 0.3943 
RTC6 2386 0.237 0.3929 
AFG2 2389 0.236 0.3934 
TIF5 2391 0.235 0.394 
MRD1 2423 0.223 0.3884 
NOB1 2464 0.201 0.3809 
GEP3 2476 0.196 0.3793 
NOP53 2501 0.18 0.375 
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DRS1 2520 0.158 0.3719 
RAT1 2540 -0.13 0.3684 
JIP5 2545 -0.152 0.3681 
LAS1 2561 -0.172 0.3657 
NIC96 2570 -0.181 0.3647 
POP4 2586 -0.192 0.3623 
LOC1 2589 -0.193 0.3626 
RPF1 2636 -0.222 0.3539 
DIS3 2637 -0.222 0.3547 
RSP5 2647 -0.226 0.3536 
CSL4 2665 -0.233 0.351 
PUS5 2711 -0.26 0.3426 
REX2 2728 -0.271 0.3403 
UTP30 2802 -0.303 0.3263 
FAL1 2833 -0.319 0.3213 
BUD22 2838 -0.324 0.3216 
SPT5 2846 -0.326 0.3214 
LTO1 2917 -0.358 0.3082 
NOP6 2930 -0.365 0.307 
SAC3  3000 -0.401 0.2942 
HIT1 3022 -0.409 0.2914 
LSM7 3026 -0.411 0.2922 
UTP11 3076 -0.434 0.2837 
NUP120 3100 -0.448 0.2806 
TOM1 3175 -0.483 0.267 
HRR25 3224 -0.506 0.259 
TOR2 3252 -0.52 0.2553 
NUP49 3256 -0.522 0.2565 
LTV1 3291 -0.541 0.2515 
RMP1 3446 -0.625 0.2219 
ECM1 3450 -0.627 0.2236 
NOP19 3453 -0.628 0.2255 
MTR2 3510 -0.653 0.2163 
BUD23 3594 -0.704 0.2017 
POP6 3607 -0.709 0.2018 
NUP116 3628 -0.724 0.2003 
YAE1 3644 -0.734 0.1998 
RIO2 3657 -0.74 0.2 
NOP16 3659 -0.74 0.2025 
RRP45 3696 -0.761 0.1979 
TMA23 3698 -0.762 0.2004 
IMP4 3699 -0.762 0.2032 
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MRH4 3713 -0.774 0.2033 
JJJ1  3714 -0.776 0.2062 
EBP2 3720 -0.781 0.208 
YRB2 3786 -0.821 0.1975 
TOR1 3799 -0.83 0.1981 
RRP15 3808 -0.837 0.1995 
DBP7 3827 -0.848 0.1988 
MOT1 3875 -0.878 0.1923 
PAF1 3903 -0.894 0.19 
RRP17 3935 -0.922 0.187 
SNU66 3972 -0.95 0.183 
TSR3 4108 -1.055 0.1589 
SNM1 4207 -1.152 0.1428 
DBP6 4227 -1.172 0.1432 
RRP14 4240 -1.182 0.145 
LRP1 4369 -1.317 0.1233 
NUP1 4382 -1.33 0.1257 
KRI1 4409 -1.365 0.1253 
RNP1 4508 -1.479 0.1104 




Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
EFT1 18 3.69 0.0853 
TEF2 29 3.473 0.1669 
TEF1 39 3.308 0.2447 
EFT2 56 3.152 0.3174 
YEF3 66 3.013 0.3881 
SSB2 98 2.756 0.4483 
SSB1 100 2.735 0.514 
EFB1 126 2.524 0.5698 
RPS2 156 2.38 0.6213 
STM1 200 2.233 0.6666 
TEF4 248 2.07 0.7071 
SSZ1 289 1.967 0.7466 
ZUO1 676 1.292 0.7015 
HYP2 858 1.134 0.693 
GCN20 1362 0.735 0.6114 
TUF1 1708 0.549 0.5565 
CAM1 1791 0.515 0.5527 
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GCN1 2111 0.36 0.4983 
SUA5 2151 0.346 0.499 
OAZ1 2300 0.275 0.4764 
DHH1 3517 -0.658 0.2521 
CTK2 3535 -0.665 0.2647 
CTK1 3555 -0.676 0.2772 




RAS2S225E vs EV- Chromosome Segredatation- Downregulated 
 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
NDJ1 266 2.036 -0.0401 
SCP160 322 1.864 -0.0387 
RFC5 551 1.462 -0.075 
TPD3 587 1.4 -0.0726 
RFC4 729 1.243 -0.0927 
POL30 906 1.086 -0.121 
SMC3 1001 1.002 -0.1333 
INO80 1249 0.815 -0.1778 
SPO16 1275 0.798 -0.1775 
KIN3 1317 0.769 -0.1806 
GLC7 1426 0.691 -0.1978 
CDC48 1461 0.675 -0.2001 
SPO22 1539 0.637 -0.2114 
HOP1 1732 0.539 -0.2467 
FOB1 1765 0.526 -0.2496 
TOF1 1833 0.486 -0.2599 
KIN4 1914 0.458 -0.273 
SMC4 1918 0.457 -0.2705 
CHL1 1923 0.451 -0.2683 
SMC6 1940 0.442 -0.2685 
LRS4 1997 0.415 -0.2771 
LTE1 2057 0.386 -0.2864 
DCC1 2087 0.372 -0.2898 
CDC20 2243 0.3 -0.3191 
BUR2 2259 0.289 -0.3202 
MND2 2305 0.274 -0.3275 
MAD2 2358 0.252 -0.3363 
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HDA3 2379 0.24 -0.3387 
NPA3 2412 0.227 -0.3437 
PAT1 2414 0.226 -0.3423 
RFC2 2450 0.21 -0.348 
PPH21 2467 0.201 -0.3499 
CDC28 2494 0.186 -0.3539 
MCK1 2576 -0.185 -0.3691 
MMS22 2587 -0.193 -0.3698 
STS1  2590 -0.193 -0.3689 
IRR1 2690 -0.248 -0.3872 
SLI15 2734 -0.274 -0.3941 
DMA1 2753 -0.283 -0.3958 
MCD1 2778 -0.291 -0.3987 
MAD3 2797 -0.3 -0.4003 
SPC72 2801 -0.303 -0.3989 
RAD61 2813 -0.309 -0.399 
CTF4  2835 -0.322 -0.4011 
CTF18  2851 -0.329 -0.4019 
RTS1 2871 -0.337 -0.4035 
ESP1 2918 -0.359 -0.4104 
HFM1 2950 -0.375 -0.4141 
SMC2 2973 -0.388 -0.416 
IML3 2991 -0.398 -0.4167 
GPN2 3014 -0.407 -0.4184 
CIN8 3031 -0.413 -0.4189 
CEP3 3055 -0.426 -0.4207 
RTT102  3065 -0.43 -0.4196 
YPI1 3083 -0.437 -0.4201 
ELG1 3091 -0.442 -0.4185 
SGS1 3097 -0.446 -0.4165 
RED1 3145 -0.467 -0.4229 
CDC55 3160 -0.478 -0.4225 
DAD2 3202 -0.496 -0.4274 
NUP170 3203 -0.496 -0.4241 
HRR25 3224 -0.506 -0.4247 
SCC2  3234 -0.51 -0.4231 
BUB1 3237 -0.511 -0.42 
GIP3 3273 -0.53 -0.4235 
CTF3  3335 -0.557 -0.4321 
MCM21 3383 -0.585 -0.4377 
STH1  3463 -0.632 -0.4494 
SIZ1 3475 -0.637 -0.4474 
331 
 
HHT2 3483 -0.641 -0.4444 
RMI1 3486 -0.641 -0.4405 
APC1 3491 -0.644 -0.437 
IES6 3519 -0.658 -0.438 
BUB2 3522 -0.66 -0.4339 
MTW1 3541 -0.667 -0.4331 
WIP1 3570 -0.685 -0.4341 
IRC15 3630 -0.725 -0.4412 
BIM1 3655 -0.74 -0.441 
POL2 3663 -0.744 -0.4374 
MAD1 3668 -0.746 -0.4332 
ZIP1 3712 -0.774 -0.4367 
RDH54 3721 -0.782 -0.433 
FIN1 3746 -0.795 -0.4325 
DUO1 3753 -0.801 -0.4283 
BMH1 3760 -0.806 -0.4241 
RSC2 3771 -0.813 -0.4206 
CNN1 3779 -0.816 -0.4165 
PDS5 3787 -0.822 -0.4124 
RAD30 3815 -0.843 -0.4121 
SRC1 3849 -0.863 -0.413 
CSE4 3850 -0.863 -0.4072 
KIP1 3898 -0.89 -0.4107 
AMA1 3943 -0.924 -0.4134 
SHP1 3970 -0.947 -0.4122 
TOP1 4017 -0.983 -0.4149 
SPC25 4040 -1.001 -0.4126 
CBF2 4045 -1.003 -0.4066 
DMA2 4092 -1.044 -0.4089 
NUD1 4095 -1.047 -0.4022 
CDC5 4118 -1.065 -0.3995 
DAM1 4122 -1.071 -0.3928 
BFA1 4124 -1.075 -0.3858 
SGO1 4134 -1.086 -0.3803 
BUD2 4152 -1.097 -0.3763 
DAD4 4162 -1.105 -0.3707 
SCC4  4166 -1.108 -0.3638 
MPS1 4193 -1.145 -0.3613 
REC8 4214 -1.16 -0.3575 
CSM4 4250 -1.195 -0.3566 
GLC8 4255 -1.201 -0.3493 
SWM1 4258 -1.203 -0.3415 
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ULP2 4259 -1.203 -0.3334 
SFH1 4288 -1.227 -0.3308 
NBL1 4289 -1.228 -0.3225 
ASK1 4298 -1.243 -0.3157 
SPC34 4310 -1.255 -0.3095 
AME1 4312 -1.257 -0.3012 
CTF8  4332 -1.281 -0.2964 
ZIP2 4381 -1.33 -0.2971 
PDS1 4421 -1.38 -0.2957 
BUB3 4453 -1.408 -0.2925 
CSM3 4466 -1.422 -0.2853 
ECO1 4584 -1.599 -0.2982 
VIK1 4608 -1.627 -0.2918 
CDH1 4620 -1.641 -0.283 
IPL1 4627 -1.657 -0.273 
TOP3 4650 -1.701 -0.266 
BIR1 4652 -1.703 -0.2547 
SCM3 4680 -1.76 -0.2482 
DMC1 4685 -1.776 -0.2371 
CDC14 4713 -1.823 -0.2302 
NFI1 4723 -1.852 -0.2195 
BRN1 4746 -1.899 -0.2112 
CHL4 4748 -1.91 -0.1985 
DAD3 4765 -1.943 -0.1886 
GAC1 4766 -1.946 -0.1754 
NNF1 4771 -1.964 -0.163 
CBF1 4792 -2.026 -0.1533 
CTF19  4845 -2.194 -0.149 
NDC80 4847 -2.199 -0.1344 
KAR3 4849 -2.21 -0.1197 
MIF2 4858 -2.23 -0.1062 
OKP1 4876 -2.305 -0.0941 
SLK19 4886 -2.343 -0.0801 
MPS3 4919 -2.483 -0.0698 
SOH1 4931 -2.508 -0.0551 
DSN1 4950 -2.595 -0.0412 
SPO13 4960 -2.647 -0.0251 
CIK1 5039 -3.286 -0.0187 





Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
NSE5 761 1.212 -0.14 
REC104 914 1.08 -0.1595 
SMC3 1001 1.002 -0.1666 
SPO16 1275 0.798 -0.2131 
GLC7 1426 0.691 -0.2361 
SPO22 1539 0.637 -0.2521 
PSY2 1584 0.61 -0.2548 
HOP1 1732 0.539 -0.2787 
SMC4 1918 0.457 -0.3111 
RFA2 1921 0.452 -0.307 
SMC6 1940 0.442 -0.3061 
LRS4 1997 0.415 -0.3131 
TOP2 2144 0.348 -0.3388 
RFA3 2190 0.326 -0.3445 
NSE3 2225 0.308 -0.3482 
RAD17 2248 0.297 -0.3496 
MAD2 2358 0.252 -0.3689 
NSE1 2510 0.173 -0.3973 
PLC1 2573 -0.184 -0.4079 
IRR1 2690 -0.248 -0.4286 
MCD1 2778 -0.291 -0.443 
RAD61 2813 -0.309 -0.4467 
RTS1 2871 -0.337 -0.4547 
RFA1 2886 -0.34 -0.4541 
SMC2 2973 -0.388 -0.4674 
IML3 2991 -0.398 -0.4668 
CIN8 3031 -0.413 -0.4704 
CEP3 3055 -0.426 -0.4707 
SMT3 3073 -0.433 -0.4698 
RED1 3145 -0.467 -0.4792 
DAD2 3202 -0.496 -0.4854 
HRR25 3224 -0.506 -0.4845 
BUB1 3237 -0.511 -0.4818 
STU2 3272 -0.53 -0.4832 
CTF3  3335 -0.557 -0.49 
MCM21 3383 -0.585 -0.4935 
MTW1 3541 -0.667 -0.5182 
MEC3 3598 -0.706 -0.5223 
PPH3 3603 -0.708 -0.516 
ZIP1 3712 -0.774 -0.5298 
FIN1 3746 -0.795 -0.5283 
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DUO1 3753 -0.801 -0.5215 
PDS5 3787 -0.822 -0.5198 
CSE4 3850 -0.863 -0.5235 
SPC25 4040 -1.001 -0.5512 
CBF2 4045 -1.003 -0.5419 
CTF13  4064 -1.019 -0.5352 
DAM1 4122 -1.071 -0.5358 
SGO1 4134 -1.086 -0.5271 
DAD4 4162 -1.105 -0.5213 
MPS1 4193 -1.145 -0.5158 
REC8 4214 -1.16 -0.5081 
NSE4 4220 -1.165 -0.4974 
ASK1 4298 -1.243 -0.5002 
SPC34 4310 -1.255 -0.4898 
AME1 4312 -1.257 -0.4773 
ZIP2 4381 -1.33 -0.4775 
REC107 4385 -1.336 -0.4647 
REC114 4394 -1.347 -0.4527 
UBC9 4427 -1.385 -0.4451 
SAE3 4438 -1.397 -0.433 
REC102 4445 -1.404 -0.4201 
BUB3 4453 -1.408 -0.4073 
RAD51 4510 -1.482 -0.4036 
GMC2 4559 -1.556 -0.3975 
IPL1 4627 -1.657 -0.3942 
BIR1 4652 -1.703 -0.3818 
SCM3 4680 -1.76 -0.3695 
DMC1 4685 -1.776 -0.3524 
BRN1 4746 -1.899 -0.3453 
CHL4 4748 -1.91 -0.3262 
TFC3  4754 -1.921 -0.3078 
DAD3 4765 -1.943 -0.2903 
NNF1 4771 -1.964 -0.2715 
KRE28 4796 -2.036 -0.2557 
MMS21 4806 -2.052 -0.2369 
CTF19  4845 -2.194 -0.2224 
NDC80 4847 -2.199 -0.2004 
MND1 4851 -2.22 -0.1786 
MIF2 4858 -2.23 -0.1573 
OKP1 4876 -2.305 -0.1375 
SLK19 4886 -2.343 -0.1157 
DSN1 4950 -2.595 -0.1021 
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ECM11 4952 -2.599 -0.0762 
SPO13 4960 -2.647 -0.0509 
MEI5 5042 -3.347 -0.0333 
SPC24 5081 -4.182 0.0012 
 
 
Microtubule Based Processes 
 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
ACT1  180 2.293 -0.013 
CMD1 324 1.862 -0.023 
LDB18 681 1.291 -0.0813 
CLB4 795 1.184 -0.092 
CRN1 810 1.172 -0.0831 
LIA1 967 1.027 -0.104 
ARP1 1133 0.891 -0.1281 
CDC48 1461 0.675 -0.1868 
TVP38 1661 0.574 -0.2208 
NDC1 1690 0.559 -0.2208 
BUD6 1724 0.541 -0.222 
RRD2 2067 0.381 -0.2867 
DSK2 2183 0.33 -0.3064 
DYN2 2216 0.313 -0.3096 
BER1 2296 0.276 -0.3227 
CDC28 2494 0.186 -0.3602 
CDC15 2736 -0.276 -0.4057 
DMA1 2753 -0.283 -0.4061 
SPC72 2801 -0.303 -0.4124 
ATS1  2804 -0.305 -0.4098 
CLB5 2829 -0.318 -0.4114 
RTS1 2871 -0.337 -0.4162 
ESP1 2918 -0.359 -0.4218 
KAR1 2939 -0.37 -0.4221 
YHR127W 2995 -0.399 -0.4291 
JNM1 3007 -0.404 -0.4273 
CIN8 3031 -0.413 -0.4277 
PAC11 3052 -0.425 -0.4275 
DAD2 3202 -0.496 -0.4523 
HRR25 3224 -0.506 -0.4515 
BUB1 3237 -0.511 -0.4487 
SPC97 3260 -0.524 -0.4479 
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STU2 3272 -0.53 -0.4448 
NBP1 3322 -0.552 -0.449 
CLB3 3354 -0.567 -0.4496 
HCM1 3356 -0.568 -0.4441 
BNI1 3387 -0.586 -0.4442 
SPC110 3396 -0.593 -0.4398 
RRD1 3412 -0.606 -0.4368 
KIP3 3490 -0.643 -0.4457 
NUM1 3500 -0.646 -0.441 
SWE1 3578 -0.692 -0.4495 
ABM1 3587 -0.699 -0.4441 
MLP2 3599 -0.707 -0.4392 
IRC15 3630 -0.725 -0.4379 
BIM1 3655 -0.74 -0.4353 
NIP100 3666 -0.745 -0.4299 
FIN1 3746 -0.795 -0.4377 
DUO1 3753 -0.801 -0.4309 
KIP1 3898 -0.89 -0.4508 
SHP1 3970 -0.947 -0.4555 
GPA1 3976 -0.954 -0.4469 
SPC25 4040 -1.001 -0.4495 
CBF2 4045 -1.003 -0.4402 
DMA2 4092 -1.044 -0.4389 
NUD1 4095 -1.047 -0.4288 
KIP2 4102 -1.052 -0.4195 
NDL1 4105 -1.054 -0.4093 
CDC5 4118 -1.065 -0.401 
DAM1 4122 -1.071 -0.3909 
SGO1 4134 -1.086 -0.3822 
DAD4 4162 -1.105 -0.3765 
STU1 4185 -1.132 -0.3696 
MPS1 4193 -1.145 -0.3595 
ASK1 4298 -1.243 -0.3678 
SPC34 4310 -1.255 -0.3574 
AME1 4312 -1.257 -0.345 
MPS2 4328 -1.272 -0.3353 
ASE1 4342 -1.294 -0.3249 
BBP1 4358 -1.304 -0.3148 
POM34 4372 -1.321 -0.3042 
UBC9 4427 -1.385 -0.3011 
CDC31 4484 -1.442 -0.2978 
SPC42 4543 -1.532 -0.2941 
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SHE1 4581 -1.596 -0.2855 
VIK1 4608 -1.627 -0.2744 
CDH1 4620 -1.641 -0.2601 
IPL1 4627 -1.657 -0.2447 
BIR1 4652 -1.703 -0.2324 
DYN3 4693 -1.797 -0.2224 
CDC14 4713 -1.823 -0.2079 
DAD3 4765 -1.943 -0.1986 
CTF19  4845 -2.194 -0.1924 
NDC80 4847 -2.199 -0.1706 
KAR3 4849 -2.21 -0.1486 
MIF2 4858 -2.23 -0.1278 
OKP1 4876 -2.305 -0.1081 
SLK19 4886 -2.343 -0.0864 
MPS3 4919 -2.483 -0.0679 
DSN1 4950 -2.595 -0.0479 
CIK1 5039 -3.286 -0.0325 
SPC24 5081 -4.182 0.0012 
 
Nuclear Division  
 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
YVH1 204 2.212 -0.0308 
RCK1 228 2.127 -0.0248 
NDJ1 266 2.036 -0.0221 
SCP160 322 1.864 -0.0241 
WTM1 396 1.708 -0.0305 
BFR1 398 1.706 -0.0221 
PSE1 452 1.619 -0.0248 
TPD3 587 1.4 -0.0453 
KAR4 616 1.362 -0.0442 
MSH2 661 1.314 -0.0466 
AMN1 673 1.296 -0.0424 
CLB4 795 1.184 -0.0613 
SPO23 816 1.168 -0.0595 
POL30 906 1.086 -0.0723 
REC104 914 1.08 -0.0683 
SMC3 1001 1.002 -0.081 
RCK2 1181 0.864 -0.1134 
MSH5 1197 0.855 -0.1122 
SPO16 1275 0.798 -0.124 
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CPR1 1294 0.788 -0.1237 
GLC7 1426 0.691 -0.1471 
TRS85 1487 0.661 -0.1561 
KAP104 1511 0.649 -0.1576 
SPO22 1539 0.637 -0.1599 
RTT101  1559 0.622 -0.1607 
PSY2 1584 0.61 -0.1625 
BRE1 1667 0.572 -0.1765 
HOP1 1732 0.539 -0.1869 
CDC10 1819 0.497 -0.2021 
TOF1 1833 0.486 -0.2023 
MRE11 1840 0.484 -0.2011 
RAD50 1855 0.478 -0.2016 
RAD1 1908 0.46 -0.21 
KIN4 1914 0.458 -0.2087 
SMC4 1918 0.457 -0.207 
RFA2 1921 0.452 -0.2051 
CHL1 1923 0.451 -0.2031 
LRS4 1997 0.415 -0.216 
DOT1 2020 0.405 -0.2185 
RME1 2025 0.403 -0.2173 
MLH1 2039 0.396 -0.2179 
LTE1 2057 0.386 -0.2195 
CDC42 2060 0.385 -0.218 
CDC7 2062 0.384 -0.2162 
DCC1 2087 0.372 -0.2193 
TOP2 2144 0.348 -0.229 
RFA3 2190 0.326 -0.2366 
SHS1 2194 0.324 -0.2356 
CDC20 2243 0.3 -0.244 
RAD17 2248 0.297 -0.2433 
BUR2 2259 0.289 -0.2439 
XRS2 2269 0.286 -0.2443 
MND2 2305 0.274 -0.2501 
SKI8 2345 0.258 -0.2568 
MAD2 2358 0.252 -0.258 
NPA3 2412 0.227 -0.2678 
SKP1 2429 0.221 -0.27 
PPH21 2467 0.201 -0.2765 
CDC28 2494 0.186 -0.2809 
HAC1 2511 0.171 -0.2834 
MCK1 2576 -0.185 -0.2956 
339 
 
MMS22 2587 -0.193 -0.2967 
KEL1 2674 -0.239 -0.3131 
IRR1 2690 -0.248 -0.315 
SNF3 2694 -0.251 -0.3143 
RIM8 2706 -0.258 -0.3153 
FPR3 2722 -0.268 -0.317 
CDC15 2736 -0.276 -0.3183 
SPO12 2748 -0.28 -0.3191 
DMA1 2753 -0.283 -0.3185 
PDR16 2760 -0.286 -0.3183 
MCD1 2778 -0.291 -0.3204 
STE20 2790 -0.298 -0.3211 
MAD3 2797 -0.3 -0.3209 
RAD10 2798 -0.301 -0.3193 
SPC72 2801 -0.303 -0.3182 
RAD61 2813 -0.309 -0.3189 
CLB5 2829 -0.318 -0.3204 
CTF4  2835 -0.322 -0.3198 
MLH3 2845 -0.326 -0.32 
CTF18  2851 -0.329 -0.3194 
RAD52 2867 -0.336 -0.3208 
RTS1 2871 -0.337 -0.3197 
RFA1 2886 -0.34 -0.3209 
ESP1 2918 -0.359 -0.3254 
HFM1 2950 -0.375 -0.3299 
SMC2 2973 -0.388 -0.3325 
NDT80 2976 -0.39 -0.3309 
IML3 2991 -0.398 -0.3318 
SAC3  3000 -0.401 -0.3314 
GPN2 3014 -0.407 -0.3321 
KEL2 3019 -0.409 -0.3308 
CIN8 3031 -0.413 -0.331 
CEP3 3055 -0.426 -0.3336 
RMR1 3057 -0.426 -0.3316 
YPI1 3083 -0.437 -0.3346 
NPR3 3085 -0.439 -0.3326 
ELG1 3091 -0.442 -0.3314 
SGS1 3097 -0.446 -0.3302 
RED1 3145 -0.467 -0.3375 
CDC55 3160 -0.478 -0.3379 
GIC2 3166 -0.482 -0.3365 
RAD6 3169 -0.482 -0.3345 
340 
 
TOM1 3175 -0.483 -0.3331 
HRR25 3224 -0.506 -0.3404 
SCC2  3234 -0.51 -0.3397 
BUB1 3237 -0.511 -0.3376 
MSH6 3295 -0.543 -0.3465 
CTF3  3335 -0.557 -0.3517 
RIM101 3345 -0.563 -0.3508 
BNS1 3351 -0.565 -0.349 
CLB3 3354 -0.567 -0.3465 
SET3 3357 -0.568 -0.3441 
MCM21 3383 -0.585 -0.3463 
MUM2 3431 -0.619 -0.3528 
IDS2 3444 -0.624 -0.3521 
STH1  3463 -0.632 -0.3526 
HHT2 3483 -0.641 -0.3533 
RMI1 3486 -0.641 -0.3505 
KIP3 3490 -0.643 -0.3479 
APC1 3491 -0.644 -0.3446 
BUB2 3522 -0.66 -0.3475 
RAD57 3527 -0.662 -0.345 
MSC3 3562 -0.678 -0.3486 
TGS1 3571 -0.686 -0.3467 
RIM15 3573 -0.689 -0.3435 
SWE1 3578 -0.692 -0.3408 
HOS2 3589 -0.701 -0.3394 
SIN3 3592 -0.703 -0.3362 
PPH3 3603 -0.708 -0.3347 
IRC15 3630 -0.725 -0.3364 
BIM1 3655 -0.74 -0.3376 
POL2 3663 -0.744 -0.3353 
MAD1 3668 -0.746 -0.3324 
SET2 3681 -0.753 -0.3311 
DON1 3706 -0.769 -0.3321 
SSN8 3711 -0.774 -0.329 
ZIP1 3712 -0.774 -0.3252 
EBP2 3720 -0.781 -0.3227 
RDH54 3721 -0.782 -0.3187 
MSH4 3725 -0.784 -0.3154 
FIN1 3746 -0.795 -0.3155 
BMH1 3760 -0.806 -0.3141 
TEM1 3780 -0.817 -0.3139 
PDS5 3787 -0.822 -0.311 
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TOR1 3799 -0.83 -0.3091 
NIS1 3813 -0.84 -0.3075 
RAD30 3815 -0.843 -0.3035 
SRC1 3849 -0.863 -0.3059 
CSE4 3850 -0.863 -0.3016 
PAP2 3878 -0.878 -0.3027 
KIP1 3898 -0.89 -0.3022 
IME1 3941 -0.923 -0.3061 
AMA1 3943 -0.924 -0.3017 
NUP53 3965 -0.945 -0.3013 
CAK1 4014 -0.982 -0.3062 
TOP1 4017 -0.983 -0.3016 
IME2 4068 -1.021 -0.3068 
DBF4 4084 -1.034 -0.3047 
DMA2 4092 -1.044 -0.3008 
NUD1 4095 -1.047 -0.296 
SPO11 4098 -1.048 -0.2911 
CDC5 4118 -1.065 -0.2897 
BFA1 4124 -1.075 -0.2853 
CDC24 4133 -1.085 -0.2815 
SGO1 4134 -1.086 -0.276 
BUD2 4152 -1.097 -0.274 
ALK1 4160 -1.104 -0.2699 
DBF20 4164 -1.106 -0.2649 
SCC4  4166 -1.108 -0.2596 
MPS1 4193 -1.145 -0.2591 
SAE2 4199 -1.149 -0.2544 
REC8 4214 -1.16 -0.2514 
RIM4 4232 -1.176 -0.249 
CSM4 4250 -1.195 -0.2465 
HOS4 4252 -1.196 -0.2407 
SWM1 4258 -1.203 -0.2357 
ULP2 4259 -1.203 -0.2296 
GMC1 4327 -1.271 -0.237 
CTF8  4332 -1.281 -0.2313 
WTM2 4359 -1.305 -0.2301 
ARP10 4360 -1.305 -0.2236 
ZIP2 4381 -1.33 -0.221 
REC107 4385 -1.336 -0.2149 
REC114 4394 -1.347 -0.2097 
PDS1 4421 -1.38 -0.2081 
SAE3 4438 -1.397 -0.2044 
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REC102 4445 -1.404 -0.1986 
BUB3 4453 -1.408 -0.1929 
CSM3 4466 -1.422 -0.1882 
RAD51 4510 -1.482 -0.1896 
PCH2 4540 -1.53 -0.1879 
GMC2 4559 -1.556 -0.1837 
ECO1 4584 -1.599 -0.1806 
VIK1 4608 -1.627 -0.1772 
CDH1 4620 -1.641 -0.1712 
IPL1 4627 -1.657 -0.1641 
TOP3 4650 -1.701 -0.16 
BIR1 4652 -1.703 -0.1517 
DMC1 4685 -1.776 -0.1493 
CDC14 4713 -1.823 -0.1457 
BRN1 4746 -1.899 -0.1427 
CHL4 4748 -1.91 -0.1333 
SLZ1 4755 -1.925 -0.1249 
MOB1 4757 -1.931 -0.1154 
GAC1 4766 -1.946 -0.1072 
UME6 4811 -2.067 -0.1059 
CTF19  4845 -2.194 -0.1016 
KAR3 4849 -2.21 -0.0911 
MND1 4851 -2.22 -0.0801 
SLK19 4886 -2.343 -0.0753 
MPS3 4919 -2.483 -0.0694 
SOH1 4931 -2.508 -0.0591 
DSN1 4950 -2.595 -0.0497 
ECM11 4952 -2.599 -0.0368 
SPO13 4960 -2.647 -0.025 
CIK1 5039 -3.286 -0.0244 
MEI5 5042 -3.347 -0.008 











Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
YVH1 204 2.212 -0.031 
RCK1 228 2.127 -0.0252 
NDJ1 266 2.036 -0.0227 
SCP160 322 1.864 -0.0248 
WTM1 396 1.708 -0.0313 
BFR1 398 1.706 -0.0231 
PSE1 452 1.619 -0.0259 
TPD3 587 1.4 -0.0466 
KAR4 616 1.362 -0.0456 
MSH2 661 1.314 -0.0481 
AMN1 673 1.296 -0.044 
CLB4 795 1.184 -0.063 
SPO23 816 1.168 -0.0613 
POL30 906 1.086 -0.0742 
REC104 914 1.08 -0.0703 
SMC3 1001 1.002 -0.083 
RCK2 1181 0.864 -0.1156 
MSH5 1197 0.855 -0.1144 
SPO16 1275 0.798 -0.1263 
CPR1 1294 0.788 -0.1261 
GLC7 1426 0.691 -0.1496 
TRS85 1487 0.661 -0.1587 
KAP104 1511 0.649 -0.1602 
SPO22 1539 0.637 -0.1626 
RTT101  1559 0.622 -0.1634 
PSY2 1584 0.61 -0.1653 
BRE1 1667 0.572 -0.1793 
HOP1 1732 0.539 -0.1898 
CDC10 1819 0.497 -0.205 
TOF1 1833 0.486 -0.2053 
MRE11 1840 0.484 -0.2041 
RAD50 1855 0.478 -0.2047 
CAF4  1865 0.473 -0.2042 
RAD1 1908 0.46 -0.2105 
KIN4 1914 0.458 -0.2093 
SMC4 1918 0.457 -0.2076 
RFA2 1921 0.452 -0.2058 
CHL1 1923 0.451 -0.2038 
PEX11 1945 0.439 -0.2059 
LRS4 1997 0.415 -0.2143 
DOT1 2020 0.405 -0.2169 
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RME1 2025 0.403 -0.2157 
MLH1 2039 0.396 -0.2164 
LTE1 2057 0.386 -0.218 
CDC42 2060 0.385 -0.2165 
CDC7 2062 0.384 -0.2148 
DCC1 2087 0.372 -0.2179 
TOP2 2144 0.348 -0.2277 
RFA3 2190 0.326 -0.2353 
SHS1 2194 0.324 -0.2343 
RPN11 2239 0.302 -0.2419 
CDC20 2243 0.3 -0.241 
RAD17 2248 0.297 -0.2404 
BUR2 2259 0.289 -0.241 
XRS2 2269 0.286 -0.2414 
MND2 2305 0.274 -0.2473 
SKI8 2345 0.258 -0.254 
MAD2 2358 0.252 -0.2552 
NPA3 2412 0.227 -0.265 
SKP1 2429 0.221 -0.2672 
PPH21 2467 0.201 -0.2738 
CDC28 2494 0.186 -0.2782 
HAC1 2511 0.171 -0.2807 
MCK1 2576 -0.185 -0.2929 
MMS22 2587 -0.193 -0.294 
KEL1 2674 -0.239 -0.3105 
IRR1 2690 -0.248 -0.3124 
SNF3 2694 -0.251 -0.3117 
RIM8 2706 -0.258 -0.3127 
FPR3 2722 -0.268 -0.3145 
CDC15 2736 -0.276 -0.3158 
SPO12 2748 -0.28 -0.3167 
DMA1 2753 -0.283 -0.3161 
PDR16 2760 -0.286 -0.3159 
MCD1 2778 -0.291 -0.3179 
STE20 2790 -0.298 -0.3187 
MAD3 2797 -0.3 -0.3185 
RAD10 2798 -0.301 -0.317 
SPC72 2801 -0.303 -0.3159 
RAD61 2813 -0.309 -0.3166 
CLB5 2829 -0.318 -0.3181 
CTF4  2835 -0.322 -0.3176 
MLH3 2845 -0.326 -0.3178 
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CTF18  2851 -0.329 -0.3172 
RAD52 2867 -0.336 -0.3186 
RTS1 2871 -0.337 -0.3176 
RFA1 2886 -0.34 -0.3188 
ESP1 2918 -0.359 -0.3234 
FIS1 2944 -0.372 -0.3267 
HFM1 2950 -0.375 -0.3258 
SMC2 2973 -0.388 -0.3284 
NDT80 2976 -0.39 -0.3269 
IML3 2991 -0.398 -0.3278 
SAC3  3000 -0.401 -0.3275 
GPN2 3014 -0.407 -0.3281 
KEL2 3019 -0.409 -0.3269 
CIN8 3031 -0.413 -0.3271 
CEP3 3055 -0.426 -0.3298 
RMR1 3057 -0.426 -0.3279 
YPI1 3083 -0.437 -0.3308 
NPR3 3085 -0.439 -0.3289 
ELG1 3091 -0.442 -0.3277 
SGS1 3097 -0.446 -0.3265 
RED1 3145 -0.467 -0.3339 
CDC55 3160 -0.478 -0.3344 
GIC2 3166 -0.482 -0.333 
RAD6 3169 -0.482 -0.331 
TOM1 3175 -0.483 -0.3297 
HRR25 3224 -0.506 -0.337 
SCC2  3234 -0.51 -0.3364 
BUB1 3237 -0.511 -0.3342 
MSH6 3295 -0.543 -0.3433 
CTF3  3335 -0.557 -0.3485 
RIM101 3345 -0.563 -0.3476 
BNS1 3351 -0.565 -0.3458 
CLB3 3354 -0.567 -0.3434 
SET3 3357 -0.568 -0.341 
MCM21 3383 -0.585 -0.3433 
MUM2 3431 -0.619 -0.3499 
IDS2 3444 -0.624 -0.3493 
STH1  3463 -0.632 -0.3498 
HHT2 3483 -0.641 -0.3506 
RMI1 3486 -0.641 -0.3478 
KIP3 3490 -0.643 -0.3452 
APC1 3491 -0.644 -0.342 
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NUM1 3500 -0.646 -0.3405 
BUB2 3522 -0.66 -0.3415 
RAD57 3527 -0.662 -0.3391 
MSC3 3562 -0.678 -0.3427 
TGS1 3571 -0.686 -0.3409 
RIM15 3573 -0.689 -0.3377 
SWE1 3578 -0.692 -0.3351 
HOS2 3589 -0.701 -0.3337 
SIN3 3592 -0.703 -0.3306 
PPH3 3603 -0.708 -0.3292 
IRC15 3630 -0.725 -0.3309 
BIM1 3655 -0.74 -0.3322 
POL2 3663 -0.744 -0.33 
MAD1 3668 -0.746 -0.3271 
SET2 3681 -0.753 -0.3258 
DON1 3706 -0.769 -0.3269 
SSN8 3711 -0.774 -0.3239 
ZIP1 3712 -0.774 -0.3201 
EBP2 3720 -0.781 -0.3177 
RDH54 3721 -0.782 -0.3138 
MSH4 3725 -0.784 -0.3105 
VPS1 3736 -0.79 -0.3087 
FIN1 3746 -0.795 -0.3066 
BMH1 3760 -0.806 -0.3053 
TEM1 3780 -0.817 -0.3051 
PDS5 3787 -0.822 -0.3023 
TOR1 3799 -0.83 -0.3004 
NIS1 3813 -0.84 -0.2989 
RAD30 3815 -0.843 -0.295 
SRC1 3849 -0.863 -0.2975 
CSE4 3850 -0.863 -0.2932 
PAP2 3878 -0.878 -0.2944 
KIP1 3898 -0.89 -0.2939 
IME1 3941 -0.923 -0.298 
AMA1 3943 -0.924 -0.2936 
NUP53 3965 -0.945 -0.2932 
CAK1 4014 -0.982 -0.2982 
TOP1 4017 -0.983 -0.2938 
IME2 4068 -1.021 -0.299 
DBF4 4084 -1.034 -0.297 
DMA2 4092 -1.044 -0.2932 
NUD1 4095 -1.047 -0.2884 
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SPO11 4098 -1.048 -0.2837 
CDC5 4118 -1.065 -0.2823 
BFA1 4124 -1.075 -0.278 
CDC24 4133 -1.085 -0.2743 
SGO1 4134 -1.086 -0.2689 
BUD2 4152 -1.097 -0.2669 
ALK1 4160 -1.104 -0.2629 
DBF20 4164 -1.106 -0.258 
SCC4  4166 -1.108 -0.2528 
MPS1 4193 -1.145 -0.2524 
SAE2 4199 -1.149 -0.2478 
REC8 4214 -1.16 -0.2449 
RIM4 4232 -1.176 -0.2426 
CSM4 4250 -1.195 -0.2402 
HOS4 4252 -1.196 -0.2344 
SWM1 4258 -1.203 -0.2295 
ULP2 4259 -1.203 -0.2235 
GMC1 4327 -1.271 -0.231 
CTF8  4332 -1.281 -0.2255 
WTM2 4359 -1.305 -0.2244 
ARP10 4360 -1.305 -0.2179 
ZIP2 4381 -1.33 -0.2154 
REC107 4385 -1.336 -0.2094 
REC114 4394 -1.347 -0.2044 
PDS1 4421 -1.38 -0.2029 
SAE3 4438 -1.397 -0.1993 
REC102 4445 -1.404 -0.1936 
BUB3 4453 -1.408 -0.188 
CSM3 4466 -1.422 -0.1835 
RAD51 4510 -1.482 -0.185 
PCH2 4540 -1.53 -0.1833 
GMC2 4559 -1.556 -0.1793 
ECO1 4584 -1.599 -0.1763 
VIK1 4608 -1.627 -0.173 
CDH1 4620 -1.641 -0.1671 
IPL1 4627 -1.657 -0.1602 
TOP3 4650 -1.701 -0.1563 
BIR1 4652 -1.703 -0.148 
DMC1 4685 -1.776 -0.1458 
CDC14 4713 -1.823 -0.1423 
BRN1 4746 -1.899 -0.1395 
CHL4 4748 -1.91 -0.1302 
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SLZ1 4755 -1.925 -0.1219 
MOB1 4757 -1.931 -0.1126 
GAC1 4766 -1.946 -0.1046 
UME6 4811 -2.067 -0.1034 
CTF19  4845 -2.194 -0.0993 
KAR3 4849 -2.21 -0.089 
MND1 4851 -2.22 -0.0782 
SLK19 4886 -2.343 -0.0736 
MPS3 4919 -2.483 -0.0678 
SOH1 4931 -2.508 -0.0577 
DSN1 4950 -2.595 -0.0485 
ECM11 4952 -2.599 -0.0358 
SPO13 4960 -2.647 -0.0242 
CIK1 5039 -3.286 -0.0239 
MEI5 5042 -3.347 -0.0077 
IME4 5045 -3.39 0.0086 
 
Sister Chromatid Segregation 
 
Gene Name Rank in Gene List Rank Metric Score Running Enrichment 
Score 
TPD3 587 1.4 -0.0999 
POL30 906 1.086 -0.15 
SMC3 1001 1.002 -0.1563 
GLC7 1426 0.691 -0.2324 
TOF1 1833 0.486 -0.3076 
KIN4 1914 0.458 -0.3178 
SMC4 1918 0.457 -0.3127 
CHL1 1923 0.451 -0.3079 
LTE1 2057 0.386 -0.3297 
DCC1 2087 0.372 -0.3309 
CDC20 2243 0.3 -0.3581 
BUR2 2259 0.289 -0.3575 
MND2 2305 0.274 -0.3631 
MAD2 2358 0.252 -0.3703 
NPA3 2412 0.227 -0.3781 
PPH21 2467 0.201 -0.3864 
MCK1 2576 -0.185 -0.4057 
MMS22 2587 -0.193 -0.4053 
IRR1 2690 -0.248 -0.4226 
DMA1 2753 -0.283 -0.4314 
MCD1 2778 -0.291 -0.4326 
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MAD3 2797 -0.3 -0.4325 
SPC72 2801 -0.303 -0.4293 
RAD61 2813 -0.309 -0.4276 
CTF4  2835 -0.322 -0.4278 
CTF18  2851 -0.329 -0.4267 
RTS1 2871 -0.337 -0.4263 
ESP1 2918 -0.359 -0.431 
SMC2 2973 -0.388 -0.437 
IML3 2991 -0.398 -0.4354 
GPN2 3014 -0.407 -0.4348 
CIN8 3031 -0.413 -0.4328 
CEP3 3055 -0.426 -0.4321 
YPI1 3083 -0.437 -0.432 
ELG1 3091 -0.442 -0.4279 
SGS1 3097 -0.446 -0.4234 
CDC55 3160 -0.478 -0.4298 
SCC2  3234 -0.51 -0.438 
BUB1 3237 -0.511 -0.4321 
CTF3  3335 -0.557 -0.4445 
MCM21 3383 -0.585 -0.4466 
HHT2 3483 -0.641 -0.4584 
RMI1 3486 -0.641 -0.4508 
APC1 3491 -0.644 -0.4436 
BUB2 3522 -0.66 -0.4414 
IRC15 3630 -0.725 -0.4537 
BIM1 3655 -0.74 -0.4493 
POL2 3663 -0.744 -0.4414 
MAD1 3668 -0.746 -0.4329 
RDH54 3721 -0.782 -0.4336 
FIN1 3746 -0.795 -0.4284 
BMH1 3760 -0.806 -0.421 
PDS5 3787 -0.822 -0.4159 
RAD30 3815 -0.843 -0.4108 
SRC1 3849 -0.863 -0.4067 
CSE4 3850 -0.863 -0.3959 
KIP1 3898 -0.89 -0.3942 
TOP1 4017 -0.983 -0.4056 
DMA2 4092 -1.044 -0.4073 
BFA1 4124 -1.075 -0.4001 
SGO1 4134 -1.086 -0.3884 
BUD2 4152 -1.097 -0.3781 
SCC4  4166 -1.108 -0.3669 
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MPS1 4193 -1.145 -0.3578 
REC8 4214 -1.16 -0.3473 
SWM1 4258 -1.203 -0.3409 
ULP2 4259 -1.203 -0.3259 
CTF8  4332 -1.281 -0.3244 
PDS1 4421 -1.38 -0.3248 
BUB3 4453 -1.408 -0.3134 
CSM3 4466 -1.422 -0.2981 
ECO1 4584 -1.599 -0.3015 
VIK1 4608 -1.627 -0.2858 
CDH1 4620 -1.641 -0.2676 
IPL1 4627 -1.657 -0.2481 
TOP3 4650 -1.701 -0.2313 
BIR1 4652 -1.703 -0.2103 
BRN1 4746 -1.899 -0.2052 
CHL4 4748 -1.91 -0.1816 
GAC1 4766 -1.946 -0.1607 
CTF19  4845 -2.194 -0.149 
KAR3 4849 -2.21 -0.122 
MPS3 4919 -2.483 -0.1048 
SOH1 4931 -2.508 -0.0757 
DSN1 4950 -2.595 -0.047 
SPO13 4960 -2.647 -0.0158 
CIK1 5039 -3.286 0.0096 
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